text,labels
Moreover,O
",",O
post,O
-,O
treatment,O
with,O
LR132,Entity
prevented,O
cocaine,Entity
-,O
induced,O
lethality,O
in,O
a,O
significant,O
proportion,O
of,O
animals,O
.,O
The,O
most,O
severe,O
adverse,O
reactions,O
to,O
carbamazepine,Entity
have,O
been,O
observed,O
in,O
the,O
haemopoietic,O
system,O
",",O
the,O
liver,O
and,O
the,O
cardiovascular,O
system,O
.,O
The,O
experience,O
of,O
this,O
case,O
",",O
together,O
with,O
a,O
review,O
of,O
the,O
literature,O
",",O
suggests,O
that,O
FBAL,Entity
is,O
related,O
to,O
5-FU,Entity
-,O
induced,O
cardiotoxicity,Entity
.,O
High,O
-,O
dose,O
tranexamic,Entity
Acid,Entity
is,O
associated,O
with,O
nonischemic,O
clinical,O
seizures,Entity
in,O
cardiac,O
surgical,O
patients,O
.,O
cross,O
-,O
over,O
",",O
controlled,O
design,O
",",O
patients,O
were,O
randomized,O
to,O
receive,O
either,O
DCF,Entity
per,O
os,O
or,O
GTN,Entity
patches,O
the,O
first,O
days,O
of,O
menses,O
",",O
when,O
menstrual,O
cramps,O
became,O
unendurable,O
.,O
10,O
monkeys,O
(,O
macaques,O
),O
received,O
adriamycin,Entity
by,O
monthly,O
intravenous,O
injections,O
at,O
12,O
mg,O
/,O
m2,O
(,O
1,O
mg,O
/,O
kg,O
),O
.,O
He,O
was,O
put,O
on,O
aspirin,Entity
following,O
surgery,O
and,O
took,O
ibuprofen,Entity
for,O
fever,Entity
for,O
nearly,O
a,O
week,O
prior,O
to,O
presentation,O
.,O
This,O
case,O
suggests,O
there,O
is,O
a,O
role,O
for,O
aggressive,O
high,O
dose,O
intravenous,O
calcium,Entity
therapy,O
in,O
severe,O
diltiazem,Entity
overdose,Entity
",",O
particularly,O
with,O
the,O
onset,O
of,O
asystole,Entity
.,O
Attenuation,O
of,O
the,O
lithium,Entity
-,O
induced,O
diabetes,Entity
-,Entity
insipidus,Entity
-,Entity
like,Entity
syndrome,Entity
by,O
amiloride,Entity
in,O
rats,O
.,O
The,O
level,O
of,O
lipid,O
peroxidation,O
was,O
higher,O
and,O
the,O
reduced,O
glutathione,Entity
concentration,O
was,O
lower,O
in,O
the,O
MA,Entity
-,O
treated,O
rats,O
.,O
For,O
liver,Entity
cancer,Entity
",",O
in,O
analyses,O
restricted,O
to,O
exposed,O
workers,O
",",O
elevations,O
observed,O
at,O
higher,O
categories,O
of,O
use,O
were,O
not,O
statistically,O
significant,O
.,O
Tremor,Entity
was,O
measured,O
simultaneously,O
by,O
two,O
independent,O
observers,O
.,O
corticosterone,Entity
without,O
TOTP,Entity
or,O
DFP,Entity
had,O
significantly,O
elevated,O
activity,O
of,O
plasma,O
cholinesterase,O
and,O
significantly,O
inhibited,O
activity,O
of,O
liver,O
carboxylesterase,O
.,O
A,O
patient,O
who,O
developed,O
paraplegia,Entity
following,O
the,O
intrathecal,O
instillation,O
of,O
methotrexate,Entity
is,O
discribed,O
.,O
However,O
",",O
in,O
vivo,O
and,O
in,O
vitro,O
studies,O
have,O
demonstrated,O
that,O
myometrial,O
cells,O
are,O
also,O
targets,O
of,O
the,O
relaxant,O
effects,O
of,O
nitric,Entity
oxide,Entity
(,O
NO,Entity
),O
.,O
The,O
nursing,O
staff,O
",",O
by,O
reviewing,O
the,O
patient,O
's,O
health,O
history,O
with,O
his,O
family,O
",",O
discovered,O
a,O
history,O
of,O
polydipsia,Entity
and,O
long,O
-,O
standing,O
lithium,Entity
use,O
.,O
Although,O
dexmedetomidine,Entity
sedation,O
was,O
associated,O
with,O
a,O
16%,O
incidence,O
of,O
bradycardia,Entity
",",O
all,O
concomitant,O
mean,O
arterial,O
blood,O
pressures,O
were,O
within,O
20%,O
of,O
age,O
-,O
adjusted,O
normal,O
range,O
and,O
Although,O
the,O
patient,O
's,O
renal,O
function,O
was,O
not,O
highly,O
impaired,O
and,O
the,O
dose,O
of,O
pilsicainide,Entity
was,O
low,O
",",O
the,O
plasma,O
concentration,O
of,O
pilsicainide,Entity
may,O
have,O
been,O
high,O
",",O
which,O
can,O
produce,O
torsades,Entity
de,Entity
pointes,Entity
in,O
the,O
octogenarian,O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
evaluate,O
two,O
endogenous,O
and,O
one,O
synthetic,O
neuroactive,O
steroid,Entity
that,O
positively,O
modulate,O
the,O
gamma,Entity
-,Entity
aminobutyric,Entity
acid,Entity
(,O
GABA(A,Entity
),O
),O
receptor,O
against,O
the,O
increase,O
in,O
sensitivity,O
to,O
the,O
convulsant,O
effects,O
of,O
cocaine,Entity
engendered,O
by,O
repeated,O
cocaine,Entity
administration,O
(,O
seizure,Entity
kindling,O
),O
.,O
BACKGROUND,O
:,O
Spinal,O
anaesthesia,O
is,O
widely,O
employed,O
in,O
clinical,O
practice,O
but,O
has,O
the,O
main,O
drawback,O
of,O
post,O
-,O
spinal,O
block,O
hypotension,Entity
.,O
Transient,O
hypotension,Entity
(,O
SAP<90mmHg,O
),O
occurred,O
in,O
1,O
patient,O
(,O
0.7%,O
),O
.,O
OBJECTIVE,O
:,O
To,O
report,O
our,O
clinical,O
experience,O
with,O
abnormal,Entity
ocular,Entity
motility,Entity
in,O
patients,O
treated,O
with,O
subtenon,O
carboplatin,Entity
chemotherapy,O
.,O
She,O
was,O
treated,O
with,O
heparin,Entity
",",O
dipyridamole,Entity
and,O
hemodialysis,O
;,O
and,O
after,O
more,O
than,O
three,O
months,O
",",O
her,O
urinary,O
output,O
rose,O
above,O
500,O
ml,O
;,O
and,O
six,O
months,O
after,O
the,O
onset,O
of,O
anuria,Entity
",",O
dialysis,O
treatment,O
was,O
stopped,O
.,O
Surgical,O
treatment,O
of,O
cataracts,Entity
",",O
band,Entity
keratopathy,Entity
",",O
and,O
glaucoma,Entity
achieved,O
uniformly,O
discouraging,O
results,O
.,O
CONCLUSIONS,O
:,O
Urine,O
volume,O
can,O
be,O
reduced,O
by,O
giving,O
lithium,Entity
once,O
daily,O
and/or,O
by,O
lowering,O
the,O
total,O
daily,O
dose,O
.,O
Intravenous,O
injection,O
of,O
the,O
specific,O
platelet,O
-,O
activating,O
factor,O
(,O
PAF,O
),O
antagonist,O
BN,Entity
52021,Entity
(,O
10,O
mg,O
/,O
kg,O
),O
",",O
30,O
min,O
before,O
bupivacaine,Entity
administration,O
(,O
2,O
mg,O
/,O
kg,O
i.v,O
.,O
),O
suppressed,O
both,O
the,O
decrease,Entity
of,Entity
MBP,Entity
and,Entity
HR,Entity
.,O
We,O
examined,O
the,O
role,O
of,O
the,O
beta4,O
subunits,O
in,O
nicotine,Entity
-,O
induced,O
seizures,Entity
and,O
hypolocomotion,Entity
in,O
beta4,O
homozygous,O
null,O
(,O
beta4,O
-/-,O
),O
and,O
alpha3,O
heterozygous,O
(,O
+,O
/-,O
Incidence,O
of,O
postoperative,Entity
delirium,Entity
is,O
high,O
even,O
in,O
a,O
population,O
without,O
known,O
risk,O
factors,O
.,O
2%,O
lidocaine,Entity
in,O
7.5%,O
glucose,Entity
",",O
2%,O
prilocaine,Entity
in,O
7.5%,O
glucose,Entity
",",O
or,O
0.5%,O
bupivacaine,Entity
in,O
7.5%,O
glucose,Entity
.,O
Here,O
we,O
report,O
a,O
case,O
of,O
acute,O
hepatitis,Entity
probably,O
associated,O
with,O
the,O
administration,O
of,O
telithromycin,Entity
.,O
The,O
recognition,O
of,O
angiotensin,Entity
-,O
converting,O
enzyme,O
(,O
ACE,O
),O
and,O
angiotensin,Entity
receptor,O
blocker,O
(,O
ARB,O
),O
Central,Entity
nervous,Entity
system,Entity
(,Entity
CNS,Entity
),Entity
complications,Entity
during,O
treatment,O
of,O
childhood,O
acute,Entity
lymphoblastic,Entity
leukemia,Entity
(,O
ALL,Entity
),O
remain,O
a,O
challenging,O
clinical,O
problem,O
.,O
Thiopentone,Entity
was,O
independently,O
associated,O
with,O
an,O
increase,O
in,O
its,O
relative,O
risk,O
.,O
Gastrointestinal,O
tolerability,O
of,O
etoricoxib,Entity
in,O
rheumatoid,Entity
arthritis,Entity
patients,O
:,O
results,O
of,O
the,O
etoricoxib,Entity
vs,O
diclofenac,Entity
sodium,Entity
gastrointestinal,O
tolerability,O
and,O
effectiveness,O
trial,O
(,O
EDGE,O
-,O
II,O
),O
.,O
We,O
investigate,O
whether,O
abnormalities,O
in,O
L,Entity
-,Entity
arginine,Entity
uptake,O
contribute,O
to,O
this,O
deficiency,O
.,O
Degenerating,Entity
myelinated,Entity
fibers,Entity
were,O
also,O
evident,O
in,O
distal,O
levels,O
of,O
the,O
peripheral,O
nerves,O
of,O
chickens,O
given,O
TOTP,Entity
or,O
DFP,Entity
.,O
Caution,O
is,O
recommended,O
in,O
combining,O
clonidine,Entity
and,O
verapamil,Entity
therapy,O
",",O
even,O
in,O
patients,O
who,O
do,O
not,O
have,O
sinus,O
or,O
AV,O
node,O
dysfunction,O
.,O
The,O
potential,O
modifying,O
effect,O
of,O
retinyl,Entity
acetate,Entity
(,O
RA,Entity
),O
on,O
butylated,Entity
hydroxyanisole,Entity
(,O
BHA)-induced,Entity
rat,O
forestomach,Entity
tumorigenesis,Entity
was,O
examined,O
.,O
Two,O
others,O
had,O
a,O
mixed,O
(,O
cholestatic,Entity
and,O
cytolytic,O
),O
hepatitis,Entity
following,O
carbimazole,Entity
.,O
This,O
report,O
describes,O
a,O
case,O
of,O
encephalopathy,Entity
developed,O
in,O
the,O
course,O
of,O
amitriptyline,Entity
therapy,O
",",O
during,O
a,O
remission,O
of,O
unipolar,Entity
depression,Entity
.,O
The,O
infections,Entity
responded,O
to,O
antibiotic,O
treatment,O
.,O
These,O
experiments,O
suggest,O
that,O
although,O
many,O
factors,O
may,O
contribute,O
to,O
the,O
increased,O
incidence,O
of,O
ventricular,Entity
arrhythmias,Entity
in,O
respiratory,Entity
failure,Entity
",",O
pharmacologic,O
agents,O
",",O
particularly,O
aminophylline,Entity
",",O
may,O
play,O
a,O
significant,O
role,O
.,O
Thereafter,O
",",O
no,O
cardiac,Entity
symptoms,Entity
were,O
observed,O
.,O
Intradermal,O
glutamate,Entity
and,O
capsaicin,Entity
injections,O
:,O
intra-,O
and,O
interindividual,O
variability,O
of,O
provoked,O
hyperalgesia,Entity
and,O
allodynia,Entity
.,O
Development,O
of,O
AKI,Entity
was,O
compared,O
between,O
groups,O
with,O
exact,O
Chi2-test,O
and,O
multivariate,O
logistic,O
regression,O
analysis,O
(,O
two,O
-,O
sided,O
P,O
<,O
0.05,O
),O
.,O
Synthesis,O
and,O
preliminary,O
pharmacological,O
investigations,O
of,O
"1-(1,2-dihydro-2-acenaphthylenyl)piperazine",Entity
derivatives,O
as,O
potential,O
atypical,O
antipsychotic,O
agents,O
in,O
mice,O
.,O
We,O
studied,O
the,O
efficacy,O
and,O
safety,O
of,O
propranolol,Entity
in,O
the,O
treatment,O
of,O
PPA,Entity
-,O
induced,O
hypertension,Entity
.,O
T,Entity
alone,O
had,O
no,O
effect,O
on,O
locomotion,O
",",O
irritability,Entity
",",O
or,O
sexual,O
behavior,O
but,O
increased,O
partner,O
preference,O
and,O
aggression,Entity
.,O
Cross,O
-,O
sectional,O
echocardiographic,O
screening,O
of,O
newborns,O
exposed,O
to,O
lithium,Entity
during,O
gestation,O
can,O
provide,O
highly,O
accurate,O
",",O
noninvasive,O
assessment,O
of,O
the,O
presence,O
or,O
absence,O
of,O
lithium,Entity
-,O
induced,O
cardiac,Entity
malformations,Entity
.,O
Each,O
concentration,O
of,O
progesterone,Entity
(,O
6.25,O
",",O
12.5,O
",",O
25,O
",",O
and,O
50,O
micrograms,O
/,O
ml,O
),O
caused,O
a,O
significant,O
and,O
concentration,O
-,O
dependent,O
reduction,O
in,O
the,O
AD50,O
for,O
bupivacaine,Entity
.,O
These,O
insights,O
might,O
have,O
useful,O
implications,O
for,O
future,O
studies,O
utilizing,O
B1R,O
antagonists,O
for,O
treatment,O
of,O
human,O
DOX,Entity
cardiomyopathy,Entity
.,O
It,O
has,O
shown,O
promising,O
results,O
alone,O
or,O
in,O
combination,O
with,O
other,O
chemotherapeutic,O
agents,O
in,O
colorectal,Entity
",",Entity
breast,Entity
",",Entity
pancreaticobiliary,Entity
",",Entity
gastric,Entity
",",Entity
renal,Entity
cell,Entity
and,Entity
head,Entity
and,Entity
neck,Entity
cancers,Entity
.,O
Her,O
medications,O
included,O
desvenlafaxine,Entity
",",O
and,O
symptoms,O
included,O
nausea,Entity
",",O
anxiety,Entity
and,O
confusion,Entity
.,O
Composition,O
of,O
gall,Entity
bladder,Entity
stones,Entity
associated,O
with,O
octreotide,Entity
:,O
response,O
to,O
oral,O
ursodeoxycholic,Entity
acid,Entity
.,O
Visual,Entity
and,Entity
auditory,Entity
neurotoxicity,Entity
was,O
previously,O
documented,O
in,O
42,O
of,O
89,O
patients,O
with,O
transfusion,O
-,O
dependent,O
anemia,Entity
who,O
were,O
receiving,O
iron,Entity
chelation,O
therapy,O
with,O
daily,O
subcutaneous,O
deferoxamine,Entity
.,O
(,O
cathepsin,O
D,O
),O
activity,O
was,O
increased,O
about,O
tenfold,O
in,O
patients,O
who,O
died,O
and,O
nearly,O
fourfold,O
in,O
those,O
who,O
survived,O
fulminant,Entity
hepatic,Entity
failure,Entity
after,O
paracetamol,Entity
overdose,Entity
",",O
whereas,O
activities,O
were,O
increased,O
equally,O
in,O
patients,O
with,O
fulminant,Entity
hepatic,Entity
failure,Entity
due,O
to,O
viral,Entity
hepatitis,Entity
whether,O
or,O
not,O
they,O
survived,O
.,O
Previous,O
research,O
in,O
this,O
laboratory,O
has,O
shown,O
that,O
a,O
diet,O
of,O
intermittent,O
excessive,O
sugar,O
consumption,O
produces,O
a,O
state,O
with,O
neurochemical,O
and,O
behavioral,O
similarities,O
to,O
drug,Entity
dependency,Entity
.,O
Further,O
work,O
is,O
warranted,O
on,O
the,O
effect,O
of,O
the,O
treatments,O
on,O
renal,O
functional,O
aspects,O
in,O
models,O
of,O
chronic,Entity
renal,Entity
failure,Entity
",",O
and,O
on,O
the,O
mechanism(s,O
),O
involved,O
.,O
The,O
opioid,O
antagonist,O
naloxone,Entity
has,O
been,O
shown,O
to,O
block,O
or,O
reverse,O
the,O
hypotensive,Entity
actions,O
of,O
captopril,Entity
.,O
HMM,Entity
gastrointestinal,Entity
toxicity,Entity
necessitated,O
discontinuation,O
of,O
the,O
drug,O
in,O
5,O
patients,O
.,O
Cocaine,Entity
is,O
a,O
widely,O
abused,O
psychostimulant,O
that,O
has,O
both,O
rewarding,O
and,O
aversive,O
properties,O
.,O
This,O
report,O
demonstrates,O
for,O
the,O
first,O
time,O
that,O
the,O
pharmacodynamic,O
properties,O
of,O
cyclosporin,Entity
A,Entity
may,O
not,O
be,O
confined,O
strictly,O
to,O
suppression,O
of,O
normal,O
T,O
-,O
cell,O
functions,O
.,O
Thirty,O
-,O
five,O
patients,O
with,O
primary,Entity
pulmonary,Entity
hypertension,Entity
and,O
85,O
matched,O
controls,O
were,O
recruited,O
over,O
32,O
months,O
(,O
1992,O
-,O
1994,O
),O
in,O
Belgium,O
.,O
The,O
administration,O
of,O
ephedrine,Entity
led,O
to,O
a,O
similar,O
increase,O
in,O
MAP,O
(,O
53,O
+,O
/-,O
METHODS,O
AND,O
RESULTS,O
:,O
In,O
20,O
patients,O
(,O
14,O
men,O
and,O
6,O
women,O
aged,O
39,O
to,O
72,O
years,O
),O
referred,O
for,O
cardiac,O
catheterization,O
for,O
the,O
evaluation,O
of,O
chest,Entity
pain,Entity
",",O
we,O
measured,O
heart,O
rate,O
",",O
systemic,O
arterial,O
pressure,O
",",O
LV,O
pressure,O
and,O
its,O
first,O
derivative,O
(,O
dP,O
/,O
dt,O
),O
",",O
and,O
LV,O
volumes,O
and,O
ejection,O
fraction,O
before,O
and,O
during,O
the,O
final,O
2,O
to,O
3,O
minutes,O
of,O
a,O
15-minute,O
intracoronary,O
infusion,O
of,O
saline,O
(,O
n=10,O
",",O
control,O
subjects,O
),O
or,O
cocaine,Entity
hydrochloride,Entity
1,O
mg,O
/,O
min,O
(,O
n=10,O
),O
.,O
The,O
presentation,O
and,O
cardiac,O
evaluation,O
(,O
hemodynamic,O
",",O
echocardiographic,O
",",O
and,O
scintigraphic,O
),O
of,O
these,O
patients,O
suggest,O
new,O
manifestations,O
of,O
5-FU,Entity
cardiotoxicity,Entity
that,O
may,O
be,O
influenced,O
by,O
CDDP,Entity
.,O
Multivariate,O
logistic,O
regression,O
showed,O
that,O
the,O
month,O
of,O
delivery,O
and,O
infant,O
birth,O
weight,O
were,O
independent,O
predictors,O
of,O
hepatitis,Entity
B,Entity
vaccination,O
.,O
She,O
however,O
remains,O
blind,Entity
.,O
None,O
of,O
the,O
patients,O
complained,O
of,O
subjective,O
hearing,Entity
loss,Entity
.,O
Sensori,Entity
-,Entity
motor,Entity
neuropathy,Entity
was,O
the,O
commonest,O
presentation,O
(,O
50%,O
),O
.,O
Male,O
CD-1,O
mice,O
were,O
treated,O
with,O
warfarin,Entity
(,O
2,O
mg,O
/,O
kg,O
over,O
24,O
h,O
),O
",",O
resulting,O
in,O
a,O
mean,O
(,O
+,O
/-s.d,O
.,O
),O
Neither,O
SOD,O
nor,O
DMTU,Entity
affected,O
the,O
renal,O
cortical,O
GM,Entity
content,O
in,O
GM,Entity
-,O
treated,O
rats,O
.,O
Calcineurin,O
inhibitors,O
",",O
such,O
as,O
cyclosporine,Entity
and,O
tacrolimus,Entity
",",O
have,O
been,O
available,O
for,O
almost,O
20,O
years,O
.,O
Regional,O
analysis,O
showed,O
a,O
reduction,O
in,O
the,O
worst,O
affected,O
segment,O
15,O
and,O
30,O
minutes,O
after,O
exercise,O
(,O
-27.9,O
(,O
7.2)%,O
and,O
-28.6,O
(,O
5.7)%,O
",",O
both,O
p,O
<,O
0.01,O
),O
",",O
and,O
at,O
30,O
minutes,O
after,O
dobutamine,Entity
The,O
rates,O
of,O
onset,O
of,O
the,O
action,O
of,O
cimetidine,Entity
and,O
ranitidine,Entity
were,O
the,O
same,O
.,O
Proximal,O
tubular,O
damage,O
caused,O
by,O
HCBD,Entity
and,O
papillary,O
damage,O
caused,O
by,O
BEA,Entity
were,O
distinguished,O
both,O
by,O
conventional,O
urinalysis,O
(,O
volume,O
and,O
specific,O
gravity,O
),O
and,O
by,O
measurement,O
of,O
the,O
two,O
urinary,O
enzymes,O
.,O
An,O
adverse,O
drug,O
interaction,O
with,O
piroxicam,Entity
",",O
which,O
she,O
took,O
occasionally,O
",",O
may,O
have,O
exacerbated,O
the,O
coagulopathy,Entity
.,O
Faster,O
relief,O
of,O
headache,Entity
was,O
the,O
most,O
important,O
reason,O
for,O
preference,O
",",O
cited,O
by,O
67.3%,O
of,O
patients,O
preferring,O
rizatriptan,Entity
and,O
54.2%,O
of,O
patients,O
who,O
preferred,O
ergotamine,Entity
/,O
caffeine,Entity
.,O
In,O
other,O
individuals,O
with,O
no,O
underlying,O
atherosclerotic,Entity
obstruction,Entity
",",O
coronary,Entity
occlusion,Entity
may,O
be,O
due,O
to,O
spasm,Entity
",",O
thrombus,Entity
",",O
or,O
both,O
.,O
Results,O
showed,O
that,O
SSR103800,Entity
(,O
10,O
-,O
30,O
mg,O
/,O
kg,O
p.o,O
.,O
),O
We,O
searched,O
the,O
following,O
databases,O
to,O
November,O
2007,O
:,O
Trials,O
Register,O
of,O
the,O
Cochrane,O
Menstrual,Entity
Disorders,Entity
and,O
Subfertility,O
Group,O
",",O
Cochrane,O
Central,O
Register,O
of,O
Controlled,O
Trials,O
",",O
MEDLINE,O
",",O
EMBASE,O
",",O
Biological,O
Abstracts,O
.,O
In,O
both,O
cases,O
",",O
QT,Entity
prolongation,Entity
and,O
hypocalcaemia,Entity
were,O
noted,O
.,O
Analysis,O
was,O
performed,O
on,O
61,O
women,O
with,O
chemotherapy,O
-,O
responsive,O
metastatic,O
breast,Entity
cancer,Entity
receiving,O
96-h,O
infusional,O
cyclophosphamide,Entity
as,O
part,O
of,O
a,O
triple,O
sequential,O
high,O
-,O
dose,O
regimen,O
to,O
assess,O
association,O
between,O
presence,O
of,O
peritransplant,O
congestive,Entity
heart,Entity
failure,Entity
(,O
CHF,Entity
),O
and,O
the,O
following,O
pretreatment,O
characteristics,O
:,O
presence,O
of,O
electrocardiogram,O
(,O
EKG,O
),O
abnormalities,O
",",O
age,O
",",O
hypertension,Entity
",",O
prior,O
cardiac,O
history,O
",",O
smoking,O
",",O
diabetes,Entity
mellitus,Entity
",",O
prior,O
use,O
of,O
anthracyclines,Entity
",",O
and,O
left,O
-,O
sided,O
chest,O
irradiation,O
.,O
However,O
",",O
three,O
case,O
control,O
studies,O
",",O
one,O
each,O
in,O
North,O
Carolina,O
",",O
northern,O
Maryland,O
",",O
and,O
West,O
Berlin,O
",",O
Germany,O
",",O
showed,O
that,O
habitual,O
use,O
of,O
acetaminophen,Entity
is,O
also,O
associated,O
with,O
chronic,Entity
renal,Entity
failure,Entity
and,O
ESRD,Entity
",",O
with,O
a,O
relative,O
risk,O
in,O
the,O
range,O
of,O
2,O
to,O
4,O
.,O
This,O
is,O
the,O
first,O
reported,O
case,O
of,O
sinus,Entity
arrest,Entity
associated,O
with,O
continuous,O
-,O
infusion,O
cimetidine,Entity
.,O
Preliminary,O
results,O
at,O
400,O
and,O
500,O
mg,O
/,O
m2,O
suggest,O
that,O
a,O
reduction,O
in,O
nephrotoxicity,Entity
may,O
have,O
been,O
achieved,O
with,O
only,O
1,O
instance,O
of,O
renal,Entity
toxicity,Entity
in,O
10,O
patients,O
.,O
The,O
incidence,O
of,O
pain,Entity
was,O
significantly,O
lower,O
in,O
Groups,O
R4,O
and,O
R6,O
than,O
in,O
the,O
control,O
and,O
R2,O
groups,O
(,O
12/32,O
and,O
6/31,O
vs,O
26/31,O
and,O
25/32,O
",",O
respectively,O
",",O
P<0.001,O
),O
.,O
LV,Entity
may,O
be,O
a,O
late,O
-,O
onset,O
adverse,O
reaction,O
associated,O
with,O
warfarin,Entity
therapy,O
.,O
After,O
a,O
30-min,O
baseline,O
measure,O
of,O
locomotor,O
activity,O
(,O
day,O
0,O
),O
",",O
animals,O
were,O
maintained,O
on,O
a,O
cyclic,O
diet,O
of,O
12-h,O
deprivation,O
followed,O
by,O
12-h,O
access,O
to,O
10%,O
sucrose,Entity
solution,O
and,O
chow,O
pellets,O
(,O
12,O
h,O
access,O
starting,O
4,O
h,O
after,O
onset,O
of,O
the,O
dark,O
period,O
),O
for,O
21,O
days,O
.,O
Reports,O
about,O
cases,O
of,O
hepatotoxicity,Entity
due,O
to,O
clopidogrel,Entity
are,O
increasing,O
in,O
the,O
last,O
few,O
years,O
",",O
after,O
the,O
increased,O
use,O
of,O
this,O
drug,O
.,O
Epithelial,O
sodium,Entity
channel,O
(,O
ENaC,O
),O
subunit,O
mRNA,O
and,O
protein,O
expression,O
in,O
rats,O
with,O
puromycin,Entity
aminonucleoside,Entity
-,O
induced,O
nephrotic,Entity
syndrome,Entity
.,O
However,O
",",O
the,O
use,O
of,O
CBDCA,Entity
higher,O
-,O
intensity,O
schedules,O
and,O
the,O
association,O
with,O
other,O
neurotoxic,Entity
drugs,O
in,O
polychemotherapy,O
may,O
cause,O
some,O
concern,O
about,O
its,O
safety,O
with,O
respect,O
to,O
peripheral,Entity
nervous,Entity
system,Entity
damage,Entity
.,O
Effect,O
of,O
humoral,O
modulators,O
of,O
morphine,Entity
-,O
induced,O
increase,Entity
in,Entity
locomotor,Entity
activity,Entity
of,O
mice,O
.,O
The,O
management,O
options,O
in,O
the,O
ED,O
",",O
as,O
exemplified,O
by,O
four,O
individual,O
case,O
reports,O
",",O
in,O
particular,O
the,O
use,O
of,O
a,O
minimally,O
invasive,O
method,O
of,O
intracorporal,O
epinephrine,Entity
instillation,O
",",O
are,O
discussed,O
.,O
5,O
patients,O
with,O
acute,Entity
renal,Entity
failure,Entity
(,O
3,O
with,O
thrombopenia,Entity
and,O
hemolysis,Entity
),O
induced,O
by,O
the,O
reintroduction,O
of,O
rifampicin,Entity
are,O
described,O
.,O
This,O
study,O
investigates,O
whether,O
polymorphisms,O
in,O
the,O
HOMER1,O
gene,O
promoter,O
region,O
are,O
associated,O
with,O
the,O
occurrence,O
of,O
the,O
chronic,O
complications,O
of,O
levodopa,Entity
therapy,O
.,O
Reported,O
adverse,O
effects,O
include,O
a,O
period,O
of,O
breathiness,O
",",O
throat,Entity
pain,Entity
",",O
and,O
difficulty,O
with,O
swallowing,O
liquids,O
.,O
There,O
was,O
statistically,O
significant,O
improvement,O
in,O
all,O
contralateral,O
major,O
parkinsonian,Entity
motor,O
signs,O
in,O
all,O
patients,O
followed,O
for,O
6,O
months,O
.,O
Electroencephalographic,O
and,O
behavioral,O
monitoring,O
revealed,O
a,O
profound,O
reduction,O
of,O
the,O
threshold,O
for,O
pilocarpine,Entity
-,O
induced,O
convulsions,Entity
.,O
Metoclopramide,Entity
should,O
be,O
used,O
cautiously,O
in,O
patients,O
with,O
a,O
risk,O
of,O
torsade,Entity
de,Entity
pointes,Entity
.,O
Myocardial,Entity
infarction,Entity
following,O
sublingual,O
administration,O
of,O
isosorbide,Entity
dinitrate,Entity
.,O
In,O
the,O
NASCIS,O
",",O
there,O
was,O
no,O
mention,O
regarding,O
the,O
possibility,O
of,O
acute,O
corticosteroid,Entity
myopathy,Entity
that,O
high,O
-,O
dose,O
methylprednisolone,Entity
may,O
cause,O
.,O
We,O
conclude,O
that,O
vancomycin,Entity
",",O
administered,O
appropriately,O
",",O
constitutes,O
safe,O
",",O
effective,O
therapy,O
for,O
infections,Entity
caused,O
by,O
susceptible,O
bacteria,O
.,O
There,O
were,O
two,O
cases,O
of,O
hypocellular,O
myelodysplasia,Entity
",",O
two,O
cases,O
of,O
hypersegmented,O
myelodysplastic,Entity
granulocytosis,O
",",O
two,O
cases,O
of,O
hypercellular,O
marrow,O
with,O
abnormal,O
megakaryocytes,O
with,O
bizarre,O
nuclei,O
",",O
one,O
case,O
of,O
megakaryocytic,O
myelosis,O
associated,O
with,O
a,O
hyperplastic,Entity
marrow,Entity
",",O
dysmyelopoiesis,Entity
and,O
a,O
hypocellular,Entity
marrow,Entity
and,O
two,O
cases,O
of,O
myelodysplasia,Entity
with,O
dyserythropoiesis,Entity
",",O
hemosiderosis,Entity
and,O
a,O
hypocellular,Entity
marrow,Entity
.,O
Systemic,O
cocaine,Entity
(,O
10,O
mg,O
/,O
kg,O
),O
significantly,O
increased,O
the,O
locomotor,O
activity,O
of,O
rats,O
.,O
Recurrent,O
reversible,O
acute,Entity
renal,Entity
failure,Entity
from,O
amphotericin,Entity
.,O
We,O
tested,O
the,O
sulfated,O
polysaccharide,O
fucoidan,Entity
",",O
which,O
has,O
been,O
reported,O
to,O
reduce,O
inflammatory,O
brain,Entity
damage,Entity
",",O
in,O
a,O
rat,O
model,O
of,O
intracerebral,Entity
hemorrhage,Entity
induced,O
by,O
injection,O
of,O
bacterial,O
collagenase,O
into,O
the,O
caudate,O
nucleus,O
.,O
Preclinical,O
toxicologic,O
investigation,O
suggested,O
that,O
a,O
new,O
calcium,Entity
channel,O
blocker,O
",",O
Ro,Entity
40,Entity
-,Entity
5967,Entity
",",O
induced,O
cardiovascular,Entity
alterations,Entity
in,O
rat,O
fetuses,O
exposed,O
to,O
this,O
agent,O
during,O
organogenesis,O
.,O
We,O
propose,O
that,O
remoxipride,Entity
and,O
benzene,Entity
may,O
induce,O
aplastic,Entity
anemia,Entity
via,O
production,O
of,O
similar,O
reactive,O
metabolites,O
and,O
that,O
the,O
ability,O
of,O
NCQ436,Entity
and,O
NCQ344,Entity
to,O
induce,O
apoptosis,O
in,O
HBMP,O
cells,O
may,O
contribute,O
to,O
the,O
mechanism,O
underlying,O
acquired,O
aplastic,Entity
anemia,Entity
that,O
has,O
been,O
associated,O
with,O
remoxipride,Entity
.,O
In,O
contrast,O
",",O
a,O
significant,O
decline,O
in,O
glomerular,O
filtration,O
rate,O
was,O
found,O
after,O
the,O
introduction,O
of,O
suprofen,Entity
to,O
the,O
kidney,O
perfused,O
with,O
uric,Entity
acid,Entity
;,O
no,O
changes,O
were,O
found,O
with,O
suprofen,Entity
in,O
the,O
absence,O
of,O
uric,Entity
acid,Entity
.,O
However,O
",",O
scopolamine,Entity
and,O
ritanserin,Entity
co,O
-,O
administration,O
resulted,O
in,O
a,O
significant,O
decrease,O
in,O
escape,O
latencies,O
and,O
traveled,O
distances,O
as,O
compared,O
to,O
the,O
scopolamine,Entity
-,O
treated,O
rats,O
.,O
Histopathological,O
examination,O
of,O
the,O
kidney,O
showed,O
tubular,Entity
necrosis,Entity
in,O
D,Entity
-,Entity
AmB,Entity
-,O
treated,O
rats,O
but,O
no,O
change,O
in,O
NS-718-treated,O
rats,O
.,O
Hepatitis,Entity
was,O
usually,O
reversible,O
when,O
treatment,O
was,O
stopped,O
",",O
with,O
the,O
results,O
of,O
liver,O
function,O
tests,O
returning,O
to,O
normal,O
after,O
an,O
average,O
of,O
3.1,O
months,O
.,O
Tic,Entity
disorders,Entity
can,O
be,O
effectively,O
treated,O
by,O
atypical,O
antipsychotics,O
such,O
as,O
risperidone,Entity
",",O
olanzapine,Entity
and,O
ziprasidone,Entity
.,O
Behavioral,O
apomorphine,Entity
-,O
induced,O
penile,O
erections,O
were,O
reduced,O
(,O
5/8,O
),O
and,O
increased,O
(,O
3/8,O
),O
in,O
uni-,O
and,O
bilateral,O
lesioned,O
animals,O
.,O
This,O
patient,O
survived,O
without,O
sequelae,O
due,O
to,O
the,O
aggressive,O
sedation,O
and,O
neuromuscular,O
paralysis,Entity
.,O
On,O
admission,O
the,O
patient,O
was,O
taking,O
carvedilol,Entity
12,O
mg,O
twice,O
daily,O
",",O
warfarin,Entity
2,O
mg,O
/,O
day,O
",",O
folic,Entity
acid,Entity
1,O
mg,O
/,O
day,O
",",O
levothyroxine,Entity
100,O
microg,O
Of,O
60,O
epileptic,Entity
women,O
with,O
periconceptional,O
folic,Entity
acid,Entity
(,O
0.8,O
mg)-containing,O
multivitamin,O
supplementation,O
",",O
no,O
one,O
developed,O
epilepsy,Entity
-,O
related,O
side,O
effects,O
during,O
the,O
periconception,O
period,O
.,O
These,O
differences,O
were,O
observed,O
even,O
though,O
the,O
serum,O
mexiletine,Entity
levels,O
obtained,O
in,O
this,O
study,O
were,O
generally,O
lower,O
than,O
those,O
observed,O
in,O
studies,O
that,O
have,O
used,O
the,O
regular,O
form,O
of,O
the,O
drug,O
.,O
Hypotension,Entity
",",O
bradycardia,Entity
",",O
and,O
asystole,Entity
after,O
high,O
-,O
dose,O
intravenous,O
methylprednisolone,Entity
in,O
a,O
monitored,O
patient,O
.,O
Injectable,O
lorazepam,Entity
should,O
be,O
used,O
with,O
caution,O
in,O
VLBW,O
infants,O
.,O
CCNU,Entity
(,O
lomustine,Entity
),O
toxicity,Entity
in,O
dogs,O
:,O
a,O
retrospective,O
study,O
(,O
2002,O
-,O
07,O
),O
.,O
14,O
of,O
the,O
38,O
patients,O
were,O
previously,O
treated,O
with,O
chemotherapy,O
",",O
1,O
with,O
radiation,O
",",O
6,O
with,O
both,O
chemotherapy,O
and,O
radiation,O
",",O
and,O
17,O
did,O
not,O
have,O
any,O
treatment,O
before,O
CPDD,Entity
combination,O
.,O
The,O
primary,O
outcome,O
of,O
this,O
study,O
was,O
a,O
composite,O
of,O
severe,O
hypotension,Entity
(,O
mean,O
arterial,O
pressure,O
<,O
60,O
mm,O
Hg,O
),O
and,O
bradycardia,Entity
(,O
heart,O
rate,O
<,O
50,O
beats,O
/,O
min,O
),O
during,O
sedative,O
infusion,O
.,O
We,O
report,O
the,O
case,O
of,O
a,O
young,O
woman,O
who,O
suffered,O
a,O
cerebral,Entity
infarction,Entity
after,O
taking,O
a,O
single,O
oral,O
dose,O
of,O
PPA,Entity
.,O
This,O
experience,O
raises,O
the,O
question,O
of,O
the,O
role,O
of,O
BMT,O
itself,O
as,O
a,O
therapeutic,O
option,O
for,O
patients,O
with,O
uncontrolled,O
destructive,O
synovitis,Entity
.,O
followed,O
by,O
succinylcholine,Entity
(,O
Group,O
PS,O
",",O
LS,O
),O
or,O
rocuronium,Entity
(,O
Group,O
PR,O
),O
for,O
tracheal,O
intubation,O
.,O
Levodopa,Entity
-,O
induced,O
dyskinesias,Entity
have,O
been,O
reported,O
in,O
Parkinson,Entity
's,Entity
disease,Entity
and,O
multiple,Entity
system,Entity
atrophy,Entity
.,O
The,O
kinetics,O
of,O
urinary,O
sodium,Entity
excretion,O
and,O
the,O
appearance,O
of,O
proteinuria,Entity
were,O
comparable,O
with,O
those,O
reported,O
previously,O
.,O
Preoperative,O
assessment,O
should,O
focus,O
on,O
cardiovascular,O
status,O
and,O
serum,O
potassium,Entity
level,O
.,O
0.0001,O
",",O
r,O
=,O
0.8,O
),O
between,O
the,O
volume,O
of,O
the,O
ventral,O
lesion,O
in,O
the,O
GPi,O
and,O
the,O
improvement,O
in,O
LID,Entity
in,O
the,O
contralateral,O
limbs,O
",",O
whereas,O
there,O
was,O
no,O
correlation,O
between,O
the,O
ventral,O
volume,O
and,O
the,O
improvement,O
in,O
parkinsonian,Entity
',O
off,O
',O
signs,O
.,O
Hyperglycemic,Entity
acidotic,Entity
coma,Entity
and,O
death,O
in,O
Kearns,Entity
-,Entity
Sayre,Entity
syndrome,Entity
.,O
Thus,O
",",O
we,O
hypothesized,O
that,O
the,O
activation,O
of,O
PARP,O
may,O
contribute,O
to,O
the,O
DOX,Entity
-,O
induced,O
cardiotoxicity,Entity
.,O
Psychologists,O
need,O
to,O
inquire,O
about,O
consumption,O
of,O
quinine,Entity
-,O
containing,O
beverages,O
as,O
part,O
of,O
an,O
evaluation,O
process,O
.,O
Hemolytic,Entity
anemia,Entity
associated,O
with,O
the,O
use,O
of,O
omeprazole,Entity
.,O
The,O
pharmacological,O
response,O
to,O
drugs,O
that,O
act,O
on,O
the,O
cholinergic,O
system,O
of,O
the,O
iris,O
has,O
been,O
used,O
to,O
predict,O
deficits,O
in,O
central,O
cholinergic,O
functioning,O
due,O
to,O
diseases,O
such,O
as,O
Alzheimer,Entity
's,Entity
disease,Entity
",",O
yet,O
correlations,O
between,O
central,O
and,O
peripheral,O
responses,O
have,O
not,O
been,O
properly,O
studied,O
.,O
infusion,O
of,O
ketamine,Entity
(,O
bolus,O
0.1,O
mg,O
kg-1,O
over,O
10,O
min,O
followed,O
by,O
infusion,O
of,O
7,O
micrograms,O
kg-1,O
A,O
61-year,O
-,O
old,O
Japanese,O
man,O
with,O
nephrotic,Entity
syndrome,Entity
due,O
to,O
focal,Entity
segmental,Entity
glomerulosclerosis,Entity
was,O
initially,O
responding,O
well,O
to,O
steroid,Entity
therapy,O
.,O
Atrial,Entity
fibrillation,Entity
or,O
other,O
cardiac,Entity
arrhythmias,Entity
are,O
unusual,O
complications,O
in,O
patients,O
treated,O
with,O
chemotherapy,O
.,O
In,O
contrast,O
",",O
eucalcemic,O
patients,O
exhibited,O
no,O
change,O
in,O
mean,O
calcium,Entity
values,O
over,O
the,O
same,O
time,O
period,O
(,O
2.3,O
+,O
/-,O
Further,O
long,O
-,O
term,O
follow,O
-,O
up,O
studies,O
will,O
be,O
necessary,O
to,O
fully,O
evaluate,O
the,O
impact,O
of,O
dexamethasone,Entity
on,O
neurological,O
and,O
cognitive,O
development,O
.,O
Using,O
five,O
tagging,O
SNPs,O
(,O
rs6693503,O
",",O
rs1805054,O
",",O
rs4912138,O
",",O
rs3790757,O
and,O
rs9659997,O
),O
",",O
we,O
conducted,O
a,O
genetic,O
association,O
analysis,O
of,O
case,O
-,O
control,O
samples,O
(,O
197,O
METH,Entity
-,O
induced,O
psychosis,Entity
patients,O
and,O
337,O
controls,O
),O
in,O
the,O
Japanese,O
population,O
.,O
DISCUSSION,O
:,O
Cholestatic,Entity
hepatitis,Entity
is,O
a,O
rare,O
complication,O
of,O
the,O
antiplatelet,O
agent,O
ticlopidine,Entity
;,O
several,O
cases,O
have,O
been,O
reported,O
but,O
few,O
in,O
the,O
English,O
literature,O
.,O
Hepatotoxicity,Entity
associated,O
with,O
sulfasalazine,Entity
in,O
inflammatory,O
arthritis,Entity
:,O
We,O
report,O
our,O
results,O
with,O
magnetic,O
resonance,O
(,O
MR,O
),O
in,O
demonstrating,O
reversible,O
cerebral,Entity
abnormalities,Entity
concurrent,O
with,O
the,O
use,O
of,O
this,O
drug,O
.,O
Papillomas,Entity
of,O
the,O
transitional,O
epithelium,O
of,O
the,O
bladder,O
developed,O
in,O
all,O
paracetamol,Entity
-,O
treated,O
groups,O
",",O
and,O
three,O
rats,O
bore,O
bladder,Entity
carcinomas,Entity
.,O
OBJECTIVE,O
:,O
To,O
evaluate,O
the,O
efficacy,O
and,O
safety,O
of,O
lovastatin,Entity
in,O
women,O
with,O
moderate,O
hypercholesterolemia,Entity
.,O
In,O
four,O
patients,O
",",O
polymorphous,O
ventricular,Entity
tachycardia,Entity
appeared,O
after,O
intravenous,O
administration,O
of,O
200,O
to,O
400,O
mg,O
of,O
procainamide,Entity
for,O
the,O
treatment,O
of,O
sustained,O
ventricular,Entity
tachycardia,Entity
.,O
Other,O
known,O
reasons,O
for,O
seizures,Entity
were,O
ruled,O
out,O
and,O
the,O
convulsions,Entity
stopped,O
a,O
few,O
hours,O
after,O
cessation,O
of,O
morphine,Entity
and,O
did,O
not,O
reoccur,O
in,O
the,O
subsequent,O
8,O
months,O
.,O
NX+HP,O
caused,O
a,O
further,O
rise,O
in,O
blood,O
pressure,O
in,O
Li,Entity
-,O
pretreated,O
rats,O
.,O
The,O
risk,O
of,O
VNR,Entity
cardiac,O
events,O
was,O
similar,O
to,O
vindesine,Entity
(,O
VDS,Entity
),O
and,O
other,O
cardiotoxic,Entity
drugs,O
[,O
fluorouracil,Entity
",",O
anthracyclines,Entity
",",O
gemcitabine,Entity
(,O
GEM,Entity
),O
em,O
leader,O
],O
.,O
Neuroprotective,O
effects,O
of,O
melatonin,Entity
upon,O
the,O
offspring,O
cerebellar,O
cortex,O
in,O
the,O
rat,O
model,O
of,O
BCNU,Entity
-,O
induced,O
cortical,Entity
dysplasia,Entity
.,O
Neuropeptide,O
-,O
Y,O
immunoreactivity,O
in,O
the,O
pilocarpine,Entity
model,O
of,O
temporal,Entity
lobe,Entity
epilepsy,Entity
.,O
Angiotensin,O
-,O
converting,O
enzyme,O
(,O
ACE,O
),O
inhibitor,O
-,O
associated,O
angioedema,Entity
of,O
the,O
stomach,O
and,O
small,O
intestine,O
:,O
a,O
case,O
report,O
.,O
The,O
mechanism,O
responsible,O
for,O
this,O
effect,O
is,O
unclear,O
and,O
paradoxical,O
",",O
considering,O
the,O
current,O
evidence,O
of,O
a,O
pulmonary,Entity
hypertension,Entity
protective,O
fluoxetine,Entity
effect,O
in,O
adult,O
rodents,O
.,O
"""""""""",O
Eyes,O
-,O
closed,O
"""""""""",O
hallucinatory,Entity
experiences,O
appear,O
to,O
be,O
an,O
unusual,O
feature,O
of,O
this,O
presentation,O
.,O
The,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
whether,O
tachyphylaxis,O
occurs,O
during,O
prolonged,O
treatment,O
with,O
high,O
dose,O
inhaled,O
salbutamol,Entity
.,O
Mild,O
hypoxia,Entity
(,O
SO2<90%,O
),O
was,O
the,O
most,O
common,O
event,O
(,O
11,O
patients,O
),O
;,O
3,O
patients,O
(,O
2%,O
),O
presented,O
transient,O
hypoxia,Entity
due,O
to,O
upper,O
airway,Entity
obstruction,Entity
by,O
probe,O
introduction,O
and,O
8,O
(,O
5.8%,O
),O
due,O
to,O
hypoxia,Entity
caused,O
by,O
MZ,Entity
use,O
.,O
In,O
contrast,O
",",O
reports,O
of,O
myocardial,Entity
dysfunction,Entity
due,O
to,O
acute,O
iatrogenic,O
overdose,Entity
are,O
rare,O
.,O
Contribution,O
of,O
sodium,Entity
valproate,Entity
to,O
the,O
syndrome,Entity
of,Entity
inappropriate,Entity
secretion,Entity
of,Entity
antidiuretic,Entity
hormone,Entity
.,O
A,O
case,O
of,O
polymyositis,Entity
in,O
a,O
patient,O
with,O
primary,Entity
biliary,Entity
cirrhosis,Entity
treated,O
with,O
D,Entity
-,Entity
penicillamine,Entity
.,O
Lenalidomide,Entity
and,O
dexamethasone,Entity
(,O
RD,Entity
),O
is,O
a,O
standard,O
of,O
care,O
for,O
relapsed,O
/,O
refractory,O
multiple,Entity
myeloma,Entity
(,O
RRMM,Entity
),O
",",O
but,O
there,O
is,O
limited,O
published,O
data,O
on,O
its,O
efficacy,O
and,O
safety,O
in,O
the,O
"""""""""",O
real,O
world,O
"""""""""",O
(,O
RW,O
),O
",",O
according,O
to,O
the,O
International,O
Society,O
of,O
Pharmacoeconomics,O
and,O
Outcomes,O
Research,O
definition,O
.,O
Infarcts,Entity
in,Entity
substantia,Entity
nigra,Entity
pars,Entity
reticulata,Entity
were,O
evoked,O
by,O
prolonged,O
pilocarpine,Entity
-,O
induced,O
status,Entity
epilepticus,Entity
.,O
Acute,Entity
renal,Entity
failure,Entity
in,O
patients,O
with,O
AIDS,Entity
on,O
tenofovir,Entity
while,O
receiving,O
prolonged,O
vancomycin,Entity
course,O
for,O
osteomyelitis,Entity
.,O
In,O
contrast,O
",",O
the,O
fear,O
-,O
potentiated,O
startle,Entity
(,O
FPS,O
),O
is,O
suggested,O
to,O
model,O
conditioned,O
fear,O
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
assess,O
minor,O
neurological,Entity
dysfunction,Entity
",",O
cognitive,O
development,O
",",O
and,O
somatic,O
development,O
after,O
dexamethasone,Entity
therapy,O
in,O
very,O
-,O
low,O
-,O
birthweight,O
infants,O
.,O
Angina,Entity
and,O
ischemic,O
electrocardiographic,O
changes,O
occurred,O
after,O
administration,O
of,O
oral,O
dipyridamole,Entity
in,O
four,O
patients,O
awaiting,O
urgent,O
myocardial,O
revascularization,O
procedures,O
.,O
Neither,O
dose,O
of,O
pentoxifylline,Entity
significantly,O
decreased,O
the,O
dipyridamole,Entity
-,O
induced,O
hyperemia,Entity
",",O
while,O
peak,O
coronary,O
blood,O
flow,O
was,O
significantly,O
lower,O
after,O
theophylline,Entity
(,O
p,O
less,O
than,O
0.01,O
),O
.,O
None,O
of,O
the,O
cows,O
treated,O
with,O
vitamin,Entity
D3,Entity
showed,O
signs,O
of,O
milk,Entity
fever,Entity
during,O
the,O
peripartal,O
period,O
;,O
however,O
",",O
22%,O
of,O
the,O
control,O
cows,O
developed,O
clinical,O
signs,O
of,O
milk,Entity
fever,Entity
during,O
this,O
period,O
.,O
The,O
first,O
group,O
of,O
patients,O
was,O
administered,O
isotonic,O
sodium,Entity
chloride,Entity
;,O
the,O
second,O
group,O
was,O
administered,O
a,O
solution,O
that,O
of,O
5%,O
dextrose,Entity
and,O
sodium,Entity
bicarbonate,Entity
",",O
while,O
the,O
third,O
group,O
was,O
administered,O
isotonic,O
sodium,Entity
chloride,Entity
before,O
and,O
after,O
the,O
contrast,Entity
injection,O
.,O
injection,O
of,O
cisplatin,Entity
(,O
5,O
mg,O
/,O
kg,O
),O
.,O
Our,O
study,O
group,O
consisted,O
of,O
74,O
HIV,O
-,O
positive,O
homosexual,O
men,O
belonging,O
to,O
groups,O
II,O
B,O
",",O
III,O
and,O
IV,O
C2,O
from,O
the,O
Centers,O
for,O
Disease,O
Control,O
(,O
CDC,O
),O
classification,O
of,O
HIV,Entity
disease,Entity
.,O
Thirty,O
-,O
six,O
patients,O
were,O
treated,O
with,O
BCNU,Entity
every,O
6,O
to,O
8,O
weeks,O
",",O
either,O
by,O
transfemoral,O
catheterization,O
of,O
the,O
internal,O
carotid,O
or,O
vertebral,O
artery,O
or,O
through,O
a,O
fully,O
implantable,O
intracarotid,O
drug,O
delivery,O
system,O
",",O
beginning,O
with,O
a,O
dose,O
of,O
200,O
mg,O
/,O
sq,O
m,O
body,O
surface,O
area,O
.,O
All,O
patients,O
with,O
a,O
diagnosed,O
cerebral,Entity
haemorrhage,Entity
at,O
three,O
hospitals,O
during,O
the,O
period,O
2000,O
-,O
2002,O
were,O
identified,O
.,O
The,O
fourth,O
patient,O
who,O
was,O
unconscious,O
after,O
chlormethiazole,Entity
administration,O
exhibite,O
generalized,O
non,O
-,O
reactive,O
activity,O
in,O
the,O
slow,O
beta,O
range,O
.,O
Acute,Entity
renal,Entity
failure,Entity
occurring,O
during,O
intravenous,O
desferrioxamine,Entity
therapy,O
:,O
recovery,O
after,O
haemodialysis,O
.,O
The,O
progressive,O
nature,O
of,O
mitochondrial,Entity
injury,Entity
suggests,O
that,O
mitochondria,O
",",O
not,O
other,O
subcellular,O
organelles,O
",",O
are,O
the,O
major,O
site,O
of,O
intracellular,O
injury,O
.,O
To,O
avoid,O
disastrous,O
outcomes,O
",",O
physicians,O
must,O
consider,O
heparin,Entity
-,O
induced,O
thrombocytopenia,Entity
whenever,O
a,O
recently,O
hospitalized,O
patient,O
returns,O
with,O
thromboembolism,Entity
;,O
therapy,O
with,O
alternative,O
anticoagulants,O
",",O
not,O
heparin,Entity
",",O
should,O
be,O
initiated,O
.,O
Most,O
patients,O
showed,O
moderate,O
to,O
severe,O
acute,Entity
hepatitis,Entity
or,O
chronic,Entity
active,Entity
hepatitis,Entity
with,O
associated,O
cholestasis,Entity
.,O
A,O
challenge,O
dose,O
of,O
quinidine,Entity
caused,O
clinical,O
symptoms,O
and,O
abrupt,O
elevation,O
of,O
SGOT,O
",",O
alkaline,O
phosphatase,O
",",O
and,O
lactic,Entity
acid,Entity
dehydrogenase,O
values,O
.,O
A,O
typical,O
multisystem,O
clinical,O
pattern,O
precedes,O
the,O
manifestations,O
of,O
hepatic,Entity
injury,Entity
.,O
The,O
present,O
results,O
may,O
suggest,O
that,O
the,O
blockade,O
of,O
striatal,O
mGluR1,O
",",O
but,O
not,O
the,O
stimulation,O
of,O
group,O
II,O
mGluRs,O
",",O
may,O
ameliorate,O
parkinsonian,Entity
muscle,Entity
rigidity,Entity
.,O
An,O
experimental,O
group,O
of,O
rats,O
was,O
treated,O
with,O
puromycin,Entity
aminonucleoside,Entity
(,O
PAN,Entity
;,O
180,O
mg,O
/,O
kg,O
iv,O
),O
",",O
whereas,O
the,O
control,O
group,O
received,O
only,O
vehicle,O
.,O
High,O
-,O
dose,O
methotrexate,Entity
(,O
HD,O
-,O
MTX,Entity
),O
is,O
an,O
important,O
treatment,O
for,O
Burkitt,Entity
lymphoma,Entity
",",O
but,O
can,O
cause,O
hepatic,Entity
and,Entity
renal,Entity
toxicity,Entity
when,O
its,O
clearance,O
is,O
delayed,O
.,O
Serotonergic,O
drugs,O
",",O
benzodiazepines,Entity
and,O
baclofen,Entity
block,O
muscimol,Entity
-,O
induced,O
myoclonic,Entity
jerks,Entity
in,O
a,O
strain,O
of,O
mice,O
.,O
In,O
contrast,O
to,O
the,O
systemic,O
renin,O
-,O
angiotensin,Entity
system,O
",",O
which,O
is,O
suppressed,O
in,O
response,O
to,O
HS,O
in,O
male,O
DS,O
",",O
intrarenal,O
angiotensinogen,O
expression,O
is,O
increased,O
",",O
and,O
intrarenal,O
levels,O
of,O
ANG,O
II,O
are,O
not,O
suppressed,O
.,O
MATERIAL,O
AND,O
METHOD,O
:,O
Thirty,O
women,O
(,O
aged,O
30,O
-,O
77,O
years,O
),O
diagnosed,O
as,O
having,O
OAB,Entity
at,O
the,O
Gynecology,O
Clinic,O
",",O
King,O
Chulalongkorn,O
Memorial,O
Hospital,O
from,O
January,O
to,O
April,O
2004,O
were,O
included,O
in,O
the,O
present,O
study,O
.,O
Adult,O
male,O
albino,O
rats,O
",",O
treated,O
with,O
ISO,Entity
(,O
200,O
mg,O
/,O
kg,O
",",O
s.c,O
.,O
),O
for,O
2,O
days,O
at,O
an,O
interval,O
of,O
24,O
h,O
caused,O
a,O
significant,O
(,O
P<0.05,O
),O
elevation,O
of,O
heart,O
weight,O
",",O
serum,O
marker,O
enzymes,O
",",O
lipid,O
peroxidation,O
and,O
Ca+2,Entity
ATPase,O
level,O
whereas,O
there,O
was,O
a,O
significant,O
(,O
P<0.05,O
),O
decrease,O
in,O
body,O
weight,O
",",O
endogenous,O
antioxidants,O
",",O
Na+/,Entity
K+,Entity
ATPase,O
and,O
Mg+2,Entity
ATPase,O
levels,O
.,O
An,O
analysis,O
for,O
factor,O
V,O
Leiden,O
and,O
the,O
G20210A,O
mutation,O
in,O
the,O
prothrombin,O
gene,O
was,O
conducted,O
in,O
217,O
patients,O
and,O
763,O
controls,O
RESULTS,O
:,O
The,O
odds,O
ratio,O
for,O
myocardial,Entity
infarction,Entity
among,O
women,O
who,O
used,O
any,O
type,O
of,O
combined,O
oral,Entity
contraceptive,Entity
",",O
as,O
compared,O
with,O
nonusers,O
",",O
was,O
2.0,O
(,O
95,O
percent,O
confidence,O
interval,O
",",O
1.5,O
to,O
2.8,O
),O
.,O
The,O
diagnosis,O
of,O
propylthiouracil,Entity
(,O
PTU)-associated,Entity
vasculitis,Entity
was,O
made,O
by,O
observation,O
of,O
consistent,O
clinical,O
features,O
",",O
the,O
detection,O
of,O
elevated,O
ANA,O
and,O
ANCA,O
in,O
the,O
blood,O
",",O
and,O
the,O
observed,O
clinical,O
resolution,O
of,O
symptoms,O
following,O
withdrawal,O
of,O
PTU,Entity
.,O
A,O
series,O
of,O
agents,O
acting,O
primarily,O
on,O
neurotransmitters,O
other,O
than,O
dopamine,Entity
were,O
then,O
tested,O
in,O
combination,O
with,O
L,Entity
-,Entity
DOPA,Entity
to,O
see,O
if,O
the,O
dyskinetic,Entity
movements,O
would,O
be,O
modified,O
.,O
We,O
found,O
that,O
maltolyl,Entity
p,Entity
-,Entity
coumarate,Entity
significantly,O
decreased,O
apoptotic,O
cell,O
death,O
and,O
reduced,O
reactive,O
oxygen,O
species,O
",",O
cytochrome,O
c,O
release,O
",",O
and,O
caspase,O
3,O
activation,O
.,O
All,O
five,O
patients,O
experienced,O
symptoms,O
of,O
encephalopathy,Entity
soon,O
after,O
(,O
within,O
12,O
h-2,O
days,O
),O
receiving,O
ifosfamide,Entity
.,O
Serum,O
samples,O
from,O
the,O
first,O
and,O
second,O
days,O
contained,O
3.6,O
and,O
1.9,O
mg,O
/,O
l,O
carbachol,Entity
",",O
respectively,O
.,O
Using,O
the,O
Naranjo,O
adverse,O
effect,O
reaction,O
probability,O
scale,O
this,O
event,O
could,O
be,O
classified,O
as,O
possible,O
(,O
score,O
5,O
points,O
),O
",",O
mostly,O
because,O
of,O
the,O
close,O
temporal,O
sequence,O
",",O
previous,O
reports,O
on,O
this,O
reaction,O
with,O
other,O
macrolides,Entity
and,O
the,O
absence,O
of,O
any,O
alternative,O
explanation,O
for,O
hiccups,Entity
.,O
The,O
difference,O
in,O
the,O
percentage,O
of,O
patients,O
with,O
a,O
50%,O
reduction,O
in,O
their,O
nausea,Entity
was,O
12.6%,O
(,O
95%,O
CI,O
-4.6%,O
to,O
29.8%,O
),O
.,O
OBJECTIVE,O
:,O
To,O
determine,O
the,O
maximum,O
tolerated,O
dose,O
(,O
MTD,O
),O
of,O
carbetocin,Entity
(,O
a,O
long,O
-,O
acting,O
synthetic,O
analogue,O
of,O
oxytocin,Entity
),O
",",O
when,O
administered,O
immediately,O
after,O
vaginal,O
delivery,O
at,O
term,O
.,O
Total,O
cumulative,O
doses,O
were,O
36,O
or,O
60,O
g,O
/,O
m2,O
of,O
ifosfamide,Entity
(,O
six,O
or,O
10,O
cycles,O
of,O
ifosfamide,Entity
",",Entity
vincristine,Entity
",",Entity
and,Entity
dactinomycin,Entity
[,O
IVA,Entity
],O
),O
.,O
HVA,O
levels,O
were,O
related,O
to,O
global,O
hyperkinesia,Entity
but,O
not,O
to,O
psychopathology,O
ratings,O
.,O
After,O
starting,O
PGE1,Entity
or,O
TMP,Entity
",",O
MAP,O
and,O
rate,O
pressure,O
product,O
(,O
RPP,O
),O
decreased,O
significantly,O
compared,O
with,O
preinfusion,O
values,O
OBJECTIVES,O
:,O
To,O
evaluate,O
the,O
effect,O
of,O
trazodone,Entity
treatment,O
on,O
behaviors,O
dependent,O
on,O
the,O
functional,O
status,O
of,O
the,O
nigrostriatal,O
DAergic,O
system,O
.,O
Each,O
patient,O
was,O
subjected,O
to,O
an,O
identical,O
anesthetic,O
protocol,O
and,O
similar,O
drug,O
-,O
induced,O
reductions,Entity
in,Entity
mean,Entity
arterial,Entity
blood,Entity
pressure,Entity
(,O
BP,O
),O
(,O
50,O
to,O
55,O
mmHg,O
),O
.,O
Serum,O
alpha,O
-,O
GST,O
levels,O
were,O
significantly,O
elevated,O
by,O
day,O
4,O
",",O
which,O
corresponded,O
to,O
hepatotoxicity,Entity
as,O
shown,O
by,O
the,O
increasing,O
incidence,O
of,O
inflammation,Entity
of,O
the,O
liver,O
capsule,O
",",O
necrosis,Entity
",",O
and,O
steatosis,Entity
throughout,O
the,O
study,O
.,O
Pentazocine,Entity
dose,O
-,O
dependently,O
decreased,O
the,O
brain,O
level,O
of,O
NA,Entity
.,O
In,O
the,O
case,O
-,O
control,O
study,O
",",O
we,O
matched,O
cases,O
to,O
controls,O
by,O
exact,O
year,O
of,O
birth,O
",",O
practice,O
",",O
and,O
current,O
use,O
of,O
OCs,Entity
.,O
The,O
association,O
of,O
the,O
tumor,Entity
with,O
preexisting,O
hydroureteronephrosis,Entity
suggests,O
that,O
stasis,O
prolonged,O
and,O
intensified,O
exposure,O
of,O
upper,O
urinary,O
tract,O
epithelium,O
to,O
cyclophosphamide,Entity
.,O
When,O
these,O
proceeded,O
to,O
tonic,Entity
seizures,Entity
",",O
death,O
occurred,O
in,O
less,O
than,O
20,O
min,O
.,O
Effects,O
of,O
suprofen,Entity
on,O
the,O
isolated,O
perfused,O
rat,O
kidney,O
.,O
The,O
use,O
of,O
adriamycin,Entity
(,O
ADR,Entity
),O
in,O
cancer,Entity
chemotherapy,O
has,O
been,O
limited,O
due,O
to,O
its,O
cumulative,O
cardiovascular,Entity
toxicity,Entity
.,O
Myocardial,O
calcium,Entity
concentrations,O
also,O
were,O
decreased,O
(,O
11.2,O
",",O
8.3,O
",",O
and,O
8.9,O
mg,O
.,O
The,O
results,O
showed,O
that,O
rats,O
treated,O
with,O
Morphine,Entity
/,O
Rg1,Entity
decreased,O
escape,O
latency,O
and,O
increased,O
the,O
time,O
spent,O
in,O
platform,O
quadrant,O
and,O
entering,O
frequency,O
.,O
Population,O
-,O
based,O
",",O
multisite,O
",",O
case,O
-,O
control,O
study,O
of,O
women,O
who,O
had,O
pregnancies,O
affected,O
by,O
1,O
of,O
more,O
than,O
30,O
eligible,O
major,O
birth,Entity
defects,Entity
identified,O
via,O
birth,Entity
defect,Entity
surveillance,O
programs,O
in,O
10,O
states,O
(,O
n,O
=,O
13,O
155,O
),O
and,O
control,O
women,O
randomly,O
selected,O
from,O
the,O
same,O
geographical,O
regions,O
(,O
n,O
=,O
4941,O
),O
.,O
atropine,Entity
(,O
3,O
mug,O
),O
or,O
hexamethonium,Entity
(,O
500,O
mug,O
),O
",",O
and,O
significantly,O
reduced,O
by,O
i.c,O
.,O
However,O
",",O
adverse,O
effects,O
include,O
cardiac,Entity
toxicity,Entity
.,O
Oral,O
rehabilitation,O
of,O
patients,O
using,O
methamphetamine,Entity
can,O
be,O
challenging,O
.,O
We,O
describe,O
the,O
clinical,O
course,O
and,O
pathological,O
findings,O
in,O
a,O
65,O
yr,O
-,O
old,O
man,O
with,O
gastric,Entity
adenocarcinoma,Entity
who,O
developed,O
renal,Entity
failure,Entity
and,O
thrombocytopenia,Entity
while,O
on,O
treatment,O
with,O
mitomycin,Entity
C,Entity
and,O
died,O
in,O
pulmonary,Entity
edema,Entity
.,O
There,O
was,O
a,O
smaller,O
excess,O
of,O
MB,Entity
in,O
antiplatelet,O
users,O
vs,O
nonusers,O
with,O
ICH,Entity
(,O
OR,O
",",O
1.7,O
;,O
95%,O
CI,O
",",O
1.3,O
-,O
2.3,O
;,O
P<0.001,O
),O
",",O
but,O
findings,O
were,O
similar,O
for,O
antiplatelet,O
users,O
with,O
IS,Entity
/,O
TIA,Entity
(,O
OR,O
",",O
1.4,O
;,O
95%,O
CI,O
",",O
1.2,O
-,O
1.7,O
;,O
P<0.001,O
;,O
P,O
difference=0.25,O
),O
.,O
The,O
results,O
showed,O
a,O
significant,O
increase,O
in,O
escape,O
latencies,O
and,O
traveled,O
distances,O
to,O
find,O
platform,O
in,O
scopolamine,Entity
-,O
treated,O
group,O
as,O
compared,O
to,O
saline,O
group,O
.,O
Choreatiform,Entity
hyperkinesias,Entity
are,O
known,O
to,O
be,O
occasional,O
movement,Entity
abnormalities,Entity
during,O
intoxications,O
with,O
cocaine,Entity
but,O
not,O
opiates,O
.,O
15,O
min,O
in,O
the,O
isoflurane,Entity
(,O
I,Entity
),O
group,O
.,O
She,O
developed,O
status,Entity
epilepticus,Entity
and,O
later,O
symptoms,O
of,O
systemic,Entity
lupus,Entity
erythematodes,Entity
.,O
Rats,O
were,O
treated,O
with,O
a,O
single,O
IV,O
injection,O
of,O
puromycin,Entity
aminonucleoside,Entity
",",O
(,O
PAN,Entity
",",O
7.5,O
mg,O
/,O
kg,O
),O
and,O
24,O
hour,O
urine,O
samples,O
were,O
obtained,O
prior,O
to,O
sacrifice,O
on,O
days,O
"3,5,7,10,17,27,41",O
(,O
N,O
=,O
5,O
-,O
10,O
per,O
group,O
),O
.,O
They,O
also,O
had,O
significantly,O
higher,O
levels,O
of,O
proteinuria,Entity
compared,O
with,O
control,O
and,O
treatment,O
groups,O
(,O
P,O
<,O
0.05,O
),O
.,O
Three,O
groups,O
were,O
established,O
:,O
a,O
control,O
group,O
(,O
n,O
=,O
10,O
),O
",",O
a,O
high,O
-,O
dose,O
group,O
(,O
n,O
=,O
10,O
),O
",",O
treated,O
with,O
one,O
intraperitoneal,O
injection,O
of,O
indomethacin,Entity
20,O
mg,O
/,O
kg,O
",",O
and,O
a,O
therapeutic,O
dose,O
group,O
(,O
n,O
=,O
10,O
),O
in,O
which,O
oral,O
indomethacin,Entity
was,O
administered,O
3.25,O
mg,O
/,O
kg,O
body,O
weight,O
daily,O
for,O
3,O
weeks,O
.,O
In,O
our,O
patient,O
",",O
transient,O
cardiac,Entity
arrhythmia,Entity
or,O
respiratory,Entity
dysfunction,Entity
related,O
to,O
cocaine,Entity
and/or,O
ethanol,Entity
use,O
were,O
the,O
most,O
likely,O
causes,O
of,O
cerebral,Entity
hypoperfusion,Entity
.,O
After,O
pretreatment,O
with,O
3,O
mg,O
of,O
cyproheptadine,Entity
",",O
2,O
mg,O
mianserin,Entity
",",O
or,O
2,O
mg,O
chlorpheniramine,Entity
",",O
only,O
5,O
of,O
105,O
animals,O
(,O
5%,O
),O
died,O
after,O
receiving,O
BSA,O
on,O
day,O
+,O
7,O
(,O
p,O
less,O
than,O
0.001,O
),O
.,O
However,O
",",O
prolonged,O
stimulation,O
(,O
8,O
-,O
12,O
days,O
),O
appears,O
to,O
represent,O
a,O
complex,O
integration,O
of,O
both,O
cellular,O
hypertrophy,Entity
and,O
hyperplasia,Entity
within,O
the,O
heart,O
.,O
brain,O
scans,O
demonstrated,O
stability,O
in,O
tumor,Entity
size,O
and,O
peritumor,O
edema,Entity
when,O
compared,O
with,O
pretransplant,O
scans,O
.,O
Sixty,O
-,O
seven,O
of,O
926,O
patients,O
(,O
7.2%,O
),O
required,O
discontinuation,O
of,O
spironolactone,Entity
due,O
to,O
hyperkalemia,Entity
(,O
n,O
=,O
33,O
),O
or,O
renal,Entity
failure,Entity
(,O
n,O
=,O
34,O
),O
.,O
Heparan,Entity
sulphate,Entity
-,O
associated,O
anionic,O
sites,O
in,O
the,O
glomerular,O
basement,O
membrane,O
were,O
studied,O
in,O
rats,O
8,O
months,O
after,O
induction,O
of,O
diabetes,Entity
by,O
streptozotocin,Entity
and,O
in,O
age-,O
adn,O
sex,O
-,O
matched,O
control,O
rats,O
",",O
employing,O
the,O
cationic,O
dye,O
cuprolinic,Entity
blue,Entity
.,O
THP,Entity
exhibited,O
an,O
antipsychotic,O
-,O
like,O
profile,O
by,O
potentiating,O
haloperidol,Entity
-,O
induced,O
catalepsy,Entity
",",O
reducing,O
amphetamine,Entity
-,O
induced,O
hyperactivity,Entity
and,O
reducing,O
apomorphine,Entity
-,O
induced,O
climbing,O
in,O
mice,O
.,O
We,O
conclude,O
that,O
in,O
patients,O
with,O
chronic,O
coronary,Entity
artery,Entity
disease,Entity
who,O
are,O
not,O
in,O
clinical,O
congestive,Entity
heart,Entity
failure,Entity
left,Entity
ventricular,Entity
end,Entity
-,Entity
diastolic,Entity
volume,Entity
falls,Entity
after,O
ouabain,Entity
administration,O
even,O
when,O
it,O
is,O
initially,O
normal,O
.,O
Five,O
PMs,O
were,O
studied,O
according,O
to,O
the,O
same,O
protocol,O
",",O
except,O
for,O
a,O
higher,O
terbutaline,Entity
dose,O
(,O
0.75,O
mg,O
),O
on,O
day,O
2,O
.,O
Indeed,O
",",O
the,O
incidence,O
of,O
liver,O
transplantation,O
and,O
death,O
in,O
this,O
group,O
was,O
11.7%,O
if,O
patients,O
had,O
jaundice,Entity
at,O
presentation,O
",",O
whereas,O
the,O
corresponding,O
figure,O
was,O
3.8%,O
in,O
nonjaundiced,O
patients,O
(,O
P,O
<,O
.04,O
),O
.,O
No,O
dogs,O
had,O
evidence,O
of,O
either,O
renal,Entity
toxicity,Entity
or,O
hemorrhagic,Entity
cystitis,Entity
.,O
0.3,O
minutes,O
per,O
patient,O
per,O
hour,O
before,O
5-FU,Entity
v,O
1.9,O
+,O
/-,O
The,O
medical,O
records,O
of,O
6,O
men,O
and,O
6,O
women,O
(,O
mean,O
age,O
55,O
years,O
),O
with,O
cyclophosphamide,Entity
associated,O
bladder,Entity
cancer,Entity
were,O
reviewed,O
.,O
A,O
significant,O
rise,O
in,O
cTnT,O
was,O
found,O
in,O
DOX,Entity
rats,O
after,O
cumulative,O
doses,O
of,O
7.5,O
and,O
12,O
mg,O
/,O
kg,O
in,O
comparison,O
with,O
baseline,O
(,O
p<0.05,O
),O
.,O
Two,O
children,O
with,O
Wilms,Entity
tumor,Entity
of,O
the,O
left,O
kidney,O
experienced,O
severe,O
anthracycline,Entity
cardiomyopathy,Entity
after,O
irradiation,O
to,O
the,O
tumor,Entity
bed,O
and,O
conventional,O
dosage,O
of,O
doxorubicin,Entity
.,O
These,O
results,O
do,O
not,O
confirm,O
or,O
exclude,O
a,O
neuroprotective,O
property,O
of,O
nimodipine,Entity
.,O
Fatal,O
myeloencephalopathy,Entity
due,O
to,O
intrathecal,O
vincristine,Entity
administration,O
.,O
CVD,Entity
?,O
BACKGROUND,O
:,O
Treatment,O
with,O
angiotensin,Entity
-,Entity
converting,Entity
enzyme,Entity
(,Entity
ACE,Entity
),Entity
inhibitors,Entity
reduces,O
mortality,O
and,O
morbidity,O
in,O
patients,O
with,O
chronic,O
heart,Entity
failure,Entity
(,O
CHF,Entity
),O
",",O
but,O
most,O
affected,O
patients,O
are,O
not,O
receiving,O
these,O
agents,O
or,O
are,O
being,O
treated,O
with,O
doses,O
lower,O
than,O
those,O
found,O
to,O
be,O
efficacious,O
in,O
trials,O
",",O
primarily,O
because,O
of,O
concerns,O
about,O
the,O
safety,O
and,O
tolerability,O
of,O
these,O
agents,O
",",O
especially,O
at,O
the,O
recommended,O
doses,O
.,O
The,O
incidence,O
of,O
discontinuations,O
for,O
hypertension,Entity
-,O
related,O
and,O
oedema,Entity
-,O
related,O
AEs,O
were,O
significantly,O
higher,O
with,O
etoricoxib,Entity
(,O
2.5%,O
and,O
1.1%,O
respectively,O
),O
compared,O
with,O
diclofenac,Entity
(,O
1.5%,O
and,O
0.4%,O
respectively,O
;,O
p<0.001,O
for,O
hypertension,Entity
and,O
p<0.01,O
for,O
oedema,Entity
),O
.,O
Lithium,Entity
remains,O
a,O
first,O
-,O
line,O
treatment,O
for,O
the,O
acute,O
and,O
maintenance,O
treatment,O
of,O
bipolar,Entity
disorder,Entity
.,O
We,O
conclude,O
that,O
previously,O
reported,O
hypoglycemia,Entity
",",O
hyperbilirubinemia,Entity
",",O
polycythemia,Entity
",",O
neonatal,Entity
apnea,Entity
",",O
and,O
bradycardia,Entity
are,O
not,O
invariable,O
and,O
can,O
not,O
be,O
statistically,O
correlated,O
with,O
chronic,O
propranolol,Entity
therapy,O
.,O
The,O
animal,O
model,O
used,O
to,O
produce,O
infarction,Entity
implies,O
artery,O
ligation,O
but,O
chemical,O
induction,O
can,O
be,O
easily,O
obtained,O
with,O
isoproterenol,Entity
.,O
:,O
We,O
suggest,O
that,O
the,O
increased,O
risk,O
of,O
venous,Entity
thromboembolism,Entity
due,O
to,O
raloxifene,Entity
treatment,O
may,O
be,O
related,O
to,O
increased,O
tPA,O
levels,O
",",O
but,O
not,O
TAFI,O
levels,O
.,O
VNB,Entity
was,O
well,O
tolerated,O
and,O
zero,O
instances,O
of,O
WHO,O
grade,O
4,O
nonhematologic,O
toxicity,Entity
occurred,O
.,O
Massive,O
proteinuria,Entity
and,O
acute,Entity
renal,Entity
failure,Entity
after,O
oral,O
bisphosphonate,Entity
(,O
alendronate,Entity
),O
administration,O
in,O
a,O
patient,O
with,O
focal,Entity
segmental,Entity
glomerulosclerosis,Entity
.,O
Of,O
388,O
liver,O
recipients,O
who,O
received,O
tacrolimus,Entity
as,O
primary,O
immunosuppression,O
",",O
70,O
required,O
conversion,O
to,O
CyA.,O
We,O
recorded,O
indication,O
for,O
conversion,O
",",O
whether,O
conversion,O
was,O
early,O
or,O
late,O
after,O
transplantation,O
",",O
tacrolimus,Entity
dose,O
and,O
trough,O
blood,O
level,O
at,O
conversion,O
",",O
and,O
incidence,O
of,O
rejection,O
after,O
conversion,O
.,O
induced,O
catalepsy,Entity
and,O
antagonized,O
apomorphine,Entity
and,O
dexamphetamine,Entity
stereotypies,O
.,O
We,O
think,O
that,O
even,O
these,O
lower,O
dosages,O
of,O
cyclosporine,Entity
can,O
cause,O
chronic,O
nephrotoxicity,Entity
and,O
that,O
further,O
modification,O
of,O
the,O
immunosuppressive,O
regimen,O
is,O
required,O
to,O
completely,O
abolish,O
this,O
toxic,O
side,O
effect,O
.,O
Two,O
samples,O
were,O
studied,O
:,O
12,O
patients,O
received,O
oxitropium,Entity
at,O
600,O
micrograms,O
(,O
6,O
subjects,O
),O
or,O
at,O
400,O
micrograms,O
t.i.d,O
.,O
Antiarrhythmic,O
effects,O
of,O
(,O
+,O
),O
-cibenzoline,Entity
and,O
(,O
-)-cibenzoline,Entity
were,O
examined,O
using,O
two,O
canine,O
ventricular,Entity
arrhythmia,Entity
models,O
.,O
Spontaneous,O
respiration,O
recommenced,O
200,O
min,O
after,O
succinylcholine,Entity
administration,O
.,O
A,O
case,O
of,O
acute,O
myocarditis,Entity
associated,O
with,O
the,O
commencement,O
of,O
clozapine,Entity
is,O
described,O
",",O
highlighting,O
the,O
onset,O
",",O
course,O
and,O
possible,O
contributing,O
factors,O
.,O
MAP,O
",",O
stroke,Entity
volume,O
(,O
SV,O
),O
",",O
cardiac,O
output,O
(,O
CO,O
),O
",",O
and,O
frontal,O
lobe,O
oxygenation,O
(,O
S(c)O(2,O
),O
),O
were,O
registered,O
.,O
CONCLUSION,O
:,O
Our,O
data,O
suggest,O
that,O
Asian,O
patients,O
may,O
be,O
at,O
increased,O
risk,O
of,O
hyponatremia,Entity
and/or,O
SIADH,Entity
associated,O
with,O
vincristine,Entity
use,O
.,O
Oxacillin,Entity
was,O
discontinued,O
and,O
patient,O
was,O
treated,O
with,O
corticosteroids,Entity
.,O
Accordingly,O
",",O
the,O
fractional,O
excretion,O
of,O
sodium,Entity
increased,O
.,O
However,O
",",O
ranitidine,Entity
was,O
threefold,O
more,O
potent,O
than,O
cimetidine,Entity
both,O
in,O
acute,O
inhibition,O
studies,O
and,O
in,O
the,O
median,O
maintenance,O
dose,O
needed,O
(,O
1.2,O
g,O
per,O
day,O
for,O
ranitidine,Entity
and,O
3.6,O
g,O
per,O
day,O
for,O
cimetidine,Entity
),O
.,O
Enflurane,Entity
administration,O
resulted,O
in,O
neoantigens,O
detected,O
in,O
both,O
the,O
microsomal,O
and,O
cytosolic,O
fraction,O
of,O
liver,O
homogenates,O
and,O
in,O
the,O
centrilobular,O
region,O
of,O
the,O
liver,O
.,O
Unreported,O
in,O
the,O
literature,O
is,O
visual,Entity
hallucinations,Entity
occurring,O
in,O
association,O
with,O
the,O
new,O
macrolide,Entity
antibiotic,O
",",O
clarithromycin,Entity
.,O
Ten,O
patients,O
with,O
acute,O
transmural,O
myocardial,Entity
infarctions,Entity
received,O
intravenous,O
nitroglycerin,Entity
",",O
sufficient,O
to,O
reduce,O
mean,O
arterial,O
pressure,O
from,O
107,O
+,O
/-,O
The,O
male,O
Wistar,O
rats,O
consuming,O
a,O
diet,O
that,O
contained,O
LiCl,Entity
(,O
60,O
mmol,O
/,O
kg,O
),O
for,O
4,O
weeks,O
developed,O
marked,O
polyuria,Entity
.,O
Patients,O
that,O
received,O
Botox,Entity
injections,O
for,O
spasmodic,Entity
dysphonia,Entity
between,O
January,O
2000,O
and,O
October,O
2009,O
were,O
evaluated,O
.,O
Eight,O
received,O
insulin,O
alone,O
",",O
and,O
eight,O
",",O
including,O
two,O
of,O
the,O
original,O
insulin,O
-,O
only,O
group,O
",",O
were,O
given,O
propranolol,Entity
and,O
insulin,O
.,O
After,O
6,O
months,O
of,O
hyperprolactinemia,Entity
",",O
dopamine,Entity
(,O
DA,Entity
),O
concentrations,O
in,O
the,O
median,O
eminence,O
(,O
ME,O
),O
increased,O
by,O
84%,O
over,O
the,O
control,O
group,O
.,O
In,O
conclusion,O
",",O
the,O
combined,O
administration,O
of,O
BPT,Entity
/,O
CLZ,Entity
is,O
safe,O
at,O
doses,O
used,O
in,O
the,O
study,O
",",O
though,O
the,O
beneficial,O
clinical,O
effect,O
of,O
the,O
combined,O
administration,O
has,O
yet,O
to,O
be,O
elucidated,O
.,O
The,O
stereotypies,O
induced,O
by,O
d,Entity
-,Entity
amphetamine,Entity
or,O
apomorphine,Entity
are,O
not,O
potentiated,O
by,O
TRI,Entity
.,O
rhIGF,O
-,O
I,O
improved,O
weight,O
gain,O
by,O
14%,O
(,O
p,O
<,O
0.05,O
),O
",",O
without,O
altering,O
hematocrit,O
or,O
blood,O
pressure,O
in,O
rats,O
with,O
renal,Entity
disease,Entity
.,O
Physical,O
and,O
quantitative,O
sensory,O
examination,O
with,O
determination,O
of,O
vibratory,O
perception,O
and,O
thermal,O
discrimination,O
thresholds,O
were,O
performed,O
",",O
four,O
to,O
77,O
months,O
(,O
median,O
34,O
months,O
),O
after,O
vincristine,Entity
treatment,O
.,O
In,O
mice,O
rendered,O
anemic,Entity
and,O
leukopenic,Entity
by,O
the,O
administration,O
of,O
AZT,Entity
for,O
28,O
days,O
in,O
drinking,O
water,O
(,O
1.5,O
mg,O
/,O
mL,O
),O
",",O
the,O
continued,O
administration,O
of,O
AZT,Entity
plus,O
daily,O
BAU,Entity
(,O
300,O
mg,O
/,O
kg,O
",",O
orally,O
),O
partially,O
reversed,O
AZT,Entity
-,O
induced,O
anemia,Entity
and,O
leukopenia,Entity
(,O
P,O
less,O
than,O
.05,O
),O
",",O
increased,O
peripheral,O
reticulocytes,O
(,O
to,O
4.9%,O
",",O
P,O
less,O
than,O
.01,O
),O
",",O
increased,O
cellularity,O
in,O
the,O
marrow,O
",",O
and,O
improved,O
megaloblastosis,Entity
.,O
Swallowing,Entity
abnormalities,Entity
and,O
dyskinesia,Entity
in,O
Parkinson,Entity
's,Entity
disease,Entity
.,O
Our,O
findings,O
indicate,O
that,O
sustained,O
-,O
release,O
nifedipine,Entity
is,O
useful,O
for,O
hypertensive,Entity
psoriatic,Entity
patients,O
under,O
long,O
-,O
term,O
treatment,O
with,O
cyclosporin,Entity
A,Entity
",",O
but,O
that,O
these,O
patients,O
should,O
be,O
monitored,O
for,O
gingival,Entity
hyperplasia,Entity
.,O
CONCLUSIONS,O
:,O
We,O
conclude,O
that,O
pretreatment,O
with,O
fentanyl,Entity
or,O
combination,O
of,O
fentanyl,Entity
and,O
midazolam,Entity
was,O
effective,O
in,O
preventing,O
etomidate,Entity
-,O
induced,O
myoclonus,Entity
.,O
leukopenia,Entity
45.5/18.2/6.1,O
",",O
thrombocytopenia,Entity
33.3/9.1/6.1,O
",",O
vomitus,Entity
24.2/9.1/0,O
",",O
diarrhea,Entity
36.4/6.1/3.0,O
",",O
stomatitis,Entity
18.2/9.1/0,O
",",O
hand,Entity
-,Entity
foot,Entity
syndrome,Entity
12.1/0/0,O
.,O
Of,O
our,O
control,O
group,O
(,O
n=,O
50,O
),O
",",O
21,O
patients,O
(,O
42%,O
),O
were,O
established,O
hepatitis,Entity
.,O
-,O
inducible,O
kinase,O
SGK1,O
has,O
been,O
shown,O
to,O
participate,O
in,O
the,O
stimulation,O
of,O
ENaC,O
and,O
to,O
mediate,O
renal,O
fibrosis,Entity
following,O
mineralocorticoid,O
and,O
salt,O
excess,O
.,O
A,O
nonregenerative,O
anemia,Entity
was,O
the,O
most,O
compromising,O
of,O
the,O
cytopenias,Entity
and,O
occurred,O
in,O
approximately,O
50%,O
of,O
dogs,O
receiving,O
400,O
-,O
500,O
mg,O
/,O
kg,O
cefonicid,Entity
or,O
540,O
-,O
840,O
mg,O
The,O
patient,O
was,O
maintained,O
on,O
levothyroxine,Entity
175,O
(,O
g,O
POorally,O
daily,O
.,O
Sulfasalazine,Entity
-,O
induced,O
lupus,Entity
erythematosus,Entity
.,O
Mean,O
serum,O
potassium,Entity
level,O
fell,O
",",O
and,O
urea,Entity
and,O
uric,Entity
acid,Entity
levels,O
rose,O
",",O
in,O
men,O
and,O
women,O
taking,O
bendrofluazide,Entity
.,O
In,O
vitro,O
work,O
has,O
demonstrated,O
that,O
cinacalcet,Entity
is,O
a,O
strong,O
inhibitor,O
of,O
cytochrome,O
P450,O
isoenzyme,O
(,O
CYP,O
),O
2D6,O
.,O
Vinorelbine,Entity
-,O
related,O
cardiac,O
events,O
concern,O
about,O
1%,O
of,O
treated,O
patients,O
in,O
clinical,O
trials,O
.,O
Patients,O
who,O
are,O
more,O
than,O
10,O
years,O
post,O
-,O
OLTX,O
have,O
CRF,Entity
and,O
ESRD,Entity
at,O
a,O
high,O
rate,O
.,O
CCB,O
was,O
reduced,O
in,O
WKY,O
and,O
SHR,O
after,O
LV,O
administration,O
of,O
AVP,Entity
during,O
SN,Entity
-,O
induced,O
hypotension,Entity
.,O
In,O
this,O
report,O
",",O
we,O
describe,O
a,O
case,O
of,O
ciprofloxacin,Entity
-,O
induced,O
interstitial,Entity
nephritis,Entity
and,O
autoimmune,Entity
hemolytic,Entity
anemia,Entity
.,O
He,O
was,O
admitted,O
with,O
acute,O
myopathy,Entity
of,O
the,O
lower,O
limbs,O
which,O
resolved,O
in,O
a,O
few,O
days,O
after,O
pravastatin,Entity
discontinuation,O
.,O
Hyperbaric,O
oxygen,Entity
therapy,O
for,O
control,O
of,O
intractable,O
cyclophosphamide,Entity
-,O
induced,O
hemorrhagic,Entity
cystitis,Entity
.,O
In,O
fact,O
the,O
concentration,O
of,O
free,O
DPH,Entity
was,O
normal,O
",",O
the,O
patient,O
presented,O
a,O
retarded,O
morbilliform,O
rash,Entity
during,O
DPH,Entity
treatment,O
",",O
the,O
protidogram,O
was,O
normal,O
",",O
and,O
an,O
intradermic,O
DPH,Entity
injection,O
had,O
no,O
local,O
effect,O
.,O
The,O
ischemia,Entity
probably,O
induced,O
by,O
coronary,Entity
artery,Entity
spasm,Entity
was,O
reversed,O
by,O
nitroglycerin,Entity
and,O
calcium,Entity
blocking,O
agents,O
.,O
Since,O
glyceryl,Entity
trinitrate,Entity
is,O
able,O
to,O
overcome,O
even,O
the,O
drastic,O
effect,O
of,O
morphine,Entity
",",O
it,O
might,O
be,O
of,O
relevance,O
in,O
the,O
treatment,O
of,O
sphincter,Entity
of,Entity
Oddi,Entity
dyskinesia,Entity
.,O
Thus,O
",",O
temsirolimus,Entity
reduced,O
tumor,Entity
burden,O
through,O
associated,O
cytostatic,O
and,O
anti,O
-,O
angiogenic,O
effects,O
.,O
Seventy,O
-,O
one,O
participants,O
completed,O
2,O
separate,O
study,O
days,O
and,O
were,O
blind,O
to,O
medication,O
condition,O
(,O
placebo,O
",",O
10-mg,O
oxycodone,Entity
),O
.,O
Lidocaine,Entity
reduced,O
the,O
area,O
of,O
punctate,O
-,O
evoked,O
hyperalgesia,Entity
significantly,O
.,O
A,O
47-year,O
-,O
old,O
woman,O
presented,O
for,O
mastectomy,O
and,O
immediate,O
latissimus,O
dorsi,O
flap,O
reconstruction,O
having,O
been,O
diagnosed,O
with,O
carcinoma,Entity
of,Entity
the,Entity
breast,Entity
6,O
months,O
previously,O
.,O
In,O
the,O
present,O
case,O
",",O
complete,O
atrioventricular,Entity
(,Entity
AV,Entity
),Entity
block,Entity
with,O
syncopal,Entity
attacks,Entity
developed,O
secondary,O
to,O
lithium,Entity
therapy,O
",",O
necessitating,O
permanent,O
pacemaker,O
implantation,O
.,O
An,O
evaluation,O
of,O
amikacin,Entity
nephrotoxicity,Entity
in,O
the,O
hematology,O
/,O
oncology,O
population,O
.,O
MATERIALS,O
AND,O
METHODS,O
:,O
Our,O
study,O
included,O
patients,O
who,O
were,O
administered,O
30,O
-,O
60,O
mL,O
of,O
iodinated,O
contrast,Entity
agent,O
for,O
percutaneous,O
coronary,O
angiography,O
(,O
PCAG,O
),O
",",O
all,O
with,O
creatinine,Entity
values,O
between,O
1.1,O
and,O
3.1,O
mg,O
/,O
dL.,O
Patients,O
were,O
divided,O
into,O
three,O
groups,O
and,O
each,O
group,O
had,O
20,O
patients,O
.,O
Although,O
the,O
patient,O
recovered,O
",",O
he,O
experienced,O
permanent,O
vision,Entity
and,Entity
hearing,Entity
loss,Entity
",",O
as,O
well,O
as,O
end,Entity
-,Entity
stage,Entity
renal,Entity
disease,Entity
.,O
The,O
concentration,O
of,O
serum,O
potassium,Entity
was,O
high,O
",",O
and,O
normal,O
sinus,O
rhythm,O
was,O
restored,O
after,O
correction,O
of,O
the,O
serum,O
potassium,Entity
level,O
.,O
Livers,O
were,O
harvested,O
on,O
2,O
",",O
5,O
",",O
and,O
10,O
days,O
during,O
PB,Entity
administration,O
.,O
The,O
clonidine,Entity
-,O
induced,O
hypotension,Entity
was,O
antagonized,O
by,O
prior,O
spinal,O
transection,O
",",O
but,O
not,O
bilateral,O
vagotomy,O
.,O
During,O
the,O
follow,O
-,O
up,O
",",O
3,O
patients,O
(,O
12%,O
),O
developed,O
steroid,Entity
-,O
induced,O
elevated,Entity
intraocular,Entity
pressure,Entity
(,O
IOP,O
),O
that,O
resolved,O
after,O
corticosteroid,Entity
therapy,O
was,O
discontinued,O
.,O
To,O
assess,O
patients,O
',O
ability,O
to,O
repeat,O
and,O
recall,O
words,O
presented,O
to,O
them,O
while,O
undergoing,O
procedural,O
sedation,O
with,O
propofol,Entity
",",O
and,O
correlate,O
their,O
recall,O
with,O
their,O
level,O
of,O
awareness,O
as,O
measured,O
by,O
bispectral,O
index,O
(,O
BIS,O
),O
monitoring,O
.,O
This,O
patient,O
presented,O
with,O
symptoms,O
of,O
neuroleptic,Entity
malignant,Entity
syndrome,Entity
(,O
NMS,Entity
),O
",",O
thus,O
demonstrating,O
that,O
NMS,Entity
-,O
like,O
symptoms,O
can,O
occur,O
after,O
combined,O
paroxetine,Entity
and,O
alprazolam,Entity
treatment,O
.,O
However,O
",",O
regardless,O
of,O
the,O
duration,O
of,O
recovery,O
(,O
and,O
irrespective,O
of,O
either,O
lesion,O
volume,O
",",O
amphetamine,Entity
dose,O
",",O
or,O
post,O
-,O
lesion,O
motor,O
exercise,O
),O
",",O
amphetamine,Entity
-,O
induced,O
rotation,Entity
tended,O
to,O
become,O
gradually,O
more,O
ipsilateral,O
as,O
the,O
observation,O
session,O
progressed,O
",",O
and,O
all,O
rats,O
circled,O
ipsilaterally,O
to,O
the,O
lesion,O
in,O
response,O
to,O
further,O
amphetamine,Entity
injections,O
.,O
Via,O
the,O
sequential,O
isolation,O
of,O
Pueraria,O
thunbergiana,O
",",O
the,O
active,O
component,O
was,O
ultimately,O
identified,O
as,O
daidzein,Entity
(,O
"4',7-dihydroxy",Entity
-,Entity
isoflavone,Entity
),O
.,O
Arterial,O
hypertension,Entity
as,O
a,O
complication,O
of,O
prolonged,O
ketoconazole,Entity
treatment,O
.,O
Following,O
instrumentation,O
",",O
halothane,Entity
was,O
discontinued,O
and,O
alfentanil,Entity
(,O
125,O
mu,O
/,O
kg,O
),O
administered,O
iv,O
during,O
emergence,O
from,O
halothane,Entity
anesthesia,O
.,O
The,O
use,O
of,O
amiodarone,Entity
has,O
",",O
however,O
",",O
been,O
limited,O
due,O
to,O
its,O
serious,O
side,O
-,O
effects,O
.,O
After,O
2,O
individuals,O
with,O
psoriasis,Entity
developed,O
a,O
capillary,Entity
leak,Entity
syndrome,Entity
following,O
treatment,O
with,O
oral,O
sirolimus,Entity
lesional,O
skin,O
cells,O
and,O
activated,O
peripheral,O
blood,O
cells,O
were,O
analyzed,O
for,O
induction,O
of,O
apoptosis,O
.,O
The,O
full,O
syndrome,O
of,O
subacute,O
myelo,Entity
-,Entity
optic,Entity
neuropathy,Entity
was,O
more,O
frequent,O
in,O
women,O
",",O
but,O
they,O
tended,O
to,O
have,O
taken,O
greater,O
quantities,O
of,O
the,O
drug,O
.,O
Prostaglandin,Entity
E2-induced,Entity
bladder,Entity
hyperactivity,Entity
in,O
normal,O
",",O
conscious,O
rats,O
:,O
involvement,O
of,O
tachykinins,Entity
?,O
Combined,O
effects,O
of,O
prolonged,O
prostaglandin,Entity
E1-induced,Entity
hypotension,Entity
and,O
haemodilution,Entity
on,O
human,O
hepatic,O
function,O
.,O
Sulpiride,Entity
induced,O
only,O
SOCS-1,O
in,O
the,O
medial,O
preoptic,O
area,O
",",O
where,O
GnRH,O
neurons,O
are,O
regulated,O
",",O
but,O
in,O
the,O
arcuate,O
nucleus,O
and,O
choroid,O
plexus,O
",",O
PRL,O
-,O
R,O
",",O
SOCS-3,O
",",O
and,O
CIS,O
mRNA,O
levels,O
were,O
also,O
induced,O
.,O
Both,O
the,O
precordial,Entity
pain,Entity
and,O
the,O
electrocardiographic,O
changes,O
disappeared,O
spontaneously,O
after,O
the,O
discontinuation,O
of,O
5-FU,Entity
.,O
Sodium,O
nitroprusside,Entity
is,O
a,O
non,O
-,O
selective,O
arteriolar,O
and,O
venous,O
vasodilator,O
that,O
can,O
produce,O
redistribution,O
of,O
blood,O
flow,O
away,O
from,O
the,O
kidney,O
during,O
induced,O
hypotension,Entity
.,O
Subsequent,O
HD,O
-,O
MTX,Entity
therapy,O
caused,O
acute,Entity
renal,Entity
failure,Entity
that,O
required,O
continuous,O
hemodialysis,O
.,O
This,O
trial,O
evaluated,O
the,O
effect,O
of,O
placebo,O
",",O
0.5%,O
aqueous,O
timolol,Entity
(,O
timolol,Entity
solution,O
),O
and,O
a,O
0.5%,O
timolol,Entity
suspension,O
that,O
forms,O
a,O
gel,O
on,O
application,O
to,O
the,O
conjunctiva,O
(,O
timolol,Entity
gellan,O
),O
on,O
the,O
24-hour,O
heart,O
rate,O
in,O
patients,O
currently,O
being,O
treated,O
for,O
glaucoma,Entity
to,O
quantify,O
the,O
reduction,O
in,O
mean,O
heart,O
rate,O
.,O
The,O
light,O
-,O
enhanced,O
startle,Entity
paradigm,O
(,O
LES,O
),O
is,O
suggested,O
to,O
model,O
anxiety,Entity
",",O
because,O
of,O
the,O
non,O
-,O
specific,O
cue,O
and,O
the,O
long,O
-,O
term,O
effect,O
.,O
RAST,O
for,O
BPO,Entity
-,Entity
PLL,Entity
and,O
AX,Entity
-,O
PLL,O
was,O
done,O
.,O
There,O
are,O
very,O
few,O
reports,O
about,O
asterixis,Entity
as,O
a,O
side,O
effect,O
of,O
treatment,O
with,O
psychopharmacologic,O
agents,O
.,O
Third,O
",",O
although,O
it,O
is,O
relatively,O
easy,O
to,O
block,O
seizures,Entity
induced,O
by,O
lithium,Entity
and,O
pilocarpine,Entity
by,O
administration,O
of,O
anticonvulsants,O
prior,O
to,O
pilocarpine,Entity
",",O
it,O
is,O
more,O
difficult,O
to,O
terminate,O
ongoing,O
status,Entity
epilepticus,Entity
and,O
block,O
the,O
lethality,O
of,O
the,O
seizures,Entity
.,O
Bepridil,Entity
hydrochloride,Entity
(,O
Bpd,Entity
),O
has,O
attracted,O
attention,O
as,O
an,O
effective,O
drug,O
for,O
atrial,Entity
fibrillation,Entity
(,O
AF,Entity
),O
and,O
atrial,Entity
flutter,Entity
(,O
AFL,Entity
),O
.,O
We,O
started,O
LMWH,O
(,O
25,O
IU,O
/,O
kg,O
/,O
h,O
),O
on,O
postoperative,O
day,O
(,O
POD,O
),O
1,O
",",O
switching,O
to,O
UFH,Entity
(,O
5000,O
U,O
/,O
d,O
),O
on,O
POD,O
2,O
or,O
3,O
.,O
Our,O
findings,O
suggest,O
that,O
the,O
changes,O
leading,O
to,O
an,O
alteration,O
of,O
myocardial,O
dynamic,O
imaging,O
with,O
I-131,Entity
HA,Entity
are,O
not,O
the,O
initiating,O
factor,O
in,O
doxorubicin,Entity
cardiotoxicity,Entity
.,O
Basic,O
and,O
clinical,O
research,O
has,O
demonstrated,O
that,O
dementia,Entity
of,O
sporadic,O
Alzheimer,Entity
's,Entity
disease,Entity
(,O
sAD,O
),O
type,O
is,O
associated,O
with,O
dysfunction,O
of,O
the,O
insulin,O
-,O
receptor,O
(,O
IR,O
),O
system,O
followed,O
by,O
decreased,O
glucose,Entity
transport,O
via,O
glucose,Entity
transporter,O
GLUT4,O
and,O
decreased,O
glucose,Entity
metabolism,O
in,O
brain,O
cells,O
.,O
Dissociated,O
learning,O
of,O
rats,O
in,O
the,O
normal,O
state,O
and,O
the,O
state,O
of,O
amnesia,Entity
produced,O
by,O
pentobarbital,Entity
(,O
15,O
mg,O
/,O
kg,O
",",O
ip,O
),O
was,O
carried,O
out,O
.,O
Pretreatment,O
with,O
reserpine,Entity
(,O
1,O
mg,O
/,O
kg,O
),O
24,O
cisplatin,Entity
-,O
induced,O
acute,Entity
renal,Entity
injury,Entity
.,O
The,O
relationship,O
between,O
hippocampal,O
acetylcholine,Entity
release,O
and,O
cholinergic,O
convulsant,O
sensitivity,O
in,O
withdrawal,O
seizure,Entity
-,O
prone,O
and,O
withdrawal,O
seizure,Entity
-,O
resistant,O
selected,O
mouse,O
lines,O
.,O
However,O
",",O
identification,O
of,O
a,O
short,O
-,O
acting,O
local,O
anesthetic,O
to,O
substitute,O
for,O
lidocaine,Entity
for,O
brief,O
surgical,O
procedures,O
remains,O
an,O
important,O
goal,O
.,O
Compared,O
to,O
healthy,O
controls,O
a,O
lower,O
DR5,O
frequency,O
was,O
observed,O
in,O
patients,O
with,O
RA,Entity
except,O
for,O
the,O
Tiopronin,Entity
related,O
nephritis,Entity
group,O
.,O
Intravenous,O
ribavirin,Entity
therapy,O
was,O
well,O
tolerated,O
.,O
Nitroglycerin,Entity
",",O
up,O
to,O
0.3,O
micrograms,O
/,O
kg,O
",",O
selectively,O
increased,O
circumflex,O
artery,O
diameter,O
(,O
CxAD,O
),O
without,O
simultaneously,O
affecting,O
any,O
other,O
cardiac,O
or,O
systemic,O
hemodynamic,O
parameter,O
.,O
We,O
included,O
prospective,O
",",O
randomised,O
peri,O
-,O
operative,O
studies,O
of,O
dexmedetomidine,Entity
that,O
reported,O
mortality,O
",",O
cardiac,O
morbidity,O
or,O
adverse,O
drug,O
events,O
.,O
Status,Entity
epilepticus,Entity
in,O
rat,O
causes,O
an,O
age,O
-,O
dependent,O
",",O
long,O
-,O
term,O
impairment,Entity
in,Entity
auditory,Entity
discrimination,Entity
.,O
n,O
=,O
9,O
),O
or,O
a,O
weak,O
NSAID,O
",",O
acetaminophen,Entity
",",O
1,O
g,O
",",O
three,O
times,O
a,O
day,O
(,O
acetaminophen,Entity
group,O
",",O
Histological,O
studies,O
demonstrated,O
that,O
the,O
rats,O
developed,O
an,O
infarct,Entity
18,O
h,O
after,O
isoproterenol,Entity
administration,O
.,O
Similarly,O
",",O
benzene,Entity
-,O
derived,O
catechol,Entity
and,O
hydroquinone,Entity
",",O
but,O
not,O
phenol,Entity
",",O
induce,O
apoptosis,O
in,O
HBMP,O
cells,O
Effect,O
of,O
nondopaminergic,O
drugs,O
on,O
L,Entity
-,Entity
dopa,Entity
-,O
induced,O
dyskinesias,Entity
in,O
MPTP,Entity
-,O
treated,O
monkeys,O
.,O
CPA,Entity
reduced,O
cocaine,Entity
action,O
at,O
the,O
doses,O
which,O
",",O
given,O
alone,O
",",O
did,O
not,O
influence,O
motility,O
",",O
while,O
CGS,Entity
21680,Entity
and,O
NECA,Entity
decreased,O
the,O
action,O
of,O
cocaine,Entity
at,O
the,O
doses,O
which,O
",",O
given,O
alone,O
",",O
decreased,O
locomotor,O
activity,O
in,O
animals,O
.,O
We,O
present,O
a,O
49-year,O
-,O
old,O
woman,O
who,O
developed,O
a,O
delusional,Entity
parasitosis,Entity
during,O
treatment,O
with,O
pegylated,Entity
interferon,Entity
alpha-2b,Entity
weekly,O
and,O
ribavirin,Entity
.,O
Nephrosis,Entity
was,O
induced,O
by,O
injection,O
of,O
PAN,Entity
(,O
15mg/100,O
g,O
body,O
weight,O
),O
in,O
male,O
Sprague,O
-,O
Dawley,O
(,O
SD,O
),O
rats,O
.,O
Intraperitoneal,O
administration,O
of,O
atropine,Entity
",",O
but,O
not,O
intraperitoneal,O
or,O
intracerebroventricular,O
injection,O
of,O
hexamethonium,Entity
",",O
decreased,O
the,O
effect,O
of,O
a,O
single,O
dose,O
of,O
morphine,Entity
.,O
RESULTS,O
:,O
All,O
patients,O
had,O
optic,Entity
neuropathy,Entity
between,O
1,O
to,O
6,O
months,O
(,O
mean,O
=,O
2.9,O
months,O
),O
after,O
starting,O
ethambutol,Entity
therapy,O
at,O
a,O
dosage,O
ranging,O
from,O
13,O
to,O
20,O
mg,O
/,O
kg,O
/,O
day,O
(,O
mean,O
=,O
17,O
mg,O
/,O
kg,O
/,O
day,O
),O
.,O
Correlation,O
of,O
plasma,O
argatroban,Entity
concentration,O
versus,O
the,O
patient,O
's,O
coagulation,O
variables,O
and,O
clinical,O
course,O
suggest,O
that,O
prolonged,O
elevated,O
levels,O
of,O
plasma,O
argatroban,Entity
may,O
have,O
contributed,O
to,O
the,O
patient,O
's,O
extended,O
coagulopathy,Entity
.,O
Low,O
-,O
risk,O
controls,O
(,O
n,O
=,O
24,O
),O
reported,O
no,O
parental,O
history,O
of,O
hypertension,Entity
and,O
had,O
screening,O
BP,O
<,O
130/85,O
mm,O
Hg,O
.,O
This,O
case,O
illustrates,O
a,O
number,O
of,O
problems,O
that,O
may,O
be,O
encountered,O
in,O
women,O
with,O
eating,Entity
disorders,Entity
in,O
pregnancy,O
",",O
including,O
prolonged,O
and,O
recurrent,O
metabolic,O
disturbances,O
and,O
diuretic,O
abuse,O
.,O
Clinicians,O
should,O
be,O
alert,O
to,O
the,O
possibility,O
of,O
hyperkalemia,Entity
",",O
especially,O
in,O
elderly,O
patients,O
using,O
ACE,O
/,O
ARB,O
in,O
combination,O
with,O
potassium,Entity
sparing,O
agents,O
and,O
who,O
have,O
mild,O
renal,Entity
disturbance,Entity
.,O
IIIB,O
or,O
IV,O
non,Entity
-,Entity
small,Entity
cell,Entity
lung,Entity
cancer,Entity
(,O
NSCLC,Entity
),O
reported,O
response,O
rates,O
of,O
21%,O
and,O
24%,O
.,O
During,O
induction,O
of,O
anaesthesia,O
with,O
TCI,O
of,O
propofol,Entity
and,O
remifentanil,Entity
",",O
a,O
significant,O
reduction,O
in,O
propofol,Entity
infusion,O
pain,Entity
was,O
achieved,O
without,O
significant,O
complications,O
by,O
prior,O
administration,O
of,O
remifentanil,Entity
at,O
a,O
target,O
Ce,O
of,O
4,O
ng,O
ml(-1,O
),O
.,O
Peripheral,O
edema,Entity
was,O
reported,O
in,O
8.5%,O
patients,O
(,O
9/106,O
),O
in,O
the,O
T+A,O
group,O
compared,O
with,O
13.5%,O
(,O
14/104,O
),O
in,O
the,O
A,O
group,O
",",O
and,O
cough,Entity
was,O
reported,O
in,O
3.8%,O
patients,O
(,O
4/106,O
),O
in,O
the,O
T+A,O
group,O
and,O
1.0%,O
(,O
1/104,O
),O
patients,O
in,O
the,O
A,O
group,O
;,O
these,O
differences,O
did,O
not,O
reach,O
statistical,O
significance,O
.,O
Although,O
the,O
transaminases,O
gradually,O
returned,O
to,O
baseline,O
after,O
withholding,O
the,O
beta,Entity
lactam,Entity
antibiotic,O
",",O
there,O
was,O
a,O
gradual,O
increase,O
in,O
serum,O
bilirubin,Entity
and,O
a,O
decrease,O
in,O
hemoglobin,O
concentration,O
caused,O
by,O
an,O
autoimmune,Entity
hemolytic,Entity
anemia,Entity
and,O
erythroblastocytopenia,Entity
.,O
Vincristine,Entity
",",O
dexamethasone,Entity
",",O
and,O
polyethylene,Entity
glycol,Entity
-,Entity
asparaginase,Entity
were,O
also,O
administered,O
before,O
the,O
episode,O
as,O
part,O
of,O
induction,O
therapy,O
.,O
The,O
topical,O
application,O
of,O
a,O
glycopyrrolate,Entity
pad,O
appeared,O
to,O
be,O
safe,O
",",O
efficacious,O
",",O
well,O
tolerated,O
",",O
and,O
a,O
convenient,O
method,O
of,O
treatment,O
for,O
moderate,O
to,O
severe,O
symptoms,O
of,O
gustatory,Entity
hyperhidrosis,Entity
in,O
post,O
transthoracic,O
endoscopic,O
sympathectomy,O
or,O
sympathicotomy,O
patients,O
",",O
with,O
few,O
side,O
effects,O
.,O
We,O
describe,O
a,O
previously,O
healthy,O
32-year,O
-,O
old,O
woman,O
who,O
developed,O
a,O
life,O
-,O
threatening,O
muscle,Entity
spasm,Entity
and,O
secondary,O
ventilation,O
difficulties,O
following,O
a,O
preoperative,O
injection,O
of,O
suxamethonium,Entity
.,O
We,O
found,O
that,O
gentamicin,Entity
treatment,O
depleted,O
respiratory,O
components,O
(,O
cytochrome,O
c,O
",",O
NADH,O
),O
",",O
probably,O
due,O
to,O
the,O
opening,O
of,O
mitochondrial,O
transition,O
pores,O
.,O
Renal,O
function,O
was,O
normal,O
but,O
hepatic,O
function,O
was,O
impaired,O
in,O
all,O
patients,O
",",O
and,O
all,O
had,O
acidosis,Entity
.,O
Use,O
of,O
glycopyrronium,Entity
5,O
micrograms,O
kg-1,O
provided,O
greater,O
cardiovascular,O
stability,O
and,O
",",O
given,O
1,O
min,O
before,O
the,O
edrophonium,Entity
",",O
was,O
sufficient,O
to,O
minimize,O
early,O
",",O
edrophonium,Entity
-,O
induced,O
bradycardias,Entity
.,O
Hematest,O
is,O
essential,O
",",O
adding,O
Mesna,Entity
to,O
the,O
infusate,O
in,O
patients,O
with,O
persistent,O
hematuria,Entity
.,O
Seizures,Entity
and,O
cardiac,Entity
arrhythmias,Entity
have,O
complicated,O
its,O
use,O
in,O
adult,O
patients,O
.,O
Investigation,O
of,O
more,O
specific,O
anti,O
-,O
inflammatory,O
agents,O
and,O
hemodiluting,O
agents,O
are,O
warranted,O
in,O
intracerebral,Entity
hemorrhage,Entity
.,O
In,O
the,O
anemia,Entity
group,O
",",O
the,O
growth,O
delay,O
was,O
significantly,O
shorter,O
compared,O
with,O
nonanemic,O
controls,O
(,O
13.3,O
days,O
versus,O
8.6,O
days,O
),O
.,O
This,O
case,O
report,O
highlights,O
the,O
fact,O
that,O
the,O
angiotensin,Entity
II,Entity
receptor,O
antagonist,O
losartan,Entity
can,O
cause,O
serious,O
unexpected,O
complications,O
in,O
patients,O
with,O
renovascular,Entity
disease,Entity
and,O
should,O
be,O
used,O
with,O
extreme,O
caution,O
in,O
this,O
setting,O
.,O
At,O
autopsy,O
",",O
analysis,O
of,O
liver,O
parenchyma,O
revealed,O
rich,O
portal,O
inflammatory,O
infiltrate,O
",",O
which,O
consisted,O
of,O
mixed,O
eosinophil,O
and,O
monocyte,O
cells,O
",",O
associated,O
with,O
several,O
foci,O
of,O
necrosis,Entity
surrounded,O
by,O
a,O
hard,O
ring,O
of,O
non,O
-,O
specific,O
granulomatous,O
tissue,O
.,O
Acute,O
peripheral,Entity
neuropathy,Entity
caused,O
by,O
a,O
disulfiram,Entity
overdose,Entity
is,O
very,O
rare,O
and,O
there,O
is,O
no,O
report,O
of,O
it,O
leading,O
to,O
vocal,Entity
fold,Entity
palsy,Entity
.,O
Myopathy,Entity
",",O
associated,O
in,O
some,O
cases,O
with,O
myoglobinuria,Entity
",",O
and,O
in,O
2,O
cases,O
with,O
transient,O
renal,Entity
failure,Entity
",",O
has,O
been,O
rarely,O
reported,O
with,O
lovastatin,Entity
",",O
especially,O
in,O
patients,O
concomitantly,O
treated,O
with,O
cyclosporin,Entity
",",O
gemfibrozil,Entity
or,O
niacin,Entity
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
investigate,O
the,O
protective,O
effect,O
of,O
the,O
Solidago,O
virgaurea,O
extract,O
on,O
isoproterenol,Entity
-,O
induced,O
cardiotoxicity,Entity
in,O
rats,O
.,O
The,O
object,O
of,O
the,O
meeting,O
was,O
to,O
analyse,O
existing,O
data,O
",",O
both,O
published,O
or,O
available,O
",",O
in,O
the,O
European,O
Group,O
for,O
Blood,O
and,O
Marrow,O
Transplantation,O
autoimmune,Entity
disease,Entity
database,O
",",O
and,O
to,O
propose,O
a,O
safe,O
approach,O
to,O
such,O
patients,O
.,O
We,O
also,O
carried,O
out,O
oral,O
and,O
parenteral,O
challenges,O
with,O
other,O
corticosteroids,Entity
and,O
found,O
intolerance,O
to,O
some,O
of,O
them,O
.,O
Stevens,Entity
-,Entity
Johnson,Entity
syndrome,Entity
is,O
a,O
well,O
-,O
recognized,O
immune,O
complex,O
-,O
mediated,O
hypersensitivity,Entity
reaction,O
that,O
affects,O
all,O
age,O
groups,O
",",O
is,O
drug,O
or,O
infection,Entity
induced,O
",",O
and,O
has,O
classic,O
systemic,O
",",O
mucosal,O
",",O
and,O
dermatologic,O
manifestations,O
.,O
The,O
outcome,O
of,O
subarachnoid,Entity
hemorrhage,Entity
associated,O
with,O
cocaine,Entity
abuse,Entity
is,O
reportedly,O
poor,O
.,O
The,O
best,O
clinical,O
effect,O
was,O
found,O
with,O
terbutaline,Entity
.,O
Cardioprotective,O
effect,O
of,O
salvianolic,Entity
acid,Entity
A,Entity
on,O
isoproterenol,Entity
-,O
induced,O
myocardial,Entity
infarction,Entity
in,O
rats,O
.,O
These,O
findings,O
suggest,O
that,O
it,O
may,O
be,O
possible,O
to,O
identify,O
a,O
succimer,Entity
treatment,O
protocol,O
that,O
improves,O
cognitive,O
outcomes,O
in,O
Pb,Entity
-,O
exposed,O
children,O
.,O
This,O
depression,Entity
was,O
followed,O
by,O
the,O
sudden,O
appearance,O
of,O
a,O
stimulatory,O
phase,O
.,O
These,O
changes,O
can,O
be,O
effectively,O
prevented,O
by,O
mesna,Entity
.,O
Chlorpropamide,Entity
-,O
induced,O
optic,Entity
neuropathy,Entity
.,O
She,O
had,O
developed,O
a,O
severe,O
acute,O
major,Entity
depression,Entity
disorder,Entity
almost,O
immediately,O
thereafter,O
",",O
possibly,O
related,O
to,O
the,O
use,O
of,O
a,O
serotonin,Entity
antagonist,O
.,O
Hydrocortisone,Entity
acetate,Entity
(,O
50,O
mg,O
),O
was,O
given,O
orally,O
every,O
6,O
hours,O
for,O
24,O
hours,O
after,O
a,O
5-day,O
fixed,O
-,O
salt,O
diet,O
(,O
150,O
mmol,O
/,O
d,O
),O
.,O
Controlled,O
hypotension,Entity
was,O
achieved,O
within,O
a,O
shorter,O
period,O
using,O
laryngeal,O
mask,O
using,O
lower,O
rates,O
of,O
remifentanil,Entity
infusion,O
and,O
lower,O
total,O
dose,O
of,O
remifentanil,Entity
.,O
Risk,O
for,O
valvular,Entity
heart,Entity
disease,Entity
among,O
users,O
of,O
fenfluramine,Entity
and,O
dexfenfluramine,Entity
who,O
underwent,O
echocardiography,O
before,O
use,O
of,O
medication,O
.,O
There,O
were,O
13,O
cases,O
of,O
adverse,O
reactions,O
(,O
0.34%,O
),O
",",O
ten,O
of,O
which,O
were,O
mild,O
reactions,O
such,O
as,O
nausea,Entity
",",O
exanthema,Entity
",",O
urtication,Entity
",",O
itchiness,Entity
",",O
and,O
urgency,O
to,O
defecate,O
",",O
and,O
did,O
not,O
require,O
treatment,O
.,O
The,O
DHEA,Entity
was,O
administered,O
intraperitoneally,O
(,O
ip,O
),O
for,O
5,O
days,O
.,O
Hyperglycemic,Entity
effect,O
of,O
amino,Entity
compounds,O
structurally,O
related,O
to,O
caproate,Entity
in,O
rats,O
.,O
Discontinuation,O
of,O
azithromycin,Entity
and,O
therapy,O
with,O
baclofen,Entity
finally,O
resolved,O
hiccups,Entity
.,O
D,Entity
-,Entity
Glucarates,Entity
had,O
the,O
ability,O
to,O
prevent,O
renal,Entity
damage,Entity
but,O
not,O
to,O
cure,O
it,O
.,O
A,O
case,O
of,O
branch,O
retinal,Entity
vein,Entity
occlusion,Entity
associated,O
with,O
fluoxetine,Entity
-,O
induced,O
secondary,O
hypertension,Entity
is,O
described,O
.,O
Cataract,Entity
and,O
band,Entity
keratopathy,Entity
occurred,O
in,O
only,O
22,O
and,O
13%,O
of,O
our,O
group,O
",",O
respectively,O
.,O
Suxamethonium,Entity
-,O
induced,O
jaw,Entity
stiffness,Entity
and,O
myalgia,Entity
associated,O
with,O
atypical,O
cholinesterase,O
:,O
case,O
report,O
.,O
Two,O
hundred,O
ninety,O
-,O
seven,O
patients,O
with,O
MBC,Entity
and,O
no,O
prior,O
chemotherapy,O
for,O
metastatic,O
disease,O
were,O
randomized,O
to,O
receive,O
either,O
60,O
mg,O
/,O
m(2,O
),O
of,O
Myocet,Entity
(,O
M,O
),O
or,O
conventional,O
doxorubicin,Entity
(,O
A,O
),O
",",O
in,O
combination,O
with,O
600,O
mg,O
/,O
m(2,O
),O
of,O
cyclophosphamide,Entity
(,O
C,O
),O
",",O
every,O
3,O
weeks,O
until,O
disease,O
progression,O
or,O
unacceptable,O
toxicity,Entity
.,O
In,O
addition,O
",",O
the,O
role,O
of,O
dopamine,Entity
receptors,O
in,O
mediating,O
nicotine,Entity
-,O
induced,O
locomotor,O
stimulation,O
was,O
investigated,O
by,O
examining,O
the,O
effects,O
of,O
selective,O
D1,O
and,O
D2,O
dopamine,Entity
receptor,O
antagonists,O
on,O
activity,O
induced,O
by,O
nicotine,Entity
.,O
The,O
two,O
metabolic,O
phenotypes,O
",",O
extensive,O
(,O
EM,O
),O
and,O
poor,O
metabolizers,O
(,O
PM,O
),O
",",O
show,O
different,O
stereoselective,O
metabolism,O
",",O
resulting,O
in,O
apparently,O
higher,O
beta-1,O
adrenoceptor,O
antagonistic,O
potency,O
of,O
racemic,O
metoprolol,Entity
in,O
EMs,O
.,O
Urinary,O
sodium,Entity
excretion,O
reached,O
signficantly,O
lower,O
values,O
in,O
sgk1(+/+,O
),O
mice,O
(,O
15,O
+,O
/-,O
Patients,O
who,O
are,O
unusually,O
sensitive,O
to,O
the,O
neuromuscular,O
effects,O
of,O
magnesium,Entity
should,O
be,O
suspected,O
of,O
having,O
an,O
underlying,O
disorder,Entity
of,Entity
neuromuscular,Entity
transmission,Entity
.,O
It,O
may,O
be,O
concluded,O
that,O
",",O
like,O
other,O
tricyclic,O
antidepressants,Entity
studied,O
previously,O
",",O
TRI,Entity
given,O
repeatedly,O
increases,O
the,O
responsiveness,O
of,O
brain,O
dopamine,Entity
D2,O
and,O
D3,O
(,O
locomotor,O
activity,O
but,O
not,O
stereotypy,O
),O
as,O
well,O
as,O
alpha1-adrenergic,O
receptors,O
to,O
their,O
agonists,O
.,O
Is,O
the,O
treatment,O
of,O
scabies,Entity
hazardous,O
?,O
This,O
calls,O
for,O
attention,O
when,O
ketoconazole,Entity
is,O
administered,O
to,O
patients,O
with,O
risk,O
factors,O
for,O
acquired,O
long,Entity
QT,Entity
syndrome,Entity
.,O
This,O
program,O
consists,O
of,O
double,O
screenings,O
of,O
pregnant,O
women,O
and,O
prophylactic,O
treatment,O
to,O
the,O
infants,O
born,O
to,O
both,O
hepatitis,Entity
B,Entity
surface,Entity
antigen,Entity
(,O
HBsAg,Entity
),O
and,O
hepatitis,Entity
B,Entity
e,Entity
antigen,Entity
(,O
HBeAg,Entity
),O
positive,O
mothers,O
.,O
Alkaline,O
phosphatase,O
and,O
glucose,Entity
were,O
markedly,O
and,O
transiently,O
elevated,O
in,O
proximal,O
tubular,O
damage,O
and,O
N,O
-,O
acetyl,O
-,O
beta,O
-,O
glucosaminidase,O
showed,O
a,O
sustained,O
elevation,O
in,O
papillary,O
damage,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
whether,O
myocardial,O
contrast,O
echocardiography,O
performed,O
with,O
a,O
stable,O
solution,O
of,O
sonicated,O
albumin,O
could,O
detect,O
regions,O
of,O
myocardial,O
underperfusion,O
resulting,O
from,O
various,O
degrees,O
of,O
coronary,Entity
stenosis,Entity
.,O
A,O
further,O
group,O
of,O
25,O
patients,O
under,O
polychemotherapy,O
with,O
IF,Entity
were,O
treated,O
by,O
conventional,O
prophylactic,O
measures,O
(,O
raised,O
fluid,O
intake,O
and,O
forced,O
diuresis,O
),O
.,O
METHODS,O
:,O
In,O
the,O
population,O
based,O
",",O
nationwide,O
Swedish,O
Inpatient,O
Register,O
a,O
cohort,O
of,O
1065,O
patients,O
with,O
Wegener,Entity
's,Entity
granulomatosis,Entity
",",O
1969,O
-,O
95,O
",",O
was,O
identified,O
.,O
Antithymocyte,Entity
globulin,Entity
in,O
the,O
treatment,O
of,O
D,Entity
-,Entity
penicillamine,Entity
-,O
induced,O
aplastic,Entity
anemia,Entity
.,O
Brainstem,Entity
dysgenesis,Entity
in,O
an,O
infant,O
prenatally,O
exposed,O
to,O
cocaine,Entity
.,O
Curcumin,Entity
has,O
shown,O
antioxidant,O
",",O
anti,O
-,O
inflammatory,O
and,O
neuro,O
-,O
protective,O
properties,O
.,O
This,O
patient,O
had,O
no,O
associated,O
personality,Entity
disorder,Entity
(,O
particularly,O
no,O
antisocial,Entity
disorder,Entity
),O
and,O
no,O
substance,Entity
abuse,Entity
disorder,Entity
.,O
However,O
",",O
L,Entity
-,Entity
dopa,Entity
restored,O
the,O
bradycardia,Entity
caused,O
by,O
norepinephrine,Entity
in,O
addition,O
to,O
decreasing,O
blood,O
pressure,O
and,O
heart,O
rate,O
.,O
We,O
found,O
an,O
increased,O
incidence,O
of,O
subependymal,Entity
cyst,Entity
formation,O
in,O
preterm,Entity
infants,Entity
who,O
were,O
exposed,O
to,O
cocaine,Entity
prenatally,O
.,O
AIMS,O
:,O
Doxorubicin,Entity
(,O
DOX,Entity
),O
is,O
an,O
effective,O
anti,O
-,O
cancer,Entity
therapeutic,O
",",O
but,O
is,O
associated,O
with,O
both,O
acute,O
and,O
late,O
-,O
stage,O
cardiotoxicity,Entity
.,O
When,O
the,O
total,O
busulfan,Entity
dose,O
was,O
taken,O
into,O
account,O
",",O
there,O
was,O
a,O
significant,O
difference,O
in,O
terms,O
of,O
neurotoxicity,Entity
incidence,O
among,O
patients,O
under,O
16,O
mg,O
/,O
kg,O
(,O
1,O
of,O
57,O
",",O
1.7%,O
),O
and,O
patients,O
under,O
600,O
mg,O
/,O
m2,O
(,O
6,O
of,O
39,O
",",O
15.4%,O
),O
(,O
P,O
less,O
than,O
0.02,O
),O
.,O
All,O
patients,O
had,O
bilateral,O
symptoms,O
and,O
their,O
levodopa,Entity
equivalent,O
dosing,O
were,O
analysed,O
.,O
OBJECTIVE,O
:,O
To,O
determine,O
whether,O
limiting,O
intraoperative,O
sedation,O
depth,O
during,O
spinal,O
anesthesia,O
for,O
hip,Entity
fracture,Entity
repair,O
in,O
elderly,O
patients,O
can,O
decrease,O
the,O
prevalence,O
of,O
postoperative,Entity
delirium,Entity
.,O
The,O
patient,O
began,O
to,O
have,O
changes,O
in,O
white,O
blood,O
cells,O
and,O
platelets,O
within,O
48,O
h,O
of,O
administration,O
of,O
fluconazole,Entity
and,O
began,O
to,O
recover,O
with,O
48,O
h,O
of,O
discontinuation,O
.,O
The,O
levodopa,Entity
-,O
treated,O
MPTP,Entity
-,O
lesioned,O
marmoset,O
was,O
used,O
as,O
a,O
model,O
of,O
neuropsychiatric,Entity
symptoms,Entity
in,O
PD,Entity
patients,O
.,O
Levodopa,Entity
-,O
induced,O
oromandibular,O
dystonia,Entity
in,O
progressive,Entity
supranuclear,Entity
palsy,Entity
.,O
A,O
50-year,O
-,O
old,O
woman,O
with,O
low,Entity
back,Entity
and,Entity
right,Entity
leg,Entity
pain,Entity
was,O
scheduled,O
for,O
epidural,O
steroid,Entity
injection,O
.,O
PURPOSE,O
:,O
To,O
determine,O
the,O
natural,O
history,O
of,O
visual,Entity
field,Entity
defects,Entity
in,O
a,O
group,O
of,O
patients,O
known,O
to,O
have,O
Vigabatrin,Entity
-,O
associated,O
changes,O
who,O
elected,O
to,O
continue,O
the,O
medication,O
because,O
of,O
good,O
seizure,Entity
control,O
.,O
Estrogen,O
replacement,O
(,O
17beta,Entity
-,Entity
estradiol,Entity
subcutaneous,O
pellet,O
",",O
14.2,O
microg,O
/,O
day,O
",",O
12,O
wk,O
),O
of,O
Ovx,O
rats,O
restored,O
the,O
hemodynamic,O
and,O
locomotor,O
effects,O
of,O
alpha,Entity
-,Entity
methyldopa,Entity
to,O
sham,O
-,O
operated,O
levels,O
.,O
A,O
65-year,O
-,O
old,O
man,O
with,O
advanced,O
renal,Entity
cell,Entity
carcinoma,Entity
was,O
admitted,O
due,O
to,O
continuing,O
chest,Entity
pain,Entity
at,O
rest,O
.,O
Despite,O
similar,O
external,O
diameters,O
among,O
CaCl(2)-treated,Entity
",",O
non,O
-,O
CaCl(2)-treated,Entity
and,O
NaCl,Entity
-,O
treated,O
segments,O
",",O
aneurymal,O
alteration,O
(,O
n=6,O
",",O
50%,O
),O
",",O
media,O
degeneration,O
with,O
regional,O
disruption,O
",",O
fragmentation,O
of,O
elastic,O
fiber,O
",",O
and,O
increased,O
collagen,O
deposition,O
(,O
n=12,O
",",O
100%,O
),O
were,O
demonstrated,O
in,O
CaCl(2)-treated,Entity
segments,O
.,O
Among,O
women,O
with,O
cardiovascular,Entity
disease,Entity
",",O
long,O
-,O
term,O
use,O
of,O
combined,O
continuous,O
HT,O
significantly,O
increased,O
the,O
risk,O
of,O
venous,Entity
thrombo,Entity
-,Entity
embolism,Entity
.,O
In,O
addition,O
",",O
interleukin-6,O
(,O
IL-6,O
),O
as,O
an,O
early,O
marker,O
of,O
inflammation,Entity
was,O
assessed,O
in,O
a,O
subgroup,O
of,O
10,O
patients,O
pretreated,O
with,O
saline,O
.,O
Timolol,Entity
(,O
but,O
not,O
pilocarpine,Entity
),O
was,O
detected,O
in,O
a,O
sample,O
of,O
plasma,O
removed,O
during,O
surgery,O
;,O
the,O
plasma,O
concentration,O
of,O
timolol,Entity
(,O
2.6,O
ng,O
ml-1,O
),O
was,O
consistent,O
with,O
partial,O
beta,O
-,O
adrenoceptor,O
blockade,O
.,O
The,O
later,O
enhancement,O
was,O
attenuated,O
after,O
intra,O
-,O
accumbens,O
shell,O
treatment,O
with,O
GR,Entity
55562,Entity
(,O
1,O
microg,O
/,O
side,O
),O
.,O
No,O
toxin,O
",",O
alcohol,Entity
",",O
or,O
other,O
drugs,O
were,O
reported,O
.,O
This,O
study,O
was,O
undertaken,O
to,O
determine,O
whether,O
oxidants,O
are,O
associated,O
with,O
the,O
hepatic,Entity
injury,Entity
and,O
to,O
determine,O
the,O
relative,O
value,O
of,O
several,O
indirect,O
methods,O
of,O
assessing,O
oxidant,O
exposure,O
in,O
vivo,O
.,O
In,O
7,O
of,O
the,O
28,O
patients,O
there,O
was,O
a,O
striking,O
temporal,O
association,O
between,O
the,O
initiation,O
of,O
sirolimus,Entity
and,O
the,O
development,O
of,O
nephrotic,Entity
-,O
range,O
proteinuria,Entity
.,O
Glial,O
activation,O
and,O
post,O
-,O
synaptic,O
neurotoxicity,Entity
:,O
the,O
key,O
events,O
in,O
Streptozotocin,Entity
(,O
ICV,O
),O
induced,O
memory,Entity
impairment,Entity
in,O
rats,O
.,O
In,O
this,O
retrospective,O
single,O
-,O
centre,O
analysis,O
",",O
patients,O
with,O
relapsed,O
or,O
refractory,O
HL,Entity
treated,O
with,O
gemcitabine,Entity
"1,000",O
mg,O
/,O
m(2,O
),O
day,O
(,O
D)1,O
",",O
D8,O
and,O
D15,O
;,O
methylprednisolone,Entity
"1,000",O
mg,O
D1,O
-,O
5,O
;,O
and,O
cisplatin,Entity
100,O
mg,O
/,O
m(2,O
),O
D15,O
",",O
every,O
28,O
days,O
(,O
GEM,Entity
-,O
P,O
),O
were,O
included,O
.,O
STUDY,O
DESIGN,O
AND,O
METHODS,O
:,O
Plasma,O
samples,O
from,O
before,O
and,O
after,O
CPB,O
were,O
analyzed,O
postoperatively,O
for,O
argatroban,Entity
concentration,O
using,O
a,O
modified,O
ecarin,O
clotting,O
time,O
(,O
ECT,O
),O
assay,O
.,O
The,O
patient,O
had,O
no,O
other,O
risk,O
factors,O
for,O
seizures,Entity
.,O
RESULTS,O
:,O
Clomipramine,Entity
exposure,O
in,O
immature,O
rats,O
produced,O
significant,O
behavioral,O
and,O
biochemical,O
changes,O
that,O
include,O
enhanced,O
anxiety,Entity
(,O
elevated,O
plus,O
maze,O
and,O
marble,O
burying,O
),O
",",O
behavioral,Entity
inflexibility,Entity
(,O
perseveration,O
in,O
the,O
spontaneous,O
alternation,O
task,O
and,O
impaired,O
reversal,O
learning,O
),O
",",O
working,O
memory,Entity
impairment,Entity
(,O
e.g.,O
",",O
win,O
-,O
shift,O
paradigm,O
),O
",",O
hoarding,Entity
",",O
and,O
corticostriatal,Entity
dysfunction,Entity
.,O
In,O
five,O
rats,O
that,O
did,O
not,O
become,O
rigid,O
",",O
ICP,O
and,O
CVP,O
did,O
not,O
change,O
following,O
alfentanil,Entity
.,O
The,O
morphological,O
analysis,O
of,O
the,O
kidneys,O
included,O
a,O
semi,O
-,O
quantitative,O
scoring,O
system,O
analysing,O
the,O
degree,O
of,O
striped,O
fibrosis,Entity
",",O
subcapsular,O
fibrosis,Entity
and,O
the,O
number,O
of,O
basophilic,O
tubules,O
",",O
plus,O
an,O
additional,O
stereological,O
analysis,O
of,O
the,O
total,O
grade,O
of,O
fibrosis,Entity
in,O
the,O
cortex,O
stained,O
with,O
Sirius,O
Red,O
.,O
The,O
anthracyclines,Entity
daunorubicin,Entity
and,O
doxorubicin,Entity
and,O
the,O
epipodophyllotoxin,Entity
etoposide,Entity
are,O
potent,O
DNA,O
cleavage,O
-,O
enhancing,O
drugs,O
that,O
are,O
widely,O
used,O
in,O
clinical,O
oncology,O
;,O
however,O
",",O
myelosuppression,Entity
and,O
cardiac,Entity
toxicity,Entity
limit,O
their,O
use,O
.,O
The,O
absolute,O
risk,O
for,O
bladder,Entity
cancer,Entity
in,O
the,O
cohort,O
reached,O
10%,O
16,O
years,O
after,O
diagnosis,O
of,O
Wegener,Entity
's,Entity
granulomatosis,Entity
",",O
and,O
a,O
history,O
of,O
bladder,Entity
cancer,Entity
was,O
(,O
non,O
-,O
significantly,O
),O
twice,O
as,O
common,O
as,O
expected,O
at,O
the,O
time,O
of,O
diagnosis,O
of,O
Wegener,Entity
's,Entity
granulomatosis,Entity
.,O
The,O
common,O
factor,O
relating,O
thromboembolism,Entity
and,O
thrombocytopenia,Entity
is,O
heparin,Entity
-,O
induced,O
platelet,Entity
aggregation,Entity
.,O
Alpha2ABC-/-,O
mice,O
were,O
completely,O
unresponsive,O
to,O
the,O
analgesic,O
and,O
hypnotic,O
effects,O
of,O
clonidine,Entity
;,O
however,O
",",O
clonidine,Entity
significantly,O
lowered,O
heart,O
rate,O
in,O
alpha2ABC-/-,O
mice,O
by,O
up,O
to,O
150,O
bpm,O
.,O
Glyceryl,Entity
trinitrate,Entity
infusion,O
completely,O
normalized,O
the,O
prostigmine,Entity
-,O
morphine,Entity
-,O
induced,O
alterations,O
in,O
these,O
quantitative,O
parameters,O
(,O
TmaX,O
over,O
the,O
LP,O
:,O
11.33,O
+,O
/-,O
Microinjection,O
of,O
ritanserin,Entity
into,O
the,O
CA1,O
region,O
of,O
hippocampus,O
improves,O
scopolamine,Entity
-,O
induced,O
amnesia,Entity
in,O
adult,O
male,O
rats,O
.,O
Nicotine,Entity
and,O
caffeine,Entity
are,O
widely,O
consumed,O
licit,O
psychoactive,O
drugs,O
worldwide,O
.,O
These,O
analyses,O
suggest,O
that,O
the,O
higher,O
risk,O
observed,O
for,O
the,O
newer,O
OC,Entity
in,O
other,O
studies,O
may,O
be,O
the,O
result,O
of,O
inadequate,O
comparisons,O
of,O
pill,O
users,O
with,O
different,O
patterns,O
of,O
pill,O
use,O
.,O
In,O
both,O
sets,O
(,O
four,O
),O
of,O
eyes,O
of,O
the,O
subjects,O
with,O
persistent,O
visual,Entity
deficits,Entity
(,O
patients,O
B,O
and,O
C,O
),O
",",O
there,O
was,O
an,O
average,O
loss,O
of,O
79%,O
of,O
nerve,O
fiber,O
thickness,O
in,O
the,O
temporal,O
quadrant,O
.,O
Resting,O
irCRF,O
levels,O
are,O
suppressed,O
only,O
at,O
the,O
highest,O
corticosterone,Entity
infusion,O
rate,O
",",O
which,O
resulted,O
in,O
systemic,O
corticosterone,Entity
levels,O
of,O
40,O
micrograms,O
/,O
dl,O
.,O
All,O
four,O
agents,O
were,O
associated,O
with,O
aortic,O
arch,O
branching,O
variants,O
",",O
although,O
significantly,O
increased,O
only,O
for,O
Ro,Entity
40,Entity
-,Entity
5967,Entity
and,O
verapamil,Entity
.,O
There,O
was,O
one,O
treatment,O
-,O
related,O
death,Entity
.,O
Clinical,O
and,O
electrophysiological,O
data,O
in,O
12,O
female,O
patients,O
with,O
CLE,Entity
during,O
treatment,O
with,O
thalidomide,Entity
and,O
up,O
to,O
47,O
months,O
after,O
discontinuation,O
of,O
treatment,O
were,O
analysed,O
.,O
Anticholinesterases,O
were,O
administered,O
in,O
an,O
attempt,O
to,O
antagonize,O
prolonged,O
neuromuscular,Entity
blockade,Entity
following,O
the,O
administration,O
of,O
succinylcholine,Entity
in,O
a,O
patient,O
later,O
found,O
to,O
be,O
homozygous,O
for,O
atypical,O
plasma,O
cholinesterase,O
.,O
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
determine,O
if,O
the,O
prophylactic,O
value,O
of,O
misoprostol,Entity
was,O
dose,O
-,O
dependent,O
.,O
The,O
extension,O
of,O
hemolysis,Entity
is,O
variable,O
with,O
erythrocyte,O
samples,O
",",O
but,O
12.5,O
microM,O
TAM,Entity
induces,O
total,O
hemolysis,Entity
of,O
all,O
tested,O
suspensions,O
.,O
Initially,O
",",O
allograft,O
rejection,O
was,O
feared,O
;,O
however,O
",",O
myocardial,O
biopsy,O
samples,O
revealed,O
only,O
interstitial,O
edema,Entity
and,O
mild,O
myocardial,Entity
hypertrophy,Entity
;,O
neither,O
cellular,O
nor,O
humoral,O
rejection,O
was,O
detected,O
.,O
Death,Entity
from,O
chemotherapy,O
in,O
gestational,Entity
trophoblastic,Entity
disease,Entity
.,O
The,O
effect,O
of,O
naloxone,Entity
could,O
be,O
antagonized,O
with,O
morphine,Entity
(,O
1,O
",",O
3,O
",",O
and,O
10,O
mg,O
/,O
kg,O
),O
",",O
demonstrating,O
the,O
opioid,O
specificity,O
of,O
the,O
naloxone,Entity
effect,O
.,O
Thus,O
",",O
dronedarone,Entity
and,O
amiodarone,Entity
displayed,O
a,O
similar,O
level,O
of,O
antiadrenergic,O
effect,O
and,O
did,O
not,O
impair,O
the,O
resting,O
left,O
ventricular,O
function,O
.,O
Additionally,O
",",O
20,O
to,O
25%,O
of,O
paracetamol,Entity
-,O
treated,O
rats,O
developed,O
hyperplasia,Entity
of,O
the,O
bladder,O
epithelium,O
",",O
which,O
was,O
not,O
coincident,O
with,O
the,O
presence,O
of,O
bladder,Entity
calculi,Entity
.,O
An,O
experiment,O
was,O
performed,O
to,O
test,O
whether,O
inclusion,O
of,O
phenobarbital,Entity
in,O
a,O
choline,Entity
-,O
devoid,O
diet,O
would,O
increase,O
the,O
hepatocarcinogenicity,O
of,O
the,O
diet,O
.,O
In,O
PMs,O
",",O
metoprolol,Entity
increased,O
the,O
terbutaline,Entity
area,O
under,O
the,O
plasma,O
concentration,O
vs.,O
time,O
curve,O
(,O
+,O
67%,O
),O
.,O
D,Entity
-,Entity
Penicillamine,Entity
caused,O
nephrotic,Entity
syndrome,Entity
in,O
1,O
patient,O
and,O
milder,O
reversible,O
proteinuria,Entity
in,O
3,O
other,O
patients,O
;,O
none,O
developed,O
renal,Entity
insufficiency,Entity
.,O
In,O
group,O
1,O
",",O
animals,O
received,O
cocaine,Entity
followed,O
by,O
vehicle,O
.,O
Methamphetamine,Entity
or,O
amphetamine,Entity
levels,O
were,O
related,O
to,O
several,O
psychopathology,O
scores,O
and,O
the,O
global,O
hyperkinesia,Entity
rating,O
.,O
Of,O
the,O
246,O
admitted,O
patients,O
",",O
34,O
(,O
14%,O
),O
met,O
CK,O
-,O
MB,O
criteria,O
for,O
MI,Entity
and,O
38,O
(,O
16%,O
),O
Absolute,O
and,O
attributable,O
risk,O
of,O
venous,Entity
thromboembolism,Entity
in,O
women,O
on,O
combined,O
cyproterone,Entity
acetate,Entity
and,O
ethinylestradiol,Entity
.,O
Because,O
Warfarin,Entity
treatment,O
had,O
no,O
effect,O
on,O
the,O
elevation,O
in,O
serum,O
calcium,Entity
produced,O
by,O
vitamin,Entity
D,Entity
",",O
the,O
synergy,O
between,O
Warfarin,Entity
and,O
vitamin,Entity
D,Entity
is,O
probably,O
best,O
explained,O
by,O
the,O
hypothesis,O
that,O
Warfarin,Entity
inhibits,O
the,O
activity,O
of,O
matrix,O
Gla,O
protein,O
as,O
a,O
calcification,Entity
inhibitor,O
.,O
The,O
neutropenia,Entity
was,O
due,O
to,O
maturation,O
arrest,O
of,O
the,O
myeloid,O
series,O
in,O
one,O
patient,O
.,O
Treated,O
rats,O
were,O
then,O
evaluated,O
for,O
incidence,O
",",O
latency,O
",",O
and,O
seizure,Entity
pattern,O
or,O
for,O
locomotor,O
activity,O
in,O
animals,O
without,O
seizures,Entity
.,O
Effects,O
of,O
pallidal,O
neurotensin,Entity
on,O
haloperidol,Entity
-,O
induced,O
parkinsonian,Entity
catalepsy,Entity
:,O
behavioral,O
and,O
electrophysiological,O
studies,O
.,O
After,O
delivery,O
of,O
the,O
infant,O
",",O
there,O
should,O
be,O
no,O
contraindication,O
to,O
the,O
use,O
of,O
an,O
alpha,O
-,O
adrenergic,O
vasopressor,O
such,O
as,O
phenylephrine,Entity
to,O
treat,O
hypotensive,Entity
patients,O
with,O
tachycardia,Entity
.,O
Added,O
in,O
vitro,O
to,O
rat,O
cortical,O
membrane,O
preparation,O
",",O
abecarnil,Entity
increased,O
[,O
3H]GABA,Entity
binding,O
",",O
enhanced,O
muscimol,Entity
-,O
stimulated,O
36Cl-,O
uptake,O
and,O
reduced,O
the,O
binding,O
of,O
t-[35S]butylbicyclophosphorothionate,Entity
(,O
[,Entity
35S]TBPS,Entity
),O
.,O
Given,O
the,O
onset,O
of,O
his,O
jaundice,Entity
2,O
wk,O
after,O
the,O
initiation,O
of,O
metformin,Entity
",",O
we,O
believe,O
that,O
this,O
case,O
represents,O
an,O
example,O
of,O
metformin,Entity
-,O
associated,O
hepatotoxicity,Entity
",",O
the,O
first,O
such,O
case,O
reported,O
.,O
Incidence,O
of,O
increased,O
aspartate,Entity
aminotransferase,O
and/or,O
alanine,Entity
aminotransferase,O
>,O
3,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
was,O
<,O
0.3%,O
.,O
Thus,O
",",O
gentamicin,Entity
was,O
associated,O
with,O
renal,Entity
failure,Entity
more,O
than,O
three,O
times,O
as,O
often,O
as,O
was,O
tobramycin,Entity
.,O
",",O
atrial,Entity
septal,Entity
defects,Entity
(,O
AOR,O
=,O
1.9,O
;,O
95%,O
CI,O
",",O
1.1,O
-,O
3.4,O
),O
",",O
and,O
cleft,Entity
lip,Entity
with,O
cleft,Entity
palate,Entity
(,O
AOR,O
=,O
2.1,O
;,O
Effect,O
of,O
polyethylene,Entity
glycol,Entity
400,Entity
on,O
adriamycin,Entity
toxicity,Entity
in,O
mice,O
.,O
In,O
particular,O
",",O
the,O
tendency,O
of,O
cocaine,Entity
to,O
produce,O
chest,Entity
pain,Entity
ought,O
to,O
be,O
in,O
the,O
mind,O
of,O
the,O
emergency,O
nurse,O
when,O
faced,O
with,O
a,O
young,O
victim,O
of,O
chest,Entity
pain,Entity
who,O
is,O
otherwise,O
at,O
low,O
risk,O
.,O
Moreover,O
",",O
the,O
abundance,O
of,O
the,O
alpha(1)-subunit,O
of,O
the,O
Na,Entity
-,O
K,Entity
-,O
ATPase,O
was,O
decreased,O
in,O
the,O
cortex,O
and,O
ISOM,O
",",O
but,O
it,O
remained,O
unchanged,O
in,O
the,O
IM,O
.,O
Data,O
were,O
acquired,O
at,O
baseline,O
",",O
after,O
induction,O
of,O
acute,O
heart,Entity
failure,Entity
",",O
and,O
after,O
MAP,O
.,O
In,O
this,O
open,O
trial,O
",",O
galantamine,Entity
was,O
well,O
-,O
tolerated,O
and,O
appeared,O
to,O
be,O
beneficial,O
for,O
the,O
treatment,O
of,O
interfering,O
behaviors,O
in,O
children,O
with,O
autism,Entity
",",O
particularly,O
aggression,Entity
",",O
behavioral,Entity
dyscontrol,Entity
",",O
and,O
inattention,Entity
.,O
The,O
role,O
of,O
methotrexate,Entity
contaminants,O
",",O
local,O
folate,Entity
deficiency,Entity
",",O
and,O
cranial,O
irradiation,O
in,O
the,O
pathogenesis,O
of,O
intrathecal,O
methotrexate,Entity
toxicity,Entity
is,O
unclear,O
.,O
KF17837,Entity
is,O
a,O
novel,O
selective,O
adenosine,Entity
A2A,O
receptor,O
antagonist,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
fatal,O
liver,Entity
failure,Entity
possibly,O
associated,O
with,O
concurrent,O
use,O
of,O
bupropion,Entity
and,O
carbimazole,Entity
.,O
There,O
were,O
no,O
infectious,O
deaths,O
in,O
renal,O
transplant,O
patients,O
on,O
cyclosporine,Entity
or,O
Aza,Entity
",",O
but,O
infection,Entity
played,O
a,O
major,O
role,O
in,O
3,O
out,O
of,O
6,O
cardiac,O
transplant,O
deaths,O
and,O
in,O
8,O
out,O
of,O
9,O
liver,O
transplant,O
deaths,O
.,O
If,O
this,O
were,O
so,O
",",O
patients,O
with,O
coronary,Entity
artery,Entity
disease,Entity
might,O
be,O
especially,O
susceptible,O
.,O
1,O
h,O
before,O
doxorubicin,Entity
),O
provided,O
almost,O
full,O
protection,O
.,O
=,O
8),O
was,O
injected,O
intrathecally,O
(,O
IT,O
),O
0.5,O
h,O
after,O
reflow,O
",",O
and,O
30,O
mug,O
of,O
morphine,Entity
(,O
group,O
SM,O
;,O
Mitochondrial,O
DNA,O
and,O
its,O
respiratory,O
chain,O
products,O
are,O
defective,O
in,O
doxorubicin,Entity
nephrosis,Entity
.,O
An,O
11-year,O
-,O
old,O
boy,O
was,O
given,O
halothane,Entity
",",O
nitrous,Entity
oxide,Entity
and,O
oxygen,Entity
",",O
pancuronium,Entity
0.4,O
mg,O
and,O
suxamethonium,Entity
100,O
mg,O
for,O
induction,O
of,O
anaesthesia,O
.,O
BP,O
before,O
dobutamine,Entity
infusion,O
.,O
Side,O
effects,O
attributable,O
to,O
mazindol,Entity
included,O
decreased,Entity
appetite,Entity
(,O
36%,O
),O
",",O
dry,Entity
mouth,Entity
(,O
10%,O
),O
",",O
behavioral,O
change,O
(,O
22%,O
),O
",",O
and,O
gastrointestinal,Entity
symptoms,Entity
(,O
18%,O
),O
;,O
mazindol,Entity
dosage,O
was,O
reduced,O
in,O
43%,O
of,O
patients,O
.,O
They,O
all,O
exhibited,O
markedly,O
reduced,O
plasma,O
catecholamines,Entity
and,O
plasma,O
renin,O
activity,O
in,O
both,O
recumbent,O
and,O
upright,O
positions,O
and,O
had,O
marked,O
hypersensitivity,Entity
to,O
the,O
pressor,O
effects,O
of,O
infused,O
norepinephrine,Entity
.,O
Oxitropium,Entity
proves,O
to,O
be,O
a,O
valuable,O
alternative,O
to,O
theophylline,Entity
in,O
nocturnal,O
asthma,Entity
",",O
since,O
it,O
is,O
equally,O
potent,O
",",O
safer,O
and,O
does,O
not,O
require,O
the,O
titration,O
of,O
dosage,O
.,O
A,O
reductase,O
inhibitor,O
(,O
statin,Entity
),O
therapy,O
.,O
This,O
is,O
the,O
first,O
study,O
to,O
link,O
risperidone,Entity
-,O
induced,O
hyperprolactinemia,Entity
and,O
SSRI,O
treatment,O
to,O
lower,O
BMD,O
in,O
children,O
and,O
adolescents,O
.,O
Persistent,O
paralysis,Entity
after,O
prolonged,O
use,O
of,O
atracurium,Entity
in,O
the,O
absence,O
of,O
corticosteroids,O
.,O
When,O
comparing,O
all,O
lithium,Entity
treated,O
versus,O
non,O
-,O
lithium,Entity
-,O
treated,O
groups,O
",",O
lithium,Entity
caused,O
a,O
reduction,O
in,O
glomerular,O
filtration,O
rate,O
(,O
GFR,O
),O
without,O
significant,O
changes,O
in,O
effective,O
renal,O
plasma,O
flow,O
(,O
as,O
determined,O
by,O
a,O
marker,O
secreted,O
into,O
the,O
proximal,O
tubules,O
),O
or,O
lithium,Entity
clearance,O
.,O
Both,O
CSSEPs,O
as,O
central,O
and,O
NMPs,O
as,O
peripheral,O
correlates,O
of,O
pain,Entity
were,O
obtained,O
in,O
response,O
to,O
the,O
CO2,Entity
stimuli,O
.,O
Her,O
acetylcholine,Entity
receptor,O
antibody,O
level,O
was,O
markedly,O
elevated,O
.,O
The,O
administration,O
of,O
pharmacologic,O
doses,O
of,O
pyridoxine,Entity
hydrochloride,Entity
led,O
to,O
a,O
disappearance,O
of,O
symptoms,O
.,O
The,O
tachyarrhythmias,Entity
generally,O
subsided,O
within,O
48,O
hours,O
after,O
administration,O
of,O
the,O
drugs,O
was,O
stopped,O
.,O
In,O
previous,O
experiments,O
we,O
found,O
that,O
decreases,O
in,O
food,O
intake,O
were,O
induced,O
by,O
local,O
administration,O
of,O
calcitonin,Entity
into,O
several,O
hypothalamic,O
sites,O
and,O
into,O
the,O
nucleus,O
accumbens,O
.,O
The,O
results,O
have,O
shown,O
that,O
the,O
degradation,O
product,O
p,Entity
-,Entity
choloroaniline,Entity
is,O
not,O
a,O
significant,O
factor,O
in,O
chlorhexidine,Entity
-,Entity
digluconate,Entity
associated,O
erosive,O
cystitis,Entity
.,O
NIN,Entity
correlated,O
with,O
blood,O
oxygen,Entity
level,O
-,O
dependent,O
(,O
BOLD,O
),O
activity,O
levels,O
in,O
a,O
midpontine,O
site,O
in,O
the,O
posterior,O
basis,O
pontis,O
.,O
The,O
possibilities,O
that,O
these,O
cardiovascular,O
findings,O
might,O
be,O
the,O
result,O
of,O
non,O
-,O
selective,O
inhibition,O
of,O
monoamine,O
oxidase,O
or,O
of,O
amphetamine,Entity
and,O
metamphetamine,Entity
are,O
discussed,O
.,O
Seventy,O
-,O
five,O
human,Entity
immunodeficiency,Entity
virus,Entity
(,Entity
HIV)-infected,Entity
patients,O
with,O
CD4,O
+,O
cell,O
counts,O
Atrial,Entity
thrombosis,Entity
involving,O
the,O
heart,O
of,O
F-344,O
rats,O
ingesting,O
quinacrine,Entity
hydrochloride,Entity
.,O
World,O
Health,O
Organization,O
Grade,O
3,O
-,O
4,O
neutropenia,Entity
and,O
thrombocytopenia,Entity
occurred,O
in,O
39.9%,O
and,O
11.4%,O
of,O
patients,O
",",O
respectively,O
.,O
Damage,Entity
of,Entity
substantia,Entity
nigra,Entity
pars,Entity
reticulata,Entity
during,O
pilocarpine,Entity
-,O
induced,O
status,Entity
epilepticus,Entity
in,O
the,O
rat,O
:,O
immunohistochemical,O
study,O
of,O
neurons,O
",",O
astrocytes,O
and,O
serum,O
-,O
protein,O
extravasation,O
.,O
Two,O
minutes,O
after,O
remifentanil,Entity
or,O
placebo,O
injection,O
",",O
etomidate,Entity
0.3,O
mg,O
/,O
kg,O
was,O
given,O
.,O
The,O
use,O
of,O
serum,O
cholinesterase,O
in,O
succinylcholine,Entity
apnoea,Entity
provided,O
considerable,O
relief,O
to,O
both,O
patient,O
and,O
anaesthetist,O
.,O
Diagnostic,O
markers,O
such,O
as,O
N,Entity
-,Entity
terminal,Entity
pro,Entity
brain,Entity
natriuretic,Entity
peptide,Entity
(,O
NT,Entity
-,Entity
proBNP,Entity
),O
or,O
high,O
-,O
sensitive,O
C,O
-,O
reactive,O
protein,O
might,O
help,O
in,O
the,O
early,O
identification,O
of,O
patients,O
at,O
risk,O
",",O
thus,O
avoiding,O
the,O
occurrence,O
of,O
serious,O
cardiovascular,Entity
toxicity,Entity
.,O
The,O
neurologic,O
evaluation,O
revealed,O
loss,Entity
of,Entity
sensation,Entity
in,O
the,O
saddle,O
area,O
and,O
medial,O
aspect,O
of,O
her,O
right,O
leg,O
.,O
We,O
designed,O
the,O
present,O
study,O
to,O
investigate,O
whether,O
an,O
inflammatory,O
reaction,O
contributes,O
to,O
this,O
myalgia,Entity
.,O
We,O
investigated,O
the,O
safety,O
and,O
efficacy,O
of,O
adding,O
different,O
doses,O
of,O
ephedrine,Entity
to,O
propofol,Entity
in,O
order,O
to,O
obtund,O
the,O
hypotensive,Entity
response,O
.,O
No,O
significant,O
differences,O
were,O
observed,O
between,O
quetiapine,Entity
and,O
placebo,O
on,O
SAS,O
and,O
BARS,O
scores,O
.,O
The,O
antiarrhythmic,O
effect,O
and,O
possible,O
ionic,O
mechanisms,O
of,O
pilocarpine,Entity
on,O
animal,O
models,O
.,O
Among,O
users,O
of,O
aspirin,Entity
",",O
both,O
celecoxib,Entity
and,O
naproxen,Entity
seemed,O
to,O
be,O
the,O
least,O
toxic,O
.,O
Every,O
patient,O
was,O
screened,O
for,O
testosterone,Entity
and,O
451,O
were,O
screened,O
for,O
prolactin,O
on,O
the,O
basis,O
of,O
low,Entity
sexual,Entity
desire,Entity
",",O
gynecomastia,Entity
or,O
testosterone,Entity
less,O
than,O
4,O
ng./ml,O
.,O
OBJECTIVE,O
:,O
Diazinon,Entity
",",O
a,O
common,O
organophosphate,Entity
insecticide,O
with,O
genotoxic,O
properties,O
",",O
was,O
previously,O
associated,O
with,O
lung,Entity
cancer,Entity
in,O
the,O
Agricultural,O
Health,O
Study,O
(,O
AHS,O
),O
cohort,O
",",O
but,O
few,O
other,O
epidemiological,O
studies,O
have,O
examined,O
diazinon,Entity
-,O
associated,O
cancer,Entity
risk,O
.,O
When,O
seen,O
at,O
the,O
emergency,O
department,O
2,O
weeks,O
later,O
",",O
she,O
still,O
had,O
severe,O
icterus,Entity
",",O
pruritus,Entity
",",O
and,O
hyperbilirubinemia,Entity
",",O
formed,O
mainly,O
of,O
the,O
conjugated,O
fraction,O
.,O
A,O
lesser,O
degree,O
of,O
orthostatic,Entity
hypotension,Entity
occurred,O
with,O
standing,O
.,O
Both,O
timolol,Entity
solution,O
and,O
timolol,Entity
gellan,O
reduced,O
the,O
mean,O
24-hour,O
heart,O
rate,O
compared,O
with,O
placebo,O
(,O
P,O
<,O
or,O
=,O
.001,O
),O
",",O
and,O
this,O
reduction,O
was,O
most,O
pronounced,O
during,O
the,O
daytime,O
(,O
-7.5%,O
change,O
in,O
mean,O
heart,O
rate,O
Anticoagulant,O
-,O
induced,O
femoral,Entity
nerve,Entity
palsy,Entity
represents,O
the,O
most,O
common,O
form,O
of,O
warfarin,Entity
-,O
induced,O
peripheral,Entity
neuropathy,Entity
;,O
it,O
is,O
characterized,O
by,O
severe,O
pain,Entity
in,O
the,O
inguinal,O
region,O
",",O
varying,O
degrees,O
of,O
motor,Entity
and,Entity
sensory,Entity
impairment,Entity
",",O
and,O
flexure,O
contracture,Entity
of,O
the,O
involved,O
extremity,O
.,O
The,O
cause,O
of,O
hearing,Entity
loss,Entity
after,O
spinal,O
anaesthesia,O
is,O
unknown,O
.,O
:,O
Verapamil,Entity
promotes,O
AF,Entity
in,O
normal,O
dogs,O
by,O
promoting,O
multiple,O
circuit,O
reentry,O
",",O
an,O
effect,O
dependent,O
on,O
intact,O
autonomic,O
tone,O
and,O
not,O
shared,O
by,O
diltiazem,Entity
.,O
Similarly,O
",",O
when,O
the,O
P450-mediated,O
metabolism,O
of,O
lindane,Entity
was,O
blocked,O
by,O
cobalt,Entity
chloride,Entity
incidence,O
of,O
convulsions,Entity
was,O
increased,O
in,O
animals,O
treated,O
with,O
lindane,Entity
indicating,O
that,O
lindane,Entity
per,O
se,O
or,O
its,O
metabolites,O
formed,O
by,O
PB,O
or,O
ethanol,Entity
inducible,O
Group,O
ADR+LOS(6,Entity
),O
received,O
losartan,Entity
We,O
report,O
a,O
case,O
of,O
hypotension,Entity
",",O
bradycardia,Entity
",",O
and,O
asystole,Entity
after,O
intravenous,O
administration,O
of,O
high,O
-,O
dose,O
methylprednisolone,Entity
in,O
a,O
73-year,O
-,O
old,O
patient,O
who,O
underwent,O
electrocardiographic,O
(,O
ECG,O
),O
monitoring,O
throughout,O
the,O
episode,O
.,O
Rifampicin,Entity
-,O
associated,O
segmental,O
necrotizing,O
glomerulonephritis,Entity
in,O
staphylococcal,Entity
endocarditis,Entity
.,O
Maximum,O
contraction,O
of,O
vena,O
cava,O
to,O
norepinephrine,Entity
(,O
37%,O
control,O
),O
also,O
was,O
reduced,O
but,O
no,O
change,O
in,O
response,O
to,O
ET-1,O
was,O
observed,O
.,O
Role,O
of,O
xanthine,Entity
oxidase,O
in,O
dexamethasone,Entity
-,O
induced,O
hypertension,Entity
in,O
rats,O
.,O
1,O
.,O
Myopathy,Entity
",",O
defined,O
as,O
muscle,O
symptoms,O
with,O
creatine,Entity
kinase,O
elevations,O
greater,O
than,O
10,O
times,O
the,O
upper,O
limit,O
of,O
normal,O
",",O
was,O
rare,O
and,O
associated,O
with,O
the,O
highest,O
recommended,O
daily,O
dose,O
of,O
lovastatin,Entity
(,O
80,O
mg,O
),O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
methicillin,Entity
-,O
sensitive,O
Staphylococcus,O
aureus,O
(,O
MSSA,O
),O
bacteremia,Entity
with,O
suspected,O
MSSA,O
meningitis,Entity
treated,O
with,O
high,O
-,O
dose,O
daptomycin,Entity
assessed,O
with,O
concurrent,O
serum,O
and,O
cerebrospinal,O
fluid,O
(,O
CSF,O
),O
concentrations,O
.,O
A,O
printout,O
of,O
all,O
cases,O
of,O
hypercalcemia,Entity
that,O
presented,O
during,O
a,O
1-year,O
period,O
was,O
generated,O
.,O
Preoperative,O
platelet,O
count,O
",",O
postoperative,O
course,O
of,O
platelets,O
",",O
and,O
clinical,O
signs,O
of,O
HIT,Entity
type,Entity
II,Entity
were,O
analyzed,O
.,O
(,O
10,O
mg,O
/,O
kg,O
/,O
b.w./day,O
by,O
gavages,O
),O
for,O
6,O
weeks,O
and,O
group,O
ADR+LOS(12,Entity
),O
for,O
12,O
weeks,O
after,O
second,O
injection,O
of,O
ADR,Entity
.,O
Cerebrospinal,O
fluid,O
penetration,O
of,O
high,O
-,O
dose,O
daptomycin,Entity
in,O
suspected,O
Staphylococcus,O
aureus,O
meningitis,Entity
.,O
To,O
determine,O
whether,O
the,O
capacity,O
for,O
reactive,O
DNA,O
synthesis,O
was,O
also,O
subject,O
to,O
genetic,O
regulation,O
",",O
cardiac,Entity
hypertrophy,Entity
was,O
induced,O
in,O
the,O
strains,O
of,O
mice,O
comprising,O
the,O
extremes,O
of,O
the,O
nuclear,O
number,O
survey,O
.,O
Age,O
-,O
dependent,O
sensitivity,O
of,O
the,O
rat,O
to,O
neurotoxic,Entity
effects,O
of,O
streptomycin,Entity
.,O
We,O
examined,O
the,O
occurrence,O
of,O
adverse,O
events,O
and,O
the,O
need,O
for,O
discontinuation,O
and,O
dose,O
reduction,O
during,O
treatment,O
",",O
with,O
a,O
focus,O
on,O
hypotension,Entity
and,O
renal,Entity
dysfunction,Entity
.,O
METHODS,O
:,O
Forty,O
-,O
nine,O
patients,O
with,O
advanced,O
NSCLC,Entity
were,O
included,O
",",O
38,O
of,O
whom,O
were,O
age,O
>,O
/=,O
70,O
years,O
and,O
11,O
were,O
age,O
Two,O
patients,O
with,O
leprosy,Entity
who,O
developed,O
hemolysis,Entity
and,O
acute,Entity
renal,Entity
failure,Entity
following,O
rifampin,Entity
are,O
reported,O
.,O
Patients,O
tapped,O
faster,O
after,O
propranolol,Entity
than,O
diazepam,Entity
and,O
they,O
were,O
more,O
sedated,O
after,O
diazepam,Entity
than,O
propranolol,Entity
.,O
OBJECTIVE,O
:,O
We,O
aimed,O
to,O
evaluate,O
the,O
rates,O
of,O
cisplatin,Entity
-,O
induced,O
nephrotoxicity,Entity
in,O
cancer,Entity
patients,O
receiving,O
single,O
-,O
agent,O
cisplatin,Entity
with,O
and,O
without,O
mannitol,Entity
.,O
We,O
suggest,O
that,O
DHEA,Entity
displays,O
typical,O
neuroleptic,O
-,O
like,O
effects,O
",",O
and,O
may,O
be,O
used,O
in,O
the,O
treatment,O
of,O
schizophrenia,Entity
.,O
Functional,O
evidence,O
relating,O
the,O
IC,O
to,O
motor,O
behavior,O
derives,O
from,O
experiments,O
showing,O
that,O
activation,O
of,O
the,O
IC,O
by,O
electrical,O
stimulation,O
or,O
excitatory,O
amino,Entity
acid,Entity
microinjection,O
causes,O
freezing,O
",",O
escape,O
-,O
like,O
behavior,O
",",O
and,O
immobility,O
.,O
From,O
day,O
0,O
to,O
day,O
3,O
",",O
the,O
mean,O
peak,O
increase,O
in,O
creatinine,Entity
was,O
0.13,O
mg,O
per,O
deciliter,O
in,O
the,O
iodixanol,Entity
group,O
and,O
0.55,O
mg,O
per,O
deciliter,O
in,O
the,O
iohexol,Entity
group,O
(,O
P=0.001,O
;,O
the,O
increase,O
with,O
iodixanol,Entity
minus,O
the,O
increase,O
with,O
iohexol,Entity
",",O
-0.42,O
mg,O
per,O
deciliter,O
[,O
95,O
percent,O
confidence,O
interval,O
",",O
-0.73,O
to,O
-0.22,O
],O
),O
.,O
(,O
3,O
),O
complete,O
protection,O
against,O
amnesia,Entity
for,O
a,O
passive,O
avoidance,O
task,O
in,O
rats,O
submitted,O
to,O
electroconvulsive,O
shock,O
immediately,O
after,O
avoidance,O
acquisition,O
;,O
(,O
4,O
),O
prevention,O
of,O
the,O
long,O
-,O
term,O
retention-,O
or,O
retrieval,O
-,O
deficit,O
for,O
a,O
passive,O
avoidance,O
task,O
induced,O
in,O
rats,O
and,O
mice,O
by,O
chloramphenicol,Entity
or,O
cycloheximide,Entity
administered,O
immediately,O
after,O
acquisition,O
;,O
(,O
5,O
),O
reversal,O
",",O
The,O
prolactinoma,Entity
cells,O
at,O
this,O
time,O
were,O
well,O
granulated,O
",",O
with,O
vesiculated,O
rough,O
endoplasmic,O
reticulum,O
and,O
markedly,O
dilated,O
Golgi,O
cisternae,O
.,O
A,O
case,O
of,O
fatal,O
aplastic,Entity
anemia,Entity
is,O
described,O
in,O
which,O
no,O
drugs,O
other,O
than,O
allopurinol,Entity
and,O
indomethacin,Entity
were,O
given,O
.,O
The,O
primary,O
outcome,O
was,O
acute,Entity
kidney,Entity
injury,Entity
(,O
AKI,Entity
),O
.,O
Seizure,Entity
end,O
points,O
included,O
latency,O
to,O
forelimb,O
or,O
hindlimb,O
clonus,O
",",O
latency,O
to,O
clonic,O
running,O
seizure,Entity
and,O
latency,O
to,O
jumping,O
bouncing,O
seizure,Entity
.,O
The,O
increased,O
concentration,O
of,O
sFas,O
in,O
serum,O
of,O
patients,O
with,O
acute,Entity
liver,Entity
failure,Entity
may,O
reflect,O
activation,O
of,O
Fas,O
-,O
mediated,O
apoptosis,O
in,O
the,O
liver,O
and,O
this,O
together,O
with,O
increased,O
tumor,Entity
necrosis,Entity
factor,O
-,O
alpha,O
may,O
be,O
an,O
important,O
factor,O
in,O
liver,O
cell,O
loss,O
.,O
Tetrabenazine,Entity
should,O
be,O
administered,O
very,O
carefully,O
in,O
combination,O
with,O
other,O
neuroleptic,Entity
drugs,Entity
",",O
particularly,O
in,O
patients,O
with,O
a,O
worsening,O
general,O
condition,O
.,O
It,O
was,O
concluded,O
that,O
labetalol,Entity
offers,O
advantages,O
over,O
nitroprusside,Entity
.,O
A,O
total,O
of,O
342,O
patients,O
(,O
105,O
dexmedetomidine,Entity
and,O
237,O
propofol,Entity
),O
were,O
included,O
in,O
the,O
analysis,O
",",O
with,O
190,O
matched,O
(,O
95,O
in,O
each,O
group,O
),O
by,O
propensity,O
score,O
.,O
A,O
significant,O
relationship,O
was,O
observed,O
between,O
the,O
rate,O
of,O
reduction,O
of,O
hemoglobin,O
concentrations,O
at,O
week,O
2,O
and,O
the,O
severity,O
of,O
anemia,Entity
(,O
P,O
<,O
0.01,O
),O
.,O
The,O
fits,Entity
ceased,O
within,O
4,O
hours,O
of,O
administering,O
intramuscular,O
pyridoxine,Entity
",",O
suggesting,O
an,O
aetiology,O
of,O
pyridoxine,Entity
deficiency,O
secondary,O
to,O
isoniazid,Entity
medication,O
.,O
Prescription,O
of,O
crocin,Entity
in,O
each,O
dose,O
was,O
repeated,O
once,O
for,O
two,O
days,O
.,O
We,O
briefly,O
describe,O
two,O
patients,O
suffering,O
from,O
recent,O
-,O
onset,O
atrial,Entity
fibrillation,Entity
",",O
who,O
experienced,O
an,O
acute,O
devastating,O
low,Entity
back,Entity
pain,Entity
a,O
few,O
minutes,O
after,O
initiation,O
of,O
intravenous,O
amiodarone,Entity
loading,O
.,O
In,O
the,O
controls,O
",",O
the,O
GTN,Entity
-,O
induced,O
headache,Entity
gradually,O
disappeared,O
",",O
whereas,O
in,O
migraineurs,Entity
peak,O
headache,Entity
intensity,O
occurred,O
at,O
a,O
mean,O
time,O
of,O
240,O
min,O
post,O
-,O
infusion,O
.,O
The,O
results,O
of,O
this,O
study,O
suggest,O
that,O
the,O
blockade,O
of,O
mGluR5,O
by,O
MPEP,Entity
may,O
protect,O
dopaminergic,O
neurones,O
against,O
methamphetamine,Entity
-,O
induced,O
toxicity,Entity
.,O
In,O
contrast,O
",",O
no,O
evidence,O
of,O
memory,Entity
impairment,Entity
was,O
observed,O
in,O
moderate,O
MDMA,Entity
users,O
.,O
Five,O
patients,O
developed,O
pneumonia,Entity
(,O
two,O
Pneumocystis,Entity
carinii,Entity
pneumonia,Entity
",",O
one,O
infectious,Entity
mononucleosis,Entity
with,O
polyclonal,O
PTLD,Entity
lung,O
infiltrate,O
),O
and,O
two,O
had,O
bronchiolitis,Entity
obliterans,Entity
.,O
The,O
incidence,O
of,O
akathisia,Entity
was,O
low,O
and,O
similar,O
with,O
quetiapine,Entity
monotherapy,O
(,O
3.3%,O
),O
and,O
placebo,O
(,O
6.1%,O
),O
",",O
and,O
with,O
QTP,Entity
+,O
Li,Entity
/,O
DVP,Entity
(,O
3.6%,O
),O
and,O
PBO,O
+,O
Li,Entity
/,O
DVP,Entity
(,O
4.9%,O
),O
.,O
The,O
goal,O
of,O
the,O
study,O
was,O
to,O
deliver,O
a,O
dose,O
rate,O
and,O
total,O
cumulative,O
dose,O
of,O
ifosfamide,Entity
that,O
would,O
be,O
comparable,O
to,O
standard,O
bolus,O
or,O
short,O
-,O
term,O
infusions,O
administered,O
with,O
Mesna,Entity
.,O
Of,O
67,O
patients,O
initially,O
enrolled,O
",",O
24,O
remained,O
on,O
thalidomide,Entity
for,O
3,O
months,O
",",O
8,O
remained,O
at,O
6,O
months,O
",",O
and,O
3,O
remained,O
at,O
9,O
months,O
.,O
/,O
kg,O
flumazenil,Entity
.,O
Similarly,O
",",O
pre,O
-,O
test,O
scopolamine,Entity
partially,O
reversed,O
the,O
scopolamine,Entity
-,O
induced,O
amnesia,Entity
",",O
but,O
not,O
significantly,O
;,O
and,O
pre,O
-,O
test,O
cycloheximide,Entity
failed,O
to,O
reverse,O
the,O
cycloheximide,Entity
-,O
induced,O
amnesia,Entity
.,O
Pneumonitis,Entity
",",O
probably,O
or,O
possibly,O
related,O
",",O
mainly,O
grade,O
1/2,O
",",O
occurred,O
in,O
25%,O
.,O
Centrally,O
acting,O
alpha-2,O
adrenergic,O
agonists,O
are,O
one,O
of,O
several,O
pharmacologic,O
agents,O
used,O
in,O
the,O
treatment,O
of,O
spasticity,Entity
related,O
to,O
disorders,Entity
of,Entity
the,Entity
central,Entity
nervous,Entity
system,Entity
.,O
Myoglobinuria,Entity
was,O
also,O
observed,O
following,O
the,O
7.0,O
mg,O
/,O
kg,O
dose,O
.,O
Thus,O
",",O
myocardial,O
contrast,O
echocardiography,O
can,O
be,O
used,O
to,O
visualize,O
and,O
quantitate,O
the,O
amount,O
of,O
jeopardized,O
myocardium,O
during,O
moderate,O
to,O
severe,O
degrees,O
of,O
coronary,Entity
stenosis,Entity
.,O
Although,O
an,O
infrequent,O
complication,O
of,O
selective,O
serotonin,Entity
reuptake,O
inhibitor,O
therapy,O
",",O
it,O
is,O
important,O
that,O
ophthalmologists,O
are,O
aware,O
that,O
these,O
agents,O
can,O
cause,O
hypertension,Entity
because,O
this,O
class,O
of,O
drugs,O
is,O
widely,O
prescribed,O
.,O
Other,O
antibacterial,O
agents,O
that,O
showed,O
associations,O
included,O
erythromycins,Entity
(,O
2,O
defects,O
),O
",",O
penicillins,Entity
(,O
1,O
defect,O
),O
",",O
cephalosporins,Entity
(,O
1,O
defect,O
),O
",",O
and,O
quinolones,Entity
(,O
1,O
defect,O
),O
.,O
In,O
the,O
bupivacaine,Entity
groups,O
",",O
epinephrine,Entity
caused,O
fewer,O
prodysrhythmic,O
effects,O
than,O
without,O
bupivacaine,Entity
.,O
As,O
the,O
first,O
dihydropyridine,Entity
available,O
for,O
use,O
in,O
the,O
United,O
States,O
",",O
nifedipine,Entity
controls,O
angina,Entity
and,O
hypertension,Entity
with,O
minimal,O
depression,O
of,O
cardiac,O
function,O
.,O
ACE,O
did,O
not,O
correlate,O
with,O
focal,Entity
glomerulosclerosis,Entity
(,O
r,O
=,O
0.22,O
",",O
NS,O
),O
.,O
We,O
now,O
advocate,O
that,O
before,O
age,O
50,O
years,O
testosterone,Entity
be,O
determined,O
only,O
in,O
cases,O
of,O
low,Entity
sexual,Entity
desire,Entity
and,O
abnormal,O
physical,O
examination,O
but,O
that,O
it,O
be,O
measured,O
in,O
all,O
men,O
older,O
than,O
50,O
years,O
.,O
intestinal,Entity
angioedema,Entity
constitutes,O
a,O
challenge,O
to,O
primary,O
care,O
physicians,O
",",O
internists,O
",",O
emergency,O
room,O
personal,O
and,O
surgeons,O
.,O
Furthermore,O
",",O
dopamine,Entity
appeared,O
to,O
act,O
on,O
systems,O
more,O
closely,O
involved,O
with,O
the,O
induction,O
of,O
ketamine,Entity
catatonia,Entity
rather,O
than,O
directly,O
on,O
the,O
pituitary,O
.,O
METHODS,O
:,O
The,O
present,O
experiments,O
explored,O
whether,O
azathioprine,Entity
influences,O
eryptosis,O
.,O
These,O
lemon,O
essential,O
oils,O
showed,O
strong,O
ability,O
to,O
improve,O
memory,Entity
impaired,Entity
by,O
scopolamine,Entity
;,O
however,O
",",O
s,Entity
-,Entity
perillyl,Entity
alcohol,Entity
relieved,O
the,O
deficit,Entity
of,Entity
associative,Entity
memory,Entity
in,O
PA,O
only,O
",",O
and,O
did,O
not,O
improve,O
non,O
-,O
associative,O
memory,O
significantly,O
in,O
OFH,O
.,O
After,O
atropine,Entity
the,O
CD25,O
was,O
unchanged,O
after,O
placebo,O
(,O
2.3,O
+,O
/-,O
Ventricular,O
DNA,O
content,O
was,O
unchanged,O
during,O
the,O
early,O
stage,O
(,O
1,O
-,O
4,O
days,O
),O
of,O
hypertrophic,Entity
growth,O
but,O
increased,O
to,O
a,O
new,O
steady,O
-,O
state,O
level,O
19%,O
above,O
the,O
controls,O
after,O
8,O
days,O
of,O
treatment,O
.,O
Late,O
-,O
onset,O
scleroderma,Entity
renal,Entity
crisis,Entity
induced,O
by,O
tacrolimus,Entity
and,O
prednisolone,Entity
:,O
a,O
case,O
report,O
.,O
Captopril,Entity
(,O
50,O
mg,O
/,O
kg,O
/,O
day,O
",",O
given,O
orally,O
),O
",",O
an,O
inhibitor,O
of,O
angiotensin,Entity
-,O
converting,O
enzyme,O
used,O
as,O
a,O
standard,O
cardioprotective,O
drug,O
",",O
was,O
used,O
as,O
a,O
positive,O
control,O
in,O
this,O
study,O
.,O
Atypical,Entity
sensations,Entity
following,O
the,O
use,O
of,O
subcutaneous,O
sumatriptan,Entity
are,O
common,O
",",O
but,O
of,O
uncertain,O
origin,O
.,O
In,O
the,O
present,O
study,O
",",O
the,O
effects,O
of,O
three,O
alkylxanthines,Entity
with,O
different,O
potencies,O
as,O
adenosine,Entity
antagonists,O
8-phenyltheophylline,Entity
",",O
theophylline,Entity
and,O
enprofylline,Entity
",",O
were,O
examined,O
in,O
rats,O
developing,O
acute,Entity
renal,Entity
failure,Entity
after,O
4,O
daily,O
injections,O
of,O
gentamicin,Entity
(,O
200,O
mg,O
kg-1,O
),O
.,O
The,O
renal,Entity
injury,Entity
was,O
probably,O
aggravated,O
by,O
the,O
concomitant,O
intake,O
of,O
a,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drug,O
",",O
diclofenac,Entity
.,O
Characterization,O
of,O
estrogen,Entity
-,O
induced,O
adenohypophyseal,Entity
tumors,Entity
in,O
the,O
Fischer,O
344,O
rat,O
.,O
In,O
a,O
16-week,O
multicenter,O
",",O
double,O
-,O
blind,O
trial,O
",",O
122,O
children,O
with,O
ADHD,Entity
were,O
randomly,O
assigned,O
to,O
clonidine,Entity
(,O
n,O
=,O
31,O
),O
",",O
Neuroactive,O
steroids,Entity
demonstrate,O
pharmacological,O
actions,O
that,O
have,O
relevance,O
for,O
a,O
host,O
of,O
neurological,Entity
and,Entity
psychiatric,Entity
disorders,Entity
.,O
HS,O
diet,O
for,O
4,O
wk,O
caused,O
a,O
progressive,O
increase,O
in,O
BP,O
",",O
protein,O
and,O
albumin,O
excretion,O
",",O
and,O
glomerular,Entity
sclerosis,Entity
in,O
male,O
DS,O
rats,O
",",O
which,O
were,O
attenuated,O
by,O
castration,O
.,O
CONCLUSION,O
:,O
Higher,O
OD,O
is,O
associated,O
with,O
significant,O
risk,O
of,O
subsequent,O
thrombosis,Entity
in,O
patients,O
with,O
isolated,O
-,O
HIT,Entity
;,O
percent,O
inhibition,O
",",O
however,O
",",O
was,O
not,O
predictive,O
.,O
Out,O
of,O
a,O
total,O
of,O
88,O
courses,O
of,O
this,O
treatment,O
we,O
observed,O
10,O
episodes,O
of,O
asymptomatic,O
microscopic,O
haematuria,Entity
and,O
no,O
episodes,O
of,O
gross,O
haematuria,Entity
.,O
Most,O
of,O
the,O
other,O
low,O
testosterone,Entity
levels,O
seemed,O
to,O
result,O
from,O
nonorganic,O
hypothalamic,Entity
dysfunction,Entity
because,O
of,O
normal,O
serum,O
luteinizing,O
hormone,O
and,O
prolactin,O
and,O
to,O
have,O
only,O
a,O
small,O
role,O
in,O
erectile,Entity
dysfunction,Entity
(,O
definite,O
improvement,O
in,O
only,O
16,O
of,O
44,O
[,O
36%,O
],O
after,O
androgen,O
therapy,O
",",O
normal,O
morning,O
or,O
nocturnal,O
erections,O
in,O
30%,O
and,O
definite,O
vasculogenic,O
contributions,O
in,O
42%,O
),O
.,O
The,O
contents,O
of,O
albumin,O
in,O
the,O
lungs,O
were,O
not,O
changed,O
",",O
indicating,O
that,O
Captopril,Entity
did,O
not,O
influence,O
the,O
extravasation,O
of,O
protein,O
.,O
On,O
this,O
schedule,O
",",O
the,O
animals,O
',O
hearts,O
appeared,O
normal,O
after,O
sacrifice,O
and,O
ICRF-187,Entity
(,O
50,O
mg,O
/,O
kg,O
given,O
i.p,O
.,O
Scopolamine,Entity
was,O
used,O
as,O
a,O
positive,O
control,O
to,O
detect,O
age,O
-,O
dependent,O
changes,O
in,O
central,O
cholinergic,O
functioning,O
in,O
the,O
elderly,O
.,O
Dental,O
patients,O
abusing,O
methamphetamine,Entity
can,O
present,O
with,O
poor,O
oral,O
hygiene,O
",",O
xerostomia,Entity
",",O
rampant,O
caries,Entity
(,O
"""""""""",O
meth,Entity
mouth,Entity
"""""""""",O
),O
",",O
and,O
excessive,O
tooth,Entity
wear,Entity
.,O
Nine,O
years,O
before,O
she,O
had,O
experienced,O
a,O
self,O
-,O
limited,O
puerperal,O
depressive,Entity
episode,Entity
.,O
These,O
observations,O
indicate,O
that,O
although,O
the,O
gamma,Entity
-,Entity
carboxyglutamate,Entity
residues,O
of,O
matrix,O
Gla,O
protein,O
are,O
apparently,O
required,O
for,O
its,O
function,O
as,O
a,O
calcification,Entity
inhibitor,O
",",O
they,O
are,O
not,O
required,O
for,O
its,O
accumulation,O
at,O
calcification,Entity
sites,O
.,O
Asterixis,Entity
induced,O
by,O
carbamazepine,Entity
therapy,O
.,O
Olanzapine,Entity
may,O
have,O
an,O
advantage,O
for,O
motor,O
side,O
effects,O
.,O
Additional,O
therapy,O
with,O
chloroquine,Entity
(,O
CQ,Entity
),O
was,O
started,O
because,O
of,O
arthralgia,Entity
.,O
Although,O
several,O
new,O
anticoagulant,O
drugs,O
are,O
in,O
development,O
",",O
heparin,Entity
remains,O
the,O
anticoagulant,O
of,O
choice,O
to,O
treat,O
acute,O
thrombotic,Entity
episodes,O
.,O
/,O
mm3,O
for,O
the,O
combination,O
and,O
zidovudine,Entity
groups,O
",",O
respectively,O
(,O
p,O
>,O
0.36,O
),O
.,O
This,O
study,O
assessed,O
the,O
ability,O
of,O
IH636,Entity
grape,Entity
seed,Entity
proanthocyanidin,Entity
extract,Entity
(,O
GSPE,Entity
),O
to,O
prevent,O
acetaminophen,Entity
(,O
AAP)-induced,Entity
nephrotoxicity,Entity
",",O
amiodarone,Entity
(,O
AMI)-induced,Entity
lung,Entity
toxicity,Entity
",",O
and,O
doxorubicin,Entity
Finally,O
",",O
a,O
pair,O
-,O
fed,O
(,O
PF,O
),O
study,O
",",O
performed,O
in,O
18,O
rats,O
(,O
C,O
",",O
T,Entity
",",O
and,O
PF,O
),O
",",O
showed,O
that,O
muscle,Entity
atrophy,Entity
was,O
considerably,O
less,O
pronounced,O
in,O
PF,O
animals,O
than,O
in,O
T,Entity
-,O
treated,O
animals,O
.,O
For,O
low,O
-,O
dose,O
nimodipine,Entity
",",O
the,O
results,O
were,O
not,O
conclusive,O
.,O
calcium,Entity
gluconate,Entity
.,O
As,O
a,O
contribution,O
to,O
this,O
issue,O
we,O
decided,O
to,O
research,O
the,O
possible,O
passage,O
of,O
mannitol,Entity
into,O
the,O
brain,O
after,O
administration,O
to,O
21,O
brain,Entity
tumor,Entity
patients,O
.,O
Based,O
on,O
nonoverdose,O
pharmacokinetics,O
and,O
pharmacodynamics,O
of,O
venlafaxine,Entity
and,O
the,O
potential,O
risks,O
of,O
available,O
interventions,O
",",O
no,O
emergent,O
therapy,O
was,O
instituted,O
.,O
Mechanisms,O
of,O
FK,Entity
506-induced,Entity
hypertension,Entity
in,O
the,O
rat,O
.,O
Increase,O
in,O
intragastric,O
pressure,O
during,O
suxamethonium,Entity
-,O
induced,O
muscle,Entity
fasciculations,Entity
in,O
children,O
:,O
inhibition,O
by,O
alfentanil,Entity
.,O
In,O
cisapride,Entity
-,O
treated,O
diarrhoea,Entity
-,O
predominant,O
patients,O
the,O
mean,O
contraction,O
amplitude,O
was,O
higher,O
(,O
29.3,O
+,O
/-,O
Doses,O
were,O
flexibly,O
titrated,O
up,O
to,O
0.6,O
mg,O
/,O
day,O
for,O
clonidine,Entity
and,O
60,O
mg,O
/,O
day,O
for,O
methylphenidate,Entity
(,O
both,O
with,O
divided,O
dosing,O
),O
.,O
At,O
the,O
same,O
time,O
",",O
slightly,O
increased,O
creatine,Entity
kinase,O
(,O
CK,O
),O
CONCLUSIONS,O
:,O
The,O
results,O
give,O
further,O
support,O
to,O
the,O
hypothesis,O
that,O
NO,Entity
plays,O
a,O
role,O
in,O
motor,O
behavior,O
control,O
and,O
suggest,O
that,O
it,O
may,O
take,O
part,O
in,O
the,O
synaptic,O
changes,O
produced,O
by,O
antipsychotic,O
treatment,O
.,O
To,O
further,O
our,O
understanding,O
of,O
the,O
mechanism,O
of,O
CS,Entity
cytoprotection,O
",",O
we,O
examined,O
in,O
rats,O
and,O
mice,O
the,O
protective,O
abilities,O
of,O
CS,Entity
and,O
the,O
non,O
-,O
hydrolyzable,O
ether,O
form,O
of,O
CS,Entity
",",O
gamma,Entity
-,Entity
cholesteryloxybutyric,Entity
acid,Entity
",",O
tris,Entity
salt,Entity
(,O
CSE,Entity
),O
against,O
acetaminophen-,Entity
",",O
adriamycin-,Entity
",",O
carbon,Entity
tetrachloride-,Entity
",",O
chloroform-,Entity
and,O
galactosamine,Entity
-,O
induced,O
toxicity,Entity
.,O
mice,O
had,O
normal,O
baseline,O
performance,O
in,O
the,O
EPM,O
but,O
were,O
completely,O
resistant,O
to,O
the,O
anxiogenic,O
effects,O
of,O
cocaine,Entity
.,O
We,O
report,O
4,O
cases,O
of,O
corneal,Entity
ulcers,Entity
associated,O
with,O
drug,Entity
abuse,Entity
.,O
Hyperkalemia,Entity
has,O
recently,O
been,O
recognized,O
as,O
a,O
complication,O
of,O
nonsteroidal,O
antiinflammatory,O
agents,O
(,O
NSAID,O
),O
such,O
as,O
indomethacin,Entity
.,O
The,O
coronary,O
vasodilating,O
properties,O
of,O
nisoldipine,Entity
have,O
led,O
to,O
the,O
investigation,O
of,O
this,O
agent,O
for,O
use,O
in,O
angina,Entity
.,O
DOX,Entity
-,O
induced,O
cardiac,Entity
damage,Entity
presumably,O
results,O
from,O
the,O
formation,O
of,O
free,O
radicals,O
by,O
DOX,Entity
.,O
We,O
have,O
recently,O
shown,O
that,O
estrogen,Entity
negatively,O
modulates,O
the,O
hypotensive,Entity
effect,O
of,O
clonidine,Entity
(,O
mixed,O
alpha2-/I1-receptor,O
agonist,O
),O
in,O
female,O
rats,O
and,O
implicates,O
the,O
cardiovascular,O
autonomic,O
control,O
in,O
this,O
interaction,O
.,O
>,O
5,O
years,O
of,O
age,O
),O
were,O
followed,O
-,O
up,O
after,O
treatment,O
with,O
injectable,O
artesunate,Entity
for,O
severe,O
malaria,Entity
in,O
hospitals,O
and,O
health,O
centers,O
of,O
the,O
Democratic,O
Republic,O
of,O
the,O
Congo,O
.,O
Under,O
proper,O
control,O
of,O
respiration,O
",",O
body,O
temperature,O
and,O
end,O
-,O
tidal,O
CO2,Entity
",",O
intravenous,O
administration,O
of,O
fentanyl,Entity
(,O
50,O
or,O
100,O
micrograms,O
/,O
kg,O
),O
consistently,O
promoted,O
an,O
increase,O
in,O
electromyographic,O
activity,O
recorded,O
from,O
the,O
gastrocnemius,O
and,O
abdominal,O
rectus,O
muscles,O
.,O
At,O
the,O
end,O
of,O
each,O
pretreatment,O
period,O
",",O
animals,O
were,O
used,O
for,O
(,O
i,O
),O
determining,O
their,O
locomotor,O
response,O
to,O
acutely,O
injected,O
nicotine,Entity
(,O
0.2,O
mg,O
/,O
kg,O
",",O
s.c,O
.,O
),O
and,O
(,O
ii,O
),O
measuring,O
the,O
density,O
of,O
L-[3H]nicotine,Entity
and,O
[,O
3H]spiperone,Entity
binding,O
sites,O
in,O
the,O
striatum,O
.,O
Valvular,Entity
heart,Entity
disease,Entity
in,O
patients,O
with,O
Parkinson,Entity
's,Entity
disease,Entity
treated,O
with,O
pergolide,Entity
.,O
The,O
hypotensive,Entity
effect,O
of,O
100,O
mg,O
/,O
kg,O
alpha,Entity
-,Entity
methyldopa,Entity
was,O
also,O
partially,O
reversed,O
by,O
naloxone,Entity
.,O
The,O
transient,O
steroid,Entity
-,O
induced,O
IOP,Entity
rise,Entity
did,O
not,O
seem,O
to,O
cause,O
functional,O
impairment,O
.,O
In,O
this,O
work,O
CCR2,O
and,O
CCL2,O
expression,O
were,O
examined,O
following,O
status,Entity
epilepticus,Entity
(,O
SE,Entity
),O
induced,O
by,O
pilocarpine,Entity
injection,O
.,O
The,O
aim,O
was,O
to,O
evaluate,O
the,O
effects,O
of,O
high,O
frequency,O
hippocampal,O
stimulation,O
on,O
cortical,O
epileptic,Entity
activity,O
in,O
penicillin,Entity
-,O
induced,O
epilepsy,Entity
model,O
.,O
Reduction,O
in,O
GFR,O
was,O
associated,O
with,O
the,O
development,O
of,O
glomerular,Entity
sclerosis,Entity
in,O
both,O
treated,O
and,O
untreated,O
rats.(ABSTRACT,O
TRUNCATED,O
AT,O
250,O
WORDS,O
),O
Toxicity,Entity
of,O
CAA,Entity
was,O
determined,O
by,O
protein,O
content,O
",",O
cell,O
number,O
",",O
LDH,O
release,O
",",O
trypan,Entity
blue,Entity
exclusion,O
assay,O
and,O
caspase-3,O
activity,O
.,O
CONCLUSION,O
:,O
The,O
administration,O
of,O
CaCl2,Entity
or,O
4-aminopyridine,Entity
did,O
not,O
reverse,O
tricyclic,O
antidepressant,O
-,O
induced,O
hypotension,Entity
in,O
rats,O
.,O
Recent,O
preclinical,O
and,O
clinical,O
studies,O
with,O
the,O
thymidylate,O
synthase,O
inhibitor,O
"N10-propargyl-5,8-dideazafolic",Entity
acid,Entity
(,O
CB,Entity
3717,Entity
),O
.,O
Compared,O
with,O
placebo,O
subjects,O
",",O
alprazolam,Entity
patients,O
developed,O
more,O
adverse,O
reactions,O
(,O
21%,O
v.,O
0%,O
),O
of,O
depression,Entity
",",O
enuresis,Entity
",",O
disinhibition,O
and,O
aggression,Entity
;,O
and,O
more,O
side,O
-,O
effects,O
",",O
particularly,O
sedation,O
",",O
irritability,Entity
",",O
impaired,Entity
memory,Entity
",",O
weight,Entity
loss,Entity
and,O
ataxia,Entity
.,O
clozapine,Entity
significantly,O
shortened,O
the,O
phencyclidine,Entity
(,O
PCP)-induced,Entity
prolonged,O
swimming,O
latency,O
in,O
rats,O
in,O
a,O
water,O
maze,O
task,O
.,O
Renal,O
pathology,O
was,O
that,O
of,O
hypocellular,O
interstitial,O
fibrosis,Entity
.,O
29,O
patients,O
were,O
enrolled,O
on,O
a,O
study,O
of,O
thalidomide,Entity
using,O
an,O
intra,O
-,O
patient,O
dose,O
escalation,O
schedule,O
.,O
A,O
single,O
case,O
report,O
suggests,O
that,O
yohimbine,Entity
may,O
be,O
used,O
to,O
treat,O
the,O
sexual,Entity
side,Entity
effects,Entity
of,O
clomipramine,Entity
.,O
Fluoxetine,Entity
-,O
induced,O
akathisia,Entity
:,O
clinical,O
and,O
theoretical,O
implications,O
.,O
The,O
data,O
suggest,O
that,O
fluocinolone,Entity
acetonide,Entity
implant,O
(,O
0.59,O
mg,O
),O
helps,O
to,O
control,O
inflammation,Entity
in,O
otherwise,O
treatment,O
-,O
refractory,O
cases,O
of,O
birdshot,Entity
retinochoroidopathy,Entity
.,O
Treatment,O
response,O
was,O
not,O
correlated,O
with,O
the,O
incidence,O
",",O
time,O
-,O
course,O
or,O
severity,O
of,O
capsaicin,Entity
-,O
induced,O
burning,O
.,O
Thereafter,O
",",O
seizures,Entity
were,O
induced,O
by,O
pilocarpine,Entity
injections,O
in,O
trained,O
and,O
non,O
-,O
trained,O
control,O
groups,O
.,O
Reduced,O
sodium,Entity
channel,O
density,O
",",O
altered,O
voltage,O
dependence,O
of,O
inactivation,O
",",O
and,O
increased,O
susceptibility,O
to,O
seizures,Entity
in,O
mice,O
lacking,O
sodium,Entity
channel,O
beta,O
2-subunits,O
.,O
Adverse,O
events,O
considered,O
to,O
be,O
related,O
to,O
levofloxacin,Entity
administration,O
were,O
reported,O
by,O
29,O
patients,O
(,O
9%,O
),O
.,O
Apomorphine,Entity
was,O
the,O
first,O
dopaminergic,O
drug,O
ever,O
used,O
to,O
treat,O
symptoms,O
of,O
Parkinson,Entity
's,Entity
disease,Entity
.,O
The,O
case,O
discussed,O
herein,O
initially,O
appeared,O
to,O
be,O
neurogenic,Entity
diabetes,Entity
insipidus,Entity
(,O
DI,Entity
),O
secondary,O
to,O
a,O
traumatic,Entity
brain,Entity
injury,Entity
.,O
The,O
hyperactivity,Entity
induced,O
by,O
nomifensine,Entity
in,O
mice,O
remained,O
unaffected,O
by,O
fluvoxamine,Entity
.,O
Two,O
cases,O
of,O
hepatic,O
adenoma,Entity
and,O
one,O
of,O
focal,Entity
nodular,Entity
hyperplasia,Entity
presumably,O
associated,O
with,O
the,O
use,O
of,O
oral,Entity
contraceptives,Entity
",",O
are,O
reported,O
.,O
A,O
clinical,O
presentation,O
is,O
made,O
of,O
a,O
2,O
-,O
3,O
year,O
follow,O
-,O
up,O
of,O
six,O
cases,O
of,O
acute,Entity
renal,Entity
failure,Entity
that,O
have,O
been,O
reported,O
earlier,O
.,O
Use,O
of,O
dexamethasone,Entity
with,O
mesna,Entity
for,O
the,O
prevention,O
of,O
ifosfamide,Entity
-,O
induced,O
hemorrhagic,Entity
cystitis,Entity
.,O
Transplantation,Entity
-,Entity
associated,Entity
microangiopathy,Entity
(,O
TMA,Entity
),O
occurred,O
in,O
7,O
patients,O
(,O
29%,O
),O
",",O
with,O
2,O
cases,O
of,O
acute,Entity
renal,Entity
failure,Entity
.,O
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
investigate,O
the,O
effects,O
of,O
propofol,Entity
in,O
intralipid,O
or,O
medialipid,O
emulsions,O
on,O
bupivacaine,Entity
-,O
induced,O
cardiotoxicity,Entity
.,O
To,O
examine,O
a,O
possibly,O
deteriorating,O
cardiotoxic,Entity
effect,O
of,O
SM-5887,Entity
",",O
low,O
-,O
grade,O
cardiomyopathy,Entity
was,O
induced,O
in,O
dogs,O
by,O
four,O
courses,O
of,O
doxorubicin,Entity
(,O
1.5,O
mg,O
/,O
kg,O
),O
.,O
Two,O
patients,O
also,O
received,O
intravenous,O
corticosteroids,Entity
.,O
We,O
conclude,O
that,O
lidocaine,Entity
reduces,O
the,O
incidence,O
and,O
severity,O
of,O
propofol,Entity
injection,O
pain,Entity
in,O
ambulatory,O
patients,O
whereas,O
thiopentone,Entity
only,O
reduces,O
its,O
severity,O
.,O
No,O
abnormal,O
matrical,O
inclusions,O
of,O
peroxisomes,O
were,O
formed,O
in,O
the,O
cells,O
of,O
hyperplastic,O
nodules,O
by,O
ethyl,Entity
-,Entity
alpha,Entity
-,Entity
p,Entity
-,Entity
chlorophenoxyisobutyrate,Entity
unlike,O
in,O
the,O
case,O
of,O
rats,O
.,O
Ribavirin,Entity
is,O
licensed,O
in,O
aerosol,O
form,O
for,O
the,O
treatment,O
of,O
respiratory,Entity
syncytial,Entity
virus,Entity
infection,Entity
",",O
and,O
orally,O
in,O
combination,O
with,O
interferon,O
to,O
treat,O
hepatitis,Entity
C.,Entity
Intravenous,O
This,O
demonstrates,O
the,O
participation,O
of,O
the,O
renin,O
--,O
angiotensin,Entity
system,O
in,O
antagonizing,O
the,O
combined,O
hypotensive,Entity
effects,O
of,O
halothane,Entity
and,O
SNP,Entity
.,O
It,O
is,O
concluded,O
that,O
PAP,Entity
formation,O
",",O
in,O
vivo,O
",",O
accounts,O
",",O
at,O
least,O
in,O
part,O
",",O
for,O
APAP,Entity
-,O
induced,O
renal,Entity
tubular,Entity
necrosis,Entity
.,O
Our,O
studies,O
indicate,O
that,O
nephrotoxicity,Entity
of,O
MTX,Entity
+,O
5-FU,Entity
+,O
CY,Entity
administered,O
jointly,O
is,O
lower,O
than,O
in,O
monotherapy,O
.,O
In,O
this,O
study,O
",",O
we,O
prospectively,O
evaluated,O
the,O
incidence,O
and,O
clinical,O
importance,O
of,O
pseudolithiasis,Entity
in,O
paediatric,O
surgical,O
patients,O
receiving,O
ceftriaxone,Entity
treatment,O
",",O
who,O
often,O
had,O
to,O
fast,O
in,O
the,O
post,O
-,O
operative,O
period,O
.,O
In,O
order,O
to,O
elucidate,O
the,O
role,O
of,O
the,O
catecholaminergic,O
system,O
in,O
the,O
cataleptogenic,O
effect,O
of,O
delta,Entity
9-tetrahydrocannabinol,Entity
(,O
THC,Entity
),O
",",O
the,O
effect,O
of,O
pretreatment,O
with,O
6-hydroxydopamine,Entity
(,O
6-OHDA,Entity
),O
or,O
with,O
desipramine,Entity
and,O
6-OHDA,Entity
and,O
lesions,O
of,O
the,O
locus,O
coeruleus,O
were,O
investigated,O
in,O
rats,O
.,O
Five,O
cases,O
of,O
paranoid,Entity
exacerbation,O
with,O
the,O
serotonin,Entity
reuptake,O
inhibitors,O
fluoxetine,Entity
and,O
amitriptyline,Entity
are,O
reported,O
here,O
.,O
The,O
side,O
effects,O
of,O
azathioprine,Entity
include,O
anemia,Entity
",",O
which,O
has,O
been,O
attributed,O
to,O
bone,O
marrow,O
suppression,O
.,O
Ninety,O
-,O
six,O
patients,O
were,O
not,O
given,O
anticonvulsive,O
prophylaxis,O
;,O
7,O
(,O
7.5%,O
),O
developed,O
seizures,Entity
during,O
the,O
4,O
days,O
of,O
the,O
busulfan,Entity
course,O
or,O
within,O
24,O
h,O
after,O
the,O
last,O
dosing,O
.,O
Autoimmune,Entity
diseases,Entity
",",O
viral,Entity
hepatitis,Entity
",",O
malignant,O
neoplasms,Entity
or,O
other,O
diseases,O
with,O
a,O
known,O
relationship,O
to,O
membranous,Entity
glomerulonephritis,Entity
were,O
not,O
found,O
.,O
Safety,O
and,O
efficacy,O
of,O
fluocinolone,Entity
acetonide,Entity
intravitreal,O
implant,O
(,O
0.59,O
mg,O
),O
in,O
birdshot,Entity
retinochoroidopathy,Entity
.,O
In,O
24,O
of,O
these,O
patients,O
chemical,O
cystitis,Entity
was,O
severe,O
enough,O
for,O
them,O
to,O
drop,O
out,O
of,O
the,O
study,O
.,O
ACE,Entity
inhibitor,Entity
and,O
angiotensin,Entity
-,Entity
releasing,Entity
blocker,Entity
(,O
ARB,Entity
),O
therapy,O
reduced,O
proteinuria,Entity
development,O
.,O
Median,O
convulsant,O
(,O
CD50,O
),O
and,O
median,O
lethal,O
(,O
LD50,O
),O
doses,O
of,O
three,O
representative,O
local,O
anesthetics,O
were,O
determined,O
in,O
adult,O
mice,O
to,O
evaluate,O
the,O
threat,O
to,O
life,O
of,O
local,O
anesthetic,O
-,O
induced,O
convulsions,Entity
.,O
Enhancement,O
of,O
morphine,Entity
antinociception,O
by,O
dextromethorphan,Entity
was,O
seen,O
in,O
both,O
males,O
and,O
females,O
in,O
the,O
acute,Entity
pain,Entity
models,O
",",O
with,O
the,O
magnitude,O
of,O
this,O
effect,O
being,O
greater,O
in,O
males,O
.,O
Myocardial,Entity
infarction,Entity
in,O
puerperium,O
is,O
infrequently,O
reported,O
.,O
Immunohistochemical,O
studies,O
with,O
antibodies,O
to,O
neurofilament,O
proteins,O
on,O
axonal,Entity
damage,Entity
in,O
experimental,O
focal,O
lesions,O
in,O
rat,O
.,O
Her,O
delirium,Entity
resolved,O
3,O
days,O
later,O
.,O
Activated,O
peripheral,O
blood,O
T,O
cells,O
from,O
patients,O
with,O
psoriasis,Entity
tended,O
to,O
exhibit,O
greater,O
spontaneous,O
or,O
dexamethasone,Entity
-,O
induced,O
apoptosis,O
than,O
did,O
normal,O
T,O
cells,O
",",O
particularly,O
in,O
the,O
presence,O
of,O
sirolimus,Entity
.,O
Factors,O
contributing,O
to,O
ribavirin,Entity
-,O
induced,O
anemia,Entity
.,O
Myocardial,Entity
ischemia,Entity
due,O
to,O
coronary,Entity
artery,Entity
spasm,Entity
during,O
dobutamine,Entity
stress,O
echocardiography,O
.,O
Plasma,O
concentration,O
and,O
urine,O
excretion,O
of,O
the,O
renin,O
-,O
angiotensin,Entity
system,O
proteins,O
are,O
altered,O
in,O
rats,O
with,O
nephrotic,Entity
syndrome,Entity
(,O
NS,Entity
),O
.,O
All,O
3,O
patients,O
had,O
some,O
permanent,O
loss,Entity
of,Entity
visual,Entity
function,Entity
.,O
She,O
also,O
had,O
advanced,O
breast,Entity
cancer,Entity
when,O
the,O
combination,O
therapy,O
was,O
initiated,O
.,O
When,O
circumflex,O
artery,O
blood,O
flow,O
was,O
maintained,O
constant,O
",",O
the,O
increases,O
in,O
CxAD,O
induced,O
by,O
cromakalim,Entity
(,O
10,O
micrograms,O
/,O
kg,O
),O
",",O
pinacidil,Entity
(,O
30,O
micrograms,O
/,O
kg,O
),O
and,O
nitroglycerin,Entity
(,O
10,O
micrograms,O
/,O
kg,O
),O
were,O
reduced,O
by,O
68,O
+,O
/-,O
CONCLUSION,O
:,O
The,O
present,O
experimental,O
findings,O
substantiate,O
the,O
clinically,O
observed,O
anxiogenic,O
potential,O
of,O
ciprofloxacin,Entity
and,O
norfloxacin,Entity
.,O
Eighty,O
patients,O
who,O
were,O
to,O
receive,O
CYA,Entity
50,O
mg,O
/,O
kg,O
/,O
d,O
for,O
four,O
days,O
as,O
preparation,O
for,O
marrow,O
grafting,O
underwent,O
a,O
total,O
of,O
84,O
transplants,O
for,O
aplastic,Entity
anemia,Entity
",",O
Wiskott,Entity
-,Entity
Aldrich,Entity
syndrome,Entity
",",O
or,O
severe,Entity
combined,Entity
immunodeficiency,Entity
syndrome,Entity
.,O
High,O
-,O
dose,O
daptomycin,Entity
may,O
be,O
an,O
alternative,O
option,O
for,O
MSSA,O
bacteremia,Entity
with,O
or,O
without,O
a,O
CNS,O
source,O
in,O
patients,O
who,O
have,O
failed,O
or,O
can,O
not,O
tolerate,O
standard,O
therapy,O
.,O
Effect,O
of,O
adriamycin,Entity
combined,O
with,O
whole,O
body,O
hyperthermia,Entity
on,O
tumor,Entity
and,O
normal,O
tissues,O
.,O
Statins,Entity
can,O
cause,O
a,O
necrotizing,O
myopathy,Entity
and,O
hyperCKaemia,Entity
which,O
is,O
reversible,O
on,O
cessation,O
of,O
the,O
drug,O
.,O
Although,O
intravenous,O
caffeine,Entity
is,O
generally,O
well,O
tolerated,O
",",O
the,O
clinician,O
should,O
be,O
aware,O
of,O
the,O
potential,O
for,O
unpredictable,O
and,O
serious,O
ventricular,Entity
arrhythmias,Entity
.,O
From,O
the,O
Danish,O
National,O
Register,O
of,O
Patients,O
(,O
NRP,O
),O
",",O
1996,O
to,O
1998,O
",",O
the,O
records,O
of,O
1.1,O
million,O
Danish,O
women,O
",",O
ages,O
15,O
to,O
44,O
years,O
",",O
were,O
searched,O
for,O
evidence,O
of,O
VTE,Entity
.,O
No,O
association,O
between,O
buprenorphine,Entity
and,O
QTc,O
was,O
found,O
.,O
In,O
an,O
attempt,O
to,O
obviate,O
the,O
inconvenience,O
of,O
bladder,O
irrigation,O
",",O
we,O
conducted,O
a,O
feasibility,O
trial,O
of,O
uroprophylaxis,O
with,O
mesna,Entity
",",O
which,O
neutralizes,O
the,O
hepatic,O
metabolite,O
of,O
cyclophosphamide,Entity
that,O
causes,O
hemorrhagic,Entity
cystitis,Entity
.,O
0.002,O
),O
versus,O
the,O
90/HTN,Entity
(,O
1.036,O
+,O
/-,O
0.003,O
),O
and,O
control,O
(,O
1.037,O
+,O
/-,O
Mean,O
circulatory,O
filling,O
pressure,O
",",O
an,O
in,O
vivo,O
measure,O
of,O
venomotor,O
tone,O
",",O
was,O
not,O
elevated,O
in,O
LNNA,Entity
hypertension,Entity
at,O
1,O
or,O
2,O
weeks,O
after,O
LNNA,Entity
.,O
VSD,Entity
also,O
was,O
noted,O
following,O
treatment,O
on,O
GD,O
11,O
.,O
Hemolytic,Entity
anemia,Entity
improved,O
after,O
stopping,O
the,O
drug,O
and,O
initiation,O
of,O
steroid,Entity
therapy,O
.,O
Common,O
side,O
effects,O
include,O
nausea,Entity
",",O
vomiting,Entity
and,O
hypotension,Entity
.,O
Clinical,O
follow,O
-,O
up,O
may,O
be,O
justified,O
by,O
the,O
cause,O
of,O
the,O
liver,Entity
failure,Entity
",",O
but,O
not,O
by,O
the,O
liver,Entity
failure,Entity
itself,O
.,O
A,O
lymphocyte,O
transformation,O
test,O
demonstrated,O
a,O
positive,O
result,O
against,O
nicergoline,Entity
.,O
Especially,O
in,O
old,O
patients,O
",",O
intensivists,O
should,O
consider,O
intoxications,O
(,O
with,O
cholinergics,O
),O
as,O
a,O
cause,O
of,O
acute,Entity
cardiovascular,Entity
failure,Entity
.,O
This,O
response,O
was,O
restricted,O
to,O
the,O
striatum,O
and,O
contrasted,O
sharply,O
with,O
unresponsive,O
eGFP,O
-,O
microglia,O
in,O
surrounding,O
brain,O
areas,O
that,O
are,O
not,O
damaged,O
by,O
METH,Entity
.,O
22-oxacalcitriol,Entity
suppresses,O
secondary,Entity
hyperparathyroidism,Entity
without,O
inducing,O
low,Entity
bone,Entity
turnover,Entity
in,O
dogs,O
with,O
renal,Entity
failure,Entity
.,O
Acute,O
toxicity,Entity
studies,O
of,O
ACC-9653,Entity
and,O
phenytoin,Entity
sodium,Entity
were,O
carried,O
out,O
in,O
mice,O
",",O
rats,O
",",O
rabbits,O
",",O
and,O
dogs,O
by,O
i.v,O
.,O
Zyban,Entity
caused,O
significant,O
neurological,Entity
and,Entity
cardiovascular,Entity
toxicity,Entity
in,O
overdose,Entity
.,O
Conscious,O
SHR,O
were,O
treated,O
for,O
4,O
days,O
with,O
prazosin,Entity
at,O
2,O
mg,O
kg-1,O
day-1,O
i.p,O
.,O
Total,O
follow,O
-,O
up,O
on,O
warfarin,Entity
was,O
530,O
years,O
(,O
mean,O
28,O
months,O
),O
.,O
These,O
models,O
may,O
also,O
be,O
useful,O
in,O
developing,O
insights,O
into,O
the,O
pathophysiology,O
of,O
aminoglycoside,Entity
-,O
induced,O
nephrotoxicity,Entity
.,O
Pheochromocytoma,Entity
unmasked,O
by,O
amisulpride,Entity
and,O
tiapride,Entity
.,O
Severe,O
gastric,O
ulcers,Entity
accompanied,O
with,O
increased,O
ulcerogenic,O
factors,O
",",O
including,O
gastric,O
acid,O
back,O
-,O
diffusion,O
",",O
histamine,Entity
release,O
",",O
LPO,O
generation,O
and,O
luminal,Entity
hemoglobin,O
content,O
were,O
also,O
observed,O
in,O
these,O
rats,O
.,O
Symptoms,O
such,O
as,O
euphoria,O
",",O
emotional,O
lability,O
and,O
puerile,O
attitude,O
noted,O
in,O
the,O
patient,O
were,O
diagnosed,O
as,O
organic,Entity
personality,Entity
syndrome,Entity
according,O
to,O
the,O
criteria,O
defined,O
in,O
the,O
DSM,O
-,O
III,O
-,O
R.,O
It,O
is,O
referred,O
to,O
as,O
a,O
frontal,Entity
lobe,Entity
syndrome,Entity
.,O
The,O
antinociceptive,O
effect,O
of,O
3,Entity
alpha,Entity
-,Entity
tropyl,Entity
2-(p,Entity
-,Entity
bromophenyl)propionate,Entity
[,O
(,O
+,O
/-)-PG-9,Entity
],O
(,O
10,O
-,O
40,O
mg,O
kg-1,O
s.c,O
.,O
While,O
the,O
CAN,Entity
and,O
PD,O
groups,O
tended,O
to,O
record,O
greater,O
deficits,O
than,O
the,O
non,O
-,O
drug,O
controls,O
",",O
the,O
MDMA,Entity
and,O
EX,O
-,O
MDMA,Entity
groups,O
recorded,O
greater,O
deficits,O
than,O
all,O
the,O
control,O
groups,O
on,O
ten,O
of,O
the,O
13,O
psychometric,O
measures,O
.,O
Following,O
phenytoin,Entity
administration,O
",",O
the,O
patient,O
developed,O
acute,O
severe,O
bradycardia,Entity
",",O
refractory,O
to,O
atropine,Entity
and,O
adrenaline,Entity
.,O
This,O
study,O
prospectively,O
evaluated,O
the,O
clinical,O
efficacy,O
",",O
the,O
incidence,O
of,O
torsades,Entity
de,Entity
pointes,Entity
",",O
and,O
the,O
presumable,O
risk,O
factors,O
for,O
torsades,Entity
de,Entity
pointes,Entity
in,O
patients,O
treated,O
with,O
d,Entity
",",Entity
l,Entity
-,Entity
sotalol,Entity
for,O
sustained,O
ventricular,Entity
tachyarrhythmias,Entity
.,O
The,O
incidence,O
of,O
abductor,O
paralysis,Entity
after,O
Botox,Entity
injection,O
for,O
ADSD,Entity
was,O
0.34%,O
.,O
Indomethacin,Entity
resulted,O
in,O
histopathologic,O
findings,O
typical,O
of,O
interstitial,Entity
cystitis,Entity
",",O
such,O
as,O
leaky,O
bladder,O
epithelium,O
and,O
mucosal,O
mastocytosis,Entity
.,O
Significant,O
increases,O
in,O
certain,O
factors,O
of,O
the,O
blood,Entity
coagulation,Entity
and,O
fibrinolysin,O
systems,O
(,O
factors,O
I,O
",",O
II,O
",",O
VII,O
",",O
VIII,O
",",O
IX,O
",",O
and,O
X,O
and,O
plasminogen,O
),O
were,O
observed,O
in,O
the,O
treated,O
groups,O
.,O
Daptomycin,Entity
was,O
initiated,O
in,O
our,O
patient,O
secondary,O
to,O
possible,O
nafcillin,Entity
-,O
induced,O
acute,O
interstitial,Entity
nephritis,Entity
and,O
relapsing,O
bacteremia,Entity
.,O
We,O
report,O
an,O
undiagnosed,O
case,O
of,O
myotonia,Entity
congenita,Entity
in,O
a,O
24-year,O
-,O
old,O
previously,O
healthy,O
primigravida,O
",",O
who,O
developed,O
life,O
threatening,O
masseter,Entity
spasm,Entity
following,O
a,O
standard,O
dose,O
of,O
intravenous,O
suxamethonium,Entity
for,O
induction,O
of,O
anaesthesia,O
.,O
Diarrhoea,Entity
-,O
predominant,O
IBS,Entity
patients,O
had,O
a,O
higher,O
pain,Entity
score,O
after,O
cisapride,Entity
therapy,O
[,O
score,O
",",O
55,O
+,O
/-,O
Animals,O
became,O
somnolent,O
after,O
diazepam,Entity
and,O
then,O
active,O
after,O
flumazenil,Entity
administration,O
.,O
A,O
case,O
of,O
a,O
busulfan,Entity
-,O
induced,O
hemorrhage,Entity
cystitis,Entity
is,O
reported,O
.,O
Cocaine,Entity
-,O
induced,O
mood,Entity
disorder,Entity
:,O
prevalence,O
rates,O
and,O
psychiatric,Entity
symptoms,O
in,O
an,O
outpatient,O
cocaine,Entity
-,O
dependent,O
sample,O
.,O
Dothiepin,Entity
thus,O
was,O
found,O
to,O
be,O
an,O
effective,O
antidepressant,Entity
drug,O
associated,O
with,O
fewer,O
side,O
effects,O
than,O
amitriptyline,Entity
in,O
the,O
treatment,O
of,O
depressed,Entity
outpatients,O
.,O
The,O
mechanism,O
of,O
chest,Entity
pain,Entity
related,O
to,O
cocaine,Entity
use,O
is,O
discussed,O
and,O
treatment,O
dilemmas,O
are,O
discussed,O
.,O
Desferrioxamine,Entity
withdrawal,O
resulted,O
in,O
a,O
complete,O
recovery,O
of,O
visual,O
function,O
in,O
1,O
patient,O
and,O
partial,O
recovery,O
in,O
3,O
",",O
and,O
a,O
complete,O
reversal,O
of,O
hearing,Entity
loss,Entity
in,O
3,O
patients,O
and,O
partial,O
recovery,O
in,O
3,O
.,O
The,O
randomized,O
Aza,Entity
patients,O
had,O
more,O
overall,O
infections,Entity
(,O
P,O
less,O
than,O
0.05,O
),O
and,O
more,O
nonviral,O
infections,Entity
(,O
P,O
less,O
than,O
0.02,O
),O
than,O
the,O
randomized,O
cyclosporine,Entity
patients,O
.,O
The,O
present,O
experiments,O
were,O
designed,O
to,O
investigate,O
the,O
role,O
of,O
the,O
midline,O
cells,O
of,O
the,O
B3,O
serotonin,Entity
neurons,O
in,O
the,O
medulla,O
",",O
coinciding,O
with,O
the,O
raphe,O
magnus,O
.,O
Caffeine,Entity
produced,O
significantly,O
greater,O
increases,O
in,O
subject,O
-,O
rated,O
anxiety,Entity
",",O
nervousness,O
",",O
fear,O
",",O
nausea,Entity
",",O
palpitations,Entity
",",O
restlessness,Entity
",",O
and,O
tremors,Entity
in,O
the,O
patients,O
compared,O
with,O
healthy,O
subjects,O
.,O
improves,O
scopolamine,Entity
-,O
induced,O
amnesia,Entity
but,O
does,O
not,O
affect,O
spontaneous,O
movement,O
.,O
In,O
conclusion,O
",",O
this,O
study,O
provides,O
new,O
insights,O
into,O
the,O
protein,O
changes,O
occurring,O
in,O
LID,Entity
.,O
The,O
more,O
profound,O
hypokalemia,Entity
",",O
the,O
greater,O
the,O
propensity,O
for,O
the,O
occurrence,O
of,O
PVC,O
's,O
.,O
Although,O
the,O
underlying,O
mechanism(s,O
),O
are,O
not,O
well,O
understood,O
",",O
these,O
effects,O
may,O
involve,O
an,O
increase,O
in,O
acetylcholine,Entity
(,O
ACh,Entity
),O
levels,O
.,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
injected,O
intraperitoneally,O
with,O
pilocarpine,Entity
",",O
and,O
the,O
hippocampal,O
formation,O
was,O
studied,O
histologically,O
at,O
1,O
",",O
2,O
",",O
4,O
",",O
and,O
8,O
week,O
intervals,O
after,O
pilocarpine,Entity
-,O
induced,O
seizures,Entity
.,O
An,O
analysis,O
of,O
the,O
75,O
cases,O
that,O
had,O
been,O
adequately,O
followed,O
up,O
suggested,O
that,O
16,O
",",O
including,O
three,O
deaths,Entity
",",O
were,O
probably,O
related,O
to,O
treatment,O
with,O
the,O
drug,O
.,O
Four,O
out,O
of,O
six,O
cases,O
with,O
blood,Entity
loss,Entity
>,O
or,O
=,O
1000,O
ml,O
occurred,O
in,O
the,O
200,O
microg,O
group,O
.,O
Animals,O
injected,O
with,O
saline,O
showed,O
statistically,O
smaller,O
gains,O
than,O
those,O
injected,O
with,O
edaravone,Entity
.,O
It,O
reduces,O
the,O
severity,O
of,O
"""""""""",O
off,O
"""""""""",O
phase,O
symptoms,O
",",O
improves,O
the,O
axial,O
symptoms,O
and,O
reduces,O
levodopa,Entity
requirements,O
.,O
Clinicians,O
should,O
be,O
aware,O
that,O
tenofovir,Entity
may,O
raise,O
the,O
risk,O
of,O
renal,Entity
failure,Entity
during,O
prolonged,O
administration,O
of,O
vancomycin,Entity
.,O
Ophthalmologists,O
at,O
15,O
institutions,O
responded,O
",",O
reporting,O
a,O
total,O
of,O
"3,774",O
indocyanine,Entity
green,Entity
angiograms,O
performed,O
on,O
"2,820",O
patients,O
between,O
June,O
1984,O
and,O
September,O
1992,O
.,O
Thirteen,O
psoriatic,Entity
patients,O
with,O
hypertension,Entity
during,O
the,O
course,O
of,O
cyclosporin,Entity
A,Entity
therapy,O
were,O
treated,O
for,O
25,O
months,O
with,O
a,O
calcium,Entity
channel,O
blocker,O
",",O
sustained,O
-,O
release,O
nifedipine,Entity
",",O
to,O
study,O
the,O
clinical,O
antihypertensive,O
effects,O
and,O
adverse,O
events,O
during,O
treatment,O
with,O
both,O
drugs,O
.,O
Lithium,Entity
induced,O
nephrogenic,Entity
diabetes,Entity
insipidus,Entity
is,O
considered,O
to,O
be,O
reversible,O
on,O
cessation,O
of,O
therapy,O
but,O
polyuria,Entity
persisted,O
in,O
this,O
patient,O
for,O
ten,O
years,O
after,O
lithium,Entity
was,O
stopped,O
.,O
The,O
results,O
suggest,O
that,O
rigidity,Entity
",",O
which,O
is,O
assumed,O
to,O
be,O
due,O
to,O
an,O
action,O
of,O
morphine,Entity
in,O
the,O
striatum,O
",",O
can,O
be,O
antagonized,O
by,O
another,O
process,O
leading,O
to,O
dopaminergic,O
activation,O
in,O
the,O
striatum,O
.,O
The,O
patient,O
also,O
received,O
simvastatin,Entity
.,O
Anaesthetists,O
',O
nightmare,O
:,O
masseter,Entity
spasm,Entity
after,O
induction,O
in,O
an,O
undiagnosed,O
case,O
of,O
myotonia,Entity
congenita,Entity
.,O
HT,O
is,O
not,O
indicated,O
for,O
the,O
routine,O
management,O
of,O
chronic,Entity
disease,Entity
.,O
The,O
results,O
suggest,O
that,O
a,O
prolonged,O
combination,O
of,O
more,O
than,O
120,O
min,O
of,O
PGE1-induced,Entity
hypotension,Entity
and,O
moderate,O
haemodilution,Entity
would,O
cause,O
impairment,Entity
of,Entity
hepatic,Entity
function,Entity
.,O
The,O
magnitude,O
of,O
the,O
hypotensive,Entity
effect,O
of,O
levodopa,Entity
was,O
concentration,O
dependent,O
and,O
was,O
fit,O
to,O
an,O
Emax,O
model,O
in,O
fluctuating,O
responders,O
.,O
Disappearance,O
of,O
seizures,Entity
and,O
normalization,O
of,O
abnormal,O
EEG,O
with,O
disappearance,O
of,O
seizures,Entity
were,O
recognized,O
in,O
77%,O
and,O
50%,O
",",O
respectively,O
.,O
Furthermore,O
",",O
there,O
have,O
been,O
reports,O
of,O
thrombotic,Entity
microangiopathy,Entity
precipitated,O
by,O
cyclosporine,Entity
in,O
patients,O
with,O
SSc,Entity
.,O
6.7,O
mm,O
Hg,O
in,O
the,O
HEM,Entity
group,O
",",O
compared,O
with,O
9.1,O
+,O
/-,O
Midazolam,Entity
compared,O
with,O
thiopentone,Entity
as,O
an,O
induction,O
agent,O
.,O
Various,O
doses,O
of,O
yohimbine,Entity
were,O
used,O
to,O
determine,O
the,O
ideal,O
dose,O
for,O
each,O
patient,O
.,O
One,O
patient,O
was,O
prematurely,O
discontinued,O
from,O
the,O
study,O
for,O
severe,O
headache,Entity
and,O
abdominal,Entity
pain,Entity
.,O
Isolated,O
myelopathy,Entity
or,O
peripheral,Entity
neuropathy,Entity
",",O
or,O
these,O
manifestations,O
occurring,O
together,O
",",O
were,O
infrequent,O
.,O
Despite,O
treatment,O
",",O
the,O
children,O
continued,O
to,O
have,O
choreoathetosis,Entity
for,O
approximately,O
24,O
hours,O
.,O
In,O
female,O
rats,O
",",O
only,O
a,O
weak,O
tendency,O
toward,O
aggressiveness,Entity
was,O
found,O
.,O
The,O
mean,O
SC-48334,Entity
steady,O
-,O
state,O
trough,O
level,O
(,O
4.04,O
+,O
/-,O
ip,O
),O
in,O
mPGES-1,O
+,O
/+,O
mice,O
led,O
to,O
a,O
marked,O
polyuria,Entity
with,O
hyposmotic,O
urine,O
.,O
Intravenous,O
propranolol,Entity
reversed,O
these,O
effects,O
.,O
The,O
median,O
number,O
of,O
bort,Entity
-,O
dex,Entity
cycles,O
was,O
6,O
",",O
up,O
to,O
a,O
maximum,O
of,O
12,O
cycles,O
.,O
Chronic,O
FK506,Entity
nephropathy,Entity
consisted,O
of,O
rough,O
and,O
foamy,O
tubular,O
vacuolization,O
(,O
5,O
biopsies,O
),O
",",O
arteriolopathy,O
(,O
angiodegeneration,O
of,O
the,O
arteriolar,O
wall,O
;,O
20,O
biopsies,O
),O
",",O
focal,Entity
segmental,Entity
glomerulosclerosis,Entity
(,O
4,O
biopsies,O
),O
and,O
the,O
striped,O
form,O
of,O
interstitial,Entity
fibrosis,Entity
(,O
11,O
biopsies,O
),O
.,O
In,O
a,O
random,O
fashion,O
",",O
they,O
received,O
cimetidine,Entity
200,O
mg,O
iv,O
on,O
one,O
day,O
",",O
and,O
on,O
the,O
other,O
",",O
a,O
pretreatment,O
of,O
diphenhydramine,Entity
40,O
mg,O
iv,O
with,O
cimetidine,Entity
200,O
mg,O
iv,O
.,O
Allopurinol,Entity
did,O
not,O
prevent,O
dex,Entity
-,O
HT,Entity
.,O
The,O
Receiver,O
Operative,O
Characteristic,O
Curve,O
showed,O
that,O
OD,O
>,O
1.27,O
in,O
the,O
isolated,O
-,O
HIT,Entity
group,O
had,O
a,O
significantly,O
higher,O
chance,O
of,O
developing,O
thrombosis,Entity
by,O
day,O
30,O
.,O
Grade,O
3/4,O
nonhematologic,O
toxicities,Entity
were,O
uncommon,O
.,O
Forty,O
-,O
eight,O
hours,O
after,O
the,O
final,O
exercise,O
period,O
",",O
S,O
-,O
I,O
and,O
E,O
-,O
I,O
animals,O
received,O
a,O
single,O
subcutaneous,O
injection,O
of,O
isoproterenol,Entity
(,O
250,O
mg,O
/,O
kg,O
body,O
weight,O
),O
.,O
We,O
describe,O
the,O
unique,O
CT,O
features,O
of,O
ureteric,Entity
calculi,Entity
in,O
six,O
HIV,Entity
-,Entity
infected,Entity
patients,O
receiving,O
indinavir,Entity
",",O
the,O
most,O
commonly,O
used,O
HIV,O
protease,O
inhibitor,O
",",O
which,O
is,O
associated,O
with,O
an,O
increased,O
incidence,O
of,O
urolithiasis,Entity
.,O
Of,O
6,O
patients,O
with,O
irreversible,O
visual,Entity
impairment,Entity
",",O
4,O
patients,O
had,O
diabetes,Entity
mellitus,Entity
",",O
glaucoma,Entity
and,O
a,O
history,O
of,O
heavy,O
smoking,O
.,O
Atrial,Entity
tachycardia,Entity
-,O
induced,O
remodeling,O
promotes,O
the,O
occurrence,O
and,O
maintenance,O
of,O
atrial,Entity
fibrillation,Entity
(,O
AF,Entity
),O
and,O
decreases,O
L,O
-,O
type,O
Ca(2,Entity
+,O
),O
current,O
.,O
Maleate,Entity
-,O
induced,O
renal,Entity
injury,Entity
included,O
increase,O
in,O
renal,O
vascular,O
resistance,O
and,O
in,O
the,O
urinary,O
excretion,O
of,O
total,O
protein,O
",",O
glucose,Entity
",",O
sodium,Entity
",",O
neutrophil,O
gelatinase,O
-,O
associated,O
lipocalin,O
(,O
NGAL,O
),O
and,O
N,O
-,O
acetyl,O
b,O
-,O
D,O
-,O
glucosaminidase,O
(,O
NAG,O
),O
",",O
upregulation,O
of,O
kidney,Entity
injury,Entity
molecule,O
(,O
KIM)-1,O
",",O
decrease,O
in,O
renal,O
blood,O
flow,O
and,O
claudin-2,O
expression,O
besides,O
of,O
necrosis,Entity
and,O
apoptosis,O
of,O
tubular,O
cells,O
on,O
24,O
h.,O
Oxidative,O
stress,O
was,O
determined,O
by,O
measuring,O
the,O
oxidation,O
of,O
lipids,O
and,O
proteins,O
and,O
diminution,O
in,O
renal,O
Nrf2,O
levels,O
.,O
Influence,O
of,O
diet,O
free,O
of,O
NAD,Entity
-,O
precursors,O
on,O
acetaminophen,Entity
hepatotoxicity,Entity
in,O
mice,O
.,O
These,O
findings,O
indicate,O
the,O
synergistic,O
protective,O
effect,O
of,O
green,Entity
tea,Entity
and,O
vitamin,Entity
E,Entity
during,O
ISO,Entity
induced,O
myocardial,Entity
infarction,Entity
in,O
rats,O
.,O
There,O
was,O
no,O
significant,O
difference,O
between,O
occupancy,O
levels,O
obtained,O
with,O
haloperidol,Entity
or,O
risperidone,Entity
.,O
In,O
the,O
mouse,O
passive,O
-,O
avoidance,O
test,O
",",O
PG-9,Entity
(,O
10,O
-,O
30,O
mg,O
/,O
kg,O
",",O
i.p,O
.,O
),O
",",O
administered,O
20,O
min,O
before,O
the,O
training,O
session,O
",",O
prevented,O
amnesia,Entity
induced,O
by,O
both,O
the,O
non,O
selective,O
antimuscarinic,O
drug,O
scopolamine,Entity
and,O
the,O
M1-selective,O
antagonist,O
S-(-)-ET-126,Entity
.,O
The,O
frequencies,O
of,O
HIT,Entity
after,O
liver,O
transplantation,O
and,O
platelet,O
factor,O
4/heparin,Entity
-,O
reactive,O
antibody,O
(,O
HIT,Entity
antibody,O
),O
positivity,O
in,O
liver,O
transplantation,O
patients,O
",",O
however,O
",",O
are,O
unknown,O
.,O
There,O
were,O
slightly,O
increased,O
proliferating,O
cell,O
nuclear,O
antigen,O
-,O
positive,O
cells,O
in,O
the,O
ILK,O
/,O
liver-/-,O
animals,O
at,O
day,O
2,O
as,O
compared,O
to,O
WT,O
after,O
PB,Entity
administration,O
.,O
The,O
attenuating,O
effect,O
of,O
carteolol,Entity
hydrochloride,Entity
",",O
a,O
beta,O
-,O
adrenoceptor,O
antagonist,O
",",O
on,O
neuroleptic,O
-,O
induced,O
catalepsy,Entity
in,O
rats,O
.,O
The,O
effects,O
of,O
progesterone,Entity
treatment,O
on,O
bupivacaine,Entity
arrhythmogenicity,O
in,O
beating,O
rat,O
heart,O
myocyte,O
cultures,O
and,O
on,O
anesthetized,O
rats,O
were,O
determined,O
.,O
These,O
data,O
suggest,O
that,O
while,O
NO,Entity
deficiency,O
increases,O
oxidative,O
stress,O
and,O
sympathetic,O
activity,O
in,O
both,O
arterial,O
and,O
venous,O
vessels,O
",",O
the,O
impact,O
on,O
veins,O
does,O
not,O
make,O
a,O
major,O
contribution,O
to,O
this,O
form,O
of,O
hypertension,Entity
.,O
Post,O
-,O
training,O
administration,O
of,O
naloxone,Entity
(,O
3,O
mg,O
/,O
kg,O
),O
as,O
a,O
single,O
or,O
as,O
a,O
split,O
dose,O
also,O
attenuated,O
the,O
scopolamine,Entity
-,O
induced,O
amnesia,Entity
.,O
The,O
resulting,O
hypotension,Entity
can,O
be,O
produced,O
by,O
a,O
decrease,O
in,O
systemic,O
vascular,O
resistance,O
or,O
cardiac,O
output,O
through,O
a,O
decrease,O
in,O
venous,O
return,O
.,O
Atorva,Entity
reversed,O
dex,Entity
-,O
induced,O
hypertension,Entity
(,O
129,O
+,O
/-,O
Nimodipine,Entity
treatment,O
resulted,O
in,O
a,O
statistically,O
significant,O
reduction,Entity
in,Entity
systolic,Entity
BP,Entity
(,O
SBP,O
),O
and,O
diastolic,O
BP,O
(,O
DBP,O
),O
from,O
baseline,O
compared,O
with,O
placebo,O
during,O
the,O
first,O
few,O
days,O
.,O
In,O
summary,O
",",O
our,O
results,O
indicate,O
that,O
airway,O
management,O
using,O
FRLMA,O
during,O
controlled,O
hypotension,Entity
anesthesia,O
provided,O
better,O
surgical,O
conditions,O
in,O
terms,O
of,O
quality,O
of,O
operative,O
field,O
and,O
blood,O
loss,O
and,O
allowed,O
for,O
convenient,O
induced,O
hypotension,Entity
with,O
low,O
doses,O
of,O
remifentanil,Entity
during,O
TIVA,O
in,O
patients,O
undergoing,O
FESS,O
.,O
Also,O
",",O
reflex,O
bradycardia,Entity
was,O
produced,O
in,O
rats,O
by,O
intravenous,O
infusion,O
of,O
adrenaline,Entity
(,O
1.25,O
-,O
2.5,O
micrograms,O
kg-1,O
),O
.,O
Our,O
findings,O
showed,O
that,O
pubertal,O
BPA,Entity
exposure,O
increased,O
anxiety,Entity
-,O
like,O
behavior,O
",",O
which,O
may,O
be,O
associated,O
with,O
decreased,O
AChE,O
activity,O
of,O
the,O
hippocampus,O
in,O
adult,O
male,O
mice,O
.,O
0.02,O
prior,O
to,O
5-FU,Entity
infusion,O
v,O
0.13,O
+,O
/-,O
We,O
concluded,O
a,O
critical,O
time,O
window,O
for,O
systemic,O
lipopolysaccharide,Entity
pretreatment,O
in,O
exerting,O
effective,O
protection,O
against,O
methamphetamine,Entity
-,O
induced,O
nigrostriatal,O
dopamine,Entity
neurotoxicity,Entity
.,O
METHODS,O
:,O
Seventy,O
Swiss,O
albino,O
female,O
mice,O
(,O
25,O
-,O
35,O
g,O
),O
were,O
divided,O
into,O
4,O
groups,O
:,O
amphetamine,Entity
-,O
free,O
(,O
control,O
),O
",",O
amphetamine,Entity
",",O
50,O
",",O
and,O
100,O
mg,O
/,O
kg,O
DHEA,Entity
.,O
Following,O
unilateral,O
6-OHDA,Entity
induced,O
SN,Entity
lesion,Entity
",",O
a,O
transient,O
period,O
of,O
contralateral,Entity
rotation,Entity
has,O
been,O
reported,O
to,O
precede,O
the,O
predominant,O
ipsilateral,Entity
circling,Entity
.,O
Because,O
rats,O
with,O
streptozotocin,Entity
-,O
induced,O
diabetes,Entity
mellitus,Entity
(,O
DM,Entity
),O
have,O
a,O
high,O
solute,O
diuresis,O
(,O
glycosuria,Entity
of,O
10,O
to,O
12,O
g,O
/,O
day,O
),O
",",O
we,O
have,O
suggested,O
that,O
this,O
may,O
in,O
part,O
be,O
responsible,O
for,O
their,O
resistance,O
to,O
gentamicin,Entity
-,O
induced,O
acute,Entity
renal,Entity
failure,Entity
(,O
ARF,Entity
),O
.,O
Neither,O
the,O
type,O
of,O
induction,O
agent,O
(,O
Althesin,Entity
or,O
Thiopentone,Entity
),O
nor,O
the,O
salt,O
preparation,O
of,O
suxamethonium,Entity
used,O
(,O
chloride,Entity
or,O
bromide,Entity
),O
",",O
affected,O
the,O
incidence,O
of,O
scoline,Entity
pain,Entity
.,O
After,O
substituting,O
VPA,Entity
with,O
zonisamide,Entity
",",O
the,O
serum,O
sodium,Entity
level,O
returned,O
to,O
normal,O
.,O
Two,O
of,O
5,O
children,O
with,O
severe,O
adenovirus,Entity
disease,Entity
treated,O
with,O
intravenous,O
ribavirin,Entity
recovered,O
.,O
Signs,O
of,O
vitamin,Entity
D3,Entity
toxicity,Entity
were,O
not,O
observed,O
in,O
nonlactating,O
nonpregnant,O
cows,O
;,O
however,O
",",O
pregnant,O
cows,O
commonly,O
developed,O
severe,O
signs,O
of,O
vitamin,Entity
D3,Entity
toxicity,Entity
and,O
10,O
of,O
17,O
cows,O
died,O
.,O
By,O
2,O
hours,O
",",O
parvalbumin,O
-,O
staining,O
changed,O
in,O
the,O
central,O
SNR,O
indicating,O
neuronal,Entity
damage,Entity
",",O
and,O
Nissl,O
-,O
staining,O
visualized,O
some,O
neuronal,O
distortion,O
.,O
/,O
day,O
for,O
21,O
days,O
and,O
Medroxyprogesterone,Entity
acetate,Entity
10,O
mg,O
/,O
day,O
for,O
10,O
days,O
in,O
each,O
month,O
.,O
The,O
electrophysiological,O
recording,O
in,O
vitro,O
showed,O
that,O
Rg1,Entity
restored,O
the,O
LTP,O
in,O
slices,O
from,O
the,O
rats,O
treated,O
with,O
morphine,Entity
",",O
but,O
not,O
changed,O
LTP,O
in,O
the,O
slices,O
from,O
normal,O
saline-,O
or,O
morphine,Entity
/,O
Rg1-treated,Entity
rats,O
;,O
this,O
restoration,O
could,O
be,O
inhibited,O
by,O
N,Entity
-,Entity
methyl,Entity
-,Entity
D,Entity
-,Entity
aspartate,Entity
(,O
NMDA,Entity
),O
receptor,O
antagonist,O
MK801,Entity
.,O
We,O
performed,O
a,O
phase,O
II,O
trial,O
of,O
paclitaxel,Entity
175,O
mg,O
/,O
m2,O
over,O
3,O
hours,O
on,O
day,O
I,O
followed,O
by,O
folinic,Entity
acid,Entity
300,O
mg,O
over,O
1,O
hour,O
before,O
5-fluorouracil,Entity
350,O
mg,O
/,O
m2,O
on,O
days,O
1,O
to,O
3,O
every,O
28,O
days,O
(,O
TFL,O
),O
in,O
women,O
with,O
metastatic,O
breast,Entity
cancer,Entity
.,O
preceded,O
by,O
monoHER,Entity
(,O
500,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
with,O
an,O
interval,O
of,O
10,O
",",O
30,O
",",O
60,O
or,O
120,O
min,O
.,O
In,O
the,O
saline,O
treated,O
group,O
",",O
the,O
first,O
significant,O
decline,O
in,O
passive,O
avoidance,O
response,O
was,O
observed,O
at,O
four,O
weeks,O
",",O
and,O
complete,O
memory,Entity
loss,Entity
was,O
found,O
five,O
weeks,O
after,O
the,O
acquisition,O
of,O
the,O
passive,O
avoidance,O
task,O
.,O
We,O
studied,O
with,O
a,O
2.5,O
years,O
follow,O
-,O
up,O
the,O
changes,O
in,O
plasma,O
cholesterols,Entity
(,O
C,Entity
),O
",",O
triglycerides,Entity
(,O
TG,Entity
),O
",",O
lipoproteins,O
(,O
LP,O
),O
",",O
and,O
apolipoproteins,O
(,O
Apo,O
),O
Significantly,O
more,O
weight,Entity
gain,Entity
occurred,O
with,O
olanzapine,Entity
than,O
with,O
risperidone,Entity
:,O
the,O
increase,O
in,O
weight,O
at,O
4,O
months,O
relative,O
to,O
baseline,O
weight,O
was,O
17.3%,O
(,O
95%,O
CI=14.2%-20.5%,O
),O
with,O
olanzapine,Entity
and,O
11.3%,O
(,O
95%,O
CI=8.4%-14.3%,O
),O
with,O
risperidone,Entity
.,O
The,O
possibility,O
of,O
choreoathetoid,Entity
movements,O
should,O
be,O
considered,O
in,O
patients,O
presenting,O
after,O
pemoline,Entity
overdose,Entity
.,O
The,O
improvement,O
in,O
ipsilateral,O
dyskinesias,Entity
was,O
lost,O
after,O
one,O
year,O
",",O
and,O
the,O
improvements,O
in,O
postural,O
stability,O
and,O
gait,O
lasted,O
only,O
three,O
to,O
six,O
months,O
.,O
Reversible,O
myocardial,Entity
hypertrophy,Entity
induced,O
by,O
tacrolimus,Entity
in,O
a,O
pediatric,O
heart,O
transplant,O
recipient,O
:,O
case,O
report,O
.,O
As,O
heparin,Entity
remains,O
one,O
of,O
the,O
most,O
frequently,O
used,O
medications,O
today,O
with,O
potential,O
for,O
HIT,Entity
with,O
every,O
heparin,Entity
exposure,O
",",O
a,O
close,O
vigilance,O
of,O
platelet,O
counts,O
must,O
be,O
practiced,O
whenever,O
heparin,Entity
is,O
initiated,O
.,O
Thymus,O
weight,O
was,O
used,O
as,O
a,O
marker,O
of,O
glucocorticoid,O
activity,O
",",O
and,O
serum,O
urate,Entity
to,O
assess,O
XO,O
inhibition,O
.,O
However,O
",",O
the,O
patient,O
tolerated,O
well,O
an,O
alternative,O
reverse,O
transcriptase,O
inhibitor,O
",",O
2'3,Entity
',Entity
dideoxyinosine,Entity
.,O
In,O
this,O
preliminary,O
report,O
",",O
divalproex,Entity
sodium,Entity
was,O
a,O
superior,O
alternative,O
to,O
lithium,Entity
in,O
bipolar,Entity
patients,O
experiencing,O
cognitive,Entity
deficits,Entity
",",O
loss,Entity
of,Entity
creativity,Entity
",",O
and,O
functional,Entity
impairments,Entity
.,O
Amiodarone,Entity
pulmonary,Entity
toxicity,Entity
.,O
METHODS,O
:,O
SE,Entity
was,O
induced,O
by,O
pilocarpine,Entity
injection,O
.,O
prostaglandin,Entity
E1,Entity
with,O
(,O
pH,O
7.05,O
),O
or,O
without,O
(,O
pH,O
4.17,O
),O
the,O
addition,O
of,O
sodium,Entity
bicarbonate,Entity
(,O
0.03,O
mEq,O
.,O
),O
.,O
The,O
muscarinic,O
receptor,O
antagonists,O
atropine,Entity
",",O
4-diphenylacetoxy,Entity
-,Entity
N,Entity
-,Entity
methylpiperidine,Entity
(,O
4-DAMP,Entity
),O
(,O
',O
M(1)/M(3)/M(5)-selective,O
',O
),O
",",O
methoctramine,Entity
(,O
',O
M(2)-selective,O
',O
),O
and,O
pirenzepine,Entity
(,O
',O
M(1)-selective,O
',O
),O
antagonized,O
the,O
tonic,O
component,O
of,O
the,O
electrical,O
field,O
stimulation,O
-,O
evoked,O
contractile,O
response,O
more,O
potently,O
than,O
the,O
phasic,O
component,O
.,O
They,O
offer,O
protection,O
against,O
seizures,Entity
in,O
a,O
range,O
of,O
models,O
and,O
seem,O
to,O
inhibit,O
certain,O
stages,O
of,O
drug,Entity
dependence,Entity
in,O
preclinical,O
assessments,O
.,O
Nitric,Entity
oxide,Entity
(,O
NO,Entity
),O
",",O
gaseous,O
neurotransmitter,O
",",O
has,O
contradictor,O
role,O
in,O
epileptogenesis,O
due,O
to,O
opposite,O
effects,O
of,O
L,Entity
-,Entity
arginine,Entity
",",O
precursor,O
of,O
NO,Entity
syntheses,O
(,O
NOS,O
),O
",",O
and,O
L,Entity
-,Entity
NAME,Entity
(,O
NOS,O
inhibitor,O
),O
observed,O
in,O
different,O
epilepsy,Entity
models,O
.,O
Ammonia,Entity
(,O
NH3,Entity
),O
was,O
higher,O
in,O
patients,O
who,O
",",O
during,O
continuous,O
therapy,O
",",O
complained,O
of,O
drowsiness,Entity
(,O
7,O
patients,O
),O
than,O
in,O
those,O
who,O
were,O
symptom,O
-,O
free,O
(,O
17,O
patients,O
),O
",",O
although,O
VPA,Entity
plasma,O
levels,O
were,O
similar,O
in,O
both,O
groups,O
.,O
Although,O
tacrolimus,Entity
was,O
suspected,O
to,O
be,O
the,O
cause,O
of,O
late,O
post,O
-,O
transplant,O
renal,O
acidosis,Entity
and,O
was,O
replaced,O
by,O
sirolimus,Entity
",",O
acidosis,Entity
",",O
and,O
electrolyte,O
imbalance,O
got,O
worse,O
.,O
At,O
pH,O
9,O
",",O
a,O
higher,O
rate,O
of,O
etodolac,Entity
release,O
from,O
ED,O
was,O
observed,O
as,O
compared,O
to,O
aqueous,O
buffer,O
of,O
pH,O
7.4,O
and,O
80%,O
human,O
plasma,O
(,O
pH,O
7.4,O
),O
",",O
following,O
first,O
-,O
order,O
kinetics,O
.,O
He,O
was,O
found,O
unconsciousness,Entity
at,O
home,O
and,O
was,O
sent,O
to,O
our,O
hospital,O
.,O
Seven,O
patients,O
developed,O
glucose,Entity
tolerance,Entity
curves,Entity
characteristic,O
of,O
diabetes,Entity
but,O
these,O
were,O
mild,O
",",O
did,O
not,O
require,O
treatment,O
and,O
returned,O
to,O
normal,O
on,O
ceasing,O
didanosine,Entity
.,O
The,O
stronger,O
antiarrhythmic,O
effect,O
of,O
(,O
-)-cibenzoline,Entity
indicates,O
that,O
(,O
-)-isomer,O
may,O
have,O
an,O
effect,O
nearly,O
5,O
-,O
20,O
times,O
stronger,O
in,O
suppressing,O
Na,Entity
channels,O
",",O
but,O
effects,O
of,O
both,O
drugs,O
on,O
Ca,Entity
channels,O
may,O
be,O
almost,O
equipotent,O
.,O
Focal,O
subtenon,O
carboplatin,Entity
injections,O
have,O
recently,O
been,O
used,O
as,O
a,O
presumably,O
toxicity,Entity
-,O
free,O
adjunct,O
to,O
systemic,O
chemotherapy,O
for,O
intraocular,O
retinoblastoma,Entity
.,O
It,O
is,O
suggested,O
that,O
nefiracetam,Entity
augments,O
molecular,O
processes,O
in,O
the,O
early,O
stages,O
of,O
events,O
which,O
ultimately,O
lead,O
to,O
consolidation,O
of,O
memory,O
.,O
The,O
replacement,O
of,O
the,O
last,O
dose,O
or,O
the,O
last,O
two,O
doses,O
of,O
mesna,Entity
with,O
dexamethasone,Entity
reduced,O
the,O
increase,O
in,O
bladder,O
wet,O
weight,O
induced,O
by,O
IFS,Entity
by,O
84.79%,O
and,O
89.13%,O
",",O
respectively,O
.,O
Risperidone,Entity
-,O
associated,O
",",O
benign,O
transient,O
visual,Entity
disturbances,Entity
in,O
schizophrenic,Entity
patients,O
with,O
a,O
past,O
history,O
of,O
LSD,Entity
abuse,O
.,O
As,O
granisetron,Entity
dose,O
increased,O
",",O
appetite,O
return,O
increased,O
(,O
P,O
=,O
.040,O
),O
.,O
Veno,Entity
-,Entity
occlusive,Entity
liver,Entity
disease,Entity
after,O
dacarbazine,Entity
therapy,O
(,O
DTIC,Entity
),O
for,O
melanoma,Entity
.,O
We,O
discuss,O
herein,O
the,O
possible,O
mechanisms,O
and,O
the,O
significance,O
of,O
mToR,O
blockade,O
-,O
induced,O
proteinuria,Entity
.,O
We,O
suggest,O
that,O
investigators,O
involved,O
in,O
similar,O
trials,O
pay,O
close,O
attention,O
to,O
pulmonary,O
pressure,O
if,O
hypoxaemia,Entity
occurs,O
after,O
prophylactic,O
administration,O
of,O
ibuprofen,Entity
.,O
The,O
goal,O
of,O
this,O
study,O
was,O
to,O
determine,O
the,O
role,O
of,O
synthesis,O
/,O
release,O
of,O
bradykinin,Entity
to,O
activate,O
B2,O
receptors,O
in,O
disruption,O
of,O
the,O
blood,O
-,O
brain,O
barrier,O
during,O
acute,O
hypertension,Entity
.,O
Peri,O
-,O
operative,O
hypotension,Entity
(,O
26%,O
",",O
OR,O
3.80,O
",",O
95%,O
OBJECTIVE,O
:,O
To,O
describe,O
associations,O
between,O
the,O
use,O
of,O
benzodiazepines,Entity
or,O
related,O
drugs,O
(,O
BZDs,Entity
/,O
RDs,O
),O
and,O
health,O
",",O
functional,O
abilities,O
and,O
cognitive,O
function,O
in,O
the,O
elderly,O
.,O
Incidence,O
of,O
neoplasms,Entity
in,O
patients,O
with,O
rheumatoid,Entity
arthritis,Entity
exposed,O
to,O
different,O
treatment,O
regimens,O
.,O
During,O
culture,O
",",O
no,O
morphological,O
changes,O
were,O
found,O
at,O
effective,O
concentrations,O
of,O
PG-9,Entity
.,O
The,O
mechanistic,O
details,O
of,O
tumor,Entity
angiogenesis,O
induction,O
",",O
during,O
estrogen,Entity
carcinogenesis,Entity
",",O
are,O
still,O
unknown,O
.,O
hyperalgesia,Entity
induced,O
by,O
capsaicin,Entity
.,O
The,O
safety,O
and,O
efficacy,O
of,O
total,O
dose,O
infusion,O
(,O
TDI,O
),O
of,O
iron,Entity
dextran,Entity
has,O
been,O
well,O
documented,O
.,O
were,O
given,O
a,O
14-day,O
treatment,O
with,O
high,O
dose,O
inhaled,O
salbutamol,Entity
(,O
HDS,O
),O
",",O
"4,000",O
micrograms,O
daily,O
",",O
low,O
dose,O
inhaled,O
salbutamol,Entity
(,O
LDS,O
),O
",",O
800,O
micrograms,O
daily,O
",",O
or,O
placebo,O
(,O
PI,O
),O
by,O
metered,O
-,O
dose,O
inhaler,O
in,O
a,O
double,O
-,O
blind,O
",",O
randomized,O
crossover,O
design,O
.,O
The,O
levels,O
of,O
cholesterol,Entity
",",O
triglyceride,Entity
and,O
LDL,O
in,O
blood,O
of,O
rats,O
were,O
analyzed,O
.,O
End,Entity
-,Entity
stage,Entity
renal,Entity
disease,Entity
(,O
ESRD,Entity
),O
after,O
orthotopic,O
liver,O
transplantation,O
(,O
OLTX,O
),O
using,O
calcineurin,O
-,O
based,O
immunotherapy,O
:,O
Quality,O
of,O
response,O
was,O
independent,O
of,O
previous,O
lines,O
of,O
therapies,O
or,O
previous,O
exposure,O
to,O
thalidomide,Entity
or,O
bortezomib,Entity
.,O
We,O
propose,O
that,O
the,O
paracetamol,Entity
dose,O
should,O
not,O
exceed,O
2,O
g,O
/,O
day,O
in,O
such,O
patients,O
and,O
that,O
their,O
liver,O
function,O
should,O
be,O
monitored,O
closely,O
while,O
being,O
treated,O
with,O
paracetamol,Entity
.,O
The,O
study,O
investigates,O
if,O
alpha,Entity
-,Entity
lipoic,Entity
acid,Entity
is,O
neuroprotective,O
against,O
chemotherapy,O
induced,O
neurotoxicity,Entity
",",O
if,O
mitochondrial,Entity
damage,Entity
plays,O
a,O
critical,O
role,O
in,O
toxic,Entity
neurodegenerative,Entity
cascade,Entity
",",O
and,O
if,O
neuroprotective,O
effects,O
of,O
alpha,Entity
-,Entity
lipoic,Entity
acid,Entity
depend,O
on,O
mitochondria,O
protection,O
.,O
An,O
increase,O
in,O
the,O
volume,O
density,O
of,O
secretory,O
granules,O
and,O
a,O
decrease,O
in,O
the,O
volume,O
densities,O
of,O
rough,O
endoplasmic,O
reticulum,O
and,O
microtubules,O
was,O
determined,O
by,O
morphometric,O
analysis,O
",",O
suggesting,O
that,O
bromocriptine,Entity
inhibits,O
protein,O
synthesis,O
as,O
well,O
as,O
bringing,O
about,O
a,O
disturbance,O
of,O
the,O
prolactin,O
secretion,O
.,O
The,O
findings,O
showed,O
that,O
peripheral,O
iron,Entity
dextran,Entity
overload,O
increased,O
the,O
iron,Entity
staining,O
positive,O
cells,O
and,O
reduced,O
the,O
number,O
of,O
TH,O
-,O
immunoreactive,O
neurons,O
in,O
the,O
SN,O
.,O
The,O
use,O
of,O
thiopentone,Entity
was,O
significantly,O
associated,O
with,O
an,O
eight,O
-,O
fold,O
-,O
higher,O
risk,O
for,O
delirium,Entity
compared,O
to,O
propofol,Entity
(,O
57.1%,O
Oxidative,O
stress,O
is,O
considered,O
to,O
play,O
an,O
important,O
role,O
in,O
epileptogenesis,O
and,O
cognitive,Entity
deficits,Entity
",",O
and,O
antioxidants,O
have,O
a,O
putative,O
antiepileptic,O
potential,O
.,O
Learning,O
of,O
rats,O
under,O
amnesia,Entity
caused,O
by,O
pentobarbital,Entity
.,O
Biological,O
evaluation,O
suggested,O
that,O
conjugates,O
(,O
ED1-ED4,O
),O
retained,O
comparable,O
analgesic,O
and,O
antiinflammatory,O
activities,O
with,O
remarkably,O
reduced,O
ulcerogenicity,O
as,O
compared,O
to,O
their,O
parent,O
drug,O
--,O
etodolac,Entity
.,O
Stopping,O
minocycline,Entity
led,O
to,O
amelioration,O
of,O
symptoms,O
and,O
normalization,O
of,O
CRP,O
level,O
.,O
A,O
literature,O
review,O
revealed,O
no,O
prior,O
reports,O
of,O
pericarditis,Entity
in,O
anti,O
-,O
MPO,O
pANCA,O
-,O
positive,O
vasculitis,Entity
associated,O
with,O
propylthio-,Entity
uracil,Entity
therapy,O
.,O
The,O
patients,O
with,O
PD,Entity
and,O
MDP,Entity
were,O
more,O
sensitive,O
to,O
caffeine,Entity
than,O
were,O
patients,O
with,O
MD,Entity
and,O
healthy,O
volunteers,O
.,O
In,O
the,O
patients,O
",",O
but,O
not,O
the,O
healthy,O
subjects,O
",",O
these,O
symptoms,O
were,O
significantly,O
correlated,O
with,O
plasma,O
caffeine,Entity
levels,O
.,O
Coexistence,O
of,O
cerebral,Entity
venous,Entity
sinus,Entity
and,Entity
internal,Entity
carotid,Entity
artery,Entity
thrombosis,Entity
associated,O
with,O
exogenous,O
sex,O
hormones,O
.,O
Concentrations,O
of,O
coniine,Entity
and,O
nicotine,Entity
sulfate,O
were,O
0.015%,O
",",O
0.03%,O
",",O
0.075%,O
",",O
0.15%,O
",",O
0.75%,O
",",O
1.5%,O
",",O
3%,O
",",O
and,O
6%,O
and,O
1%,O
",",O
5%,O
",",O
and,O
10%,O
",",O
respectively,O
.,O
Current,O
animal,O
models,O
of,O
obsessive,Entity
-,Entity
compulsive,Entity
disorder,Entity
(,O
OCD,Entity
),O
typically,O
involve,O
acute,O
",",O
drug,O
-,O
induced,O
symptom,O
provocation,O
or,O
a,O
genetic,O
association,O
with,O
stereotypies,O
or,O
anxiety,Entity
.,O
In,O
this,O
prevention,O
study,O
",",O
SBP,O
in,O
the,O
atorva,Entity
+,O
dex,Entity
group,O
was,O
increased,O
from,O
115,O
+,O
/-,O
Caffeine,Entity
increased,O
plasma,O
cortisol,Entity
levels,O
equally,O
in,O
the,O
patient,O
and,O
healthy,O
groups,O
.,O
Metformin,Entity
treatment,O
fully,O
blocked,O
gentamicin,Entity
-,O
mediated,O
acute,Entity
renal,Entity
failure,Entity
.,O
In,O
postrenal,O
transplantation,O
",",O
thrombotic,Entity
microangiopathy,Entity
is,O
often,O
a,O
reflection,O
of,O
hemolytic,Entity
uremic,Entity
syndrome,Entity
.,O
This,O
coma,Entity
was,O
prevented,O
with,O
1.68,O
mmol,O
L,Entity
-,Entity
dopa,Entity
given,O
by,O
gastric,O
intubation,O
15,O
minutes,O
before,O
the,O
ammonium,Entity
salt,Entity
injection,O
.,O
While,O
the,O
mutual,O
potentiation,O
",",O
antagonism,O
and,O
tolerance,O
suggest,O
common,O
mechanisms,O
for,O
the,O
induced,O
catalepsy,Entity
",",O
differences,O
in,O
latency,O
",",O
rigidity,Entity
and,O
behavior,O
",",O
asymmetry,O
of,O
cross,O
-,O
tolerance,O
and,O
a,O
widely,O
-,O
different,O
ID50,O
for,O
naloxone,Entity
would,O
argue,O
against,O
an,O
action,O
at,O
a,O
single,O
opioid,O
site,O
.,O
For,O
specific,O
groups,O
of,O
drugs,O
",",O
the,O
risks,O
were,O
1.56,O
(,O
1.05,O
-,O
2.30,O
),O
for,O
aspirin,Entity
",",O
1.03,O
(,O
0.60,O
-,O
1.76,O
),O
The,O
increase,O
in,O
pressure,O
rate,O
product,O
after,O
dipyridamole,Entity
was,O
significantly,O
less,O
than,O
that,O
during,O
the,O
treadmill,O
exercise,O
.,O
After,O
the,O
target,O
Ce,O
was,O
achieved,O
",",O
the,O
infusion,O
of,O
propofol,Entity
was,O
started,O
.,O
Such,O
disparity,O
suggests,O
an,O
inhibition,O
of,O
creatine,Entity
phosphokinase,O
.,O
The,O
left,Entity
ventricular,Entity
dysfunction,Entity
was,O
significantly,O
lower,O
in,O
the,O
groups,O
treated,O
with,O
25,O
and,O
50mg,O
/,O
These,O
findings,O
show,O
a,O
significant,O
interaction,O
between,O
morphine,Entity
and,O
metamizol,Entity
in,O
chronically,O
treated,O
rats,O
",",O
suggesting,O
that,O
this,O
combination,O
could,O
be,O
useful,O
for,O
the,O
treatment,O
of,O
chronic,Entity
pain,Entity
.,O
We,O
also,O
used,O
microdialysis,O
to,O
measure,O
basal,O
and,O
potassium,Entity
-,O
stimulated,O
acetylcholine,Entity
(,O
ACh,Entity
),O
release,O
in,O
the,O
CA1,O
region,O
of,O
the,O
hippocampus,O
.,O
Although,O
the,O
ability,O
of,O
cyclophosphamide,Entity
to,O
cause,O
hemorrhagic,Entity
cystitis,Entity
and,O
urine,O
cytologic,O
abnormalities,O
indistinguishable,O
from,O
high,O
grade,O
carcinoma,Entity
is,O
well,O
known,O
",",O
it,O
is,O
less,O
widely,O
appreciated,O
that,O
it,O
is,O
also,O
associated,O
with,O
carcinoma,Entity
of,Entity
the,Entity
urinary,Entity
tract,Entity
.,O
Forty,O
-,O
three,O
ovarian,Entity
cancer,Entity
patients,O
were,O
available,O
for,O
analysis,O
following,O
six,O
cycles,O
of,O
the,O
same,O
PAC,Entity
-,O
containing,O
regimen,O
:,O
23,O
had,O
been,O
supplemented,O
by,O
glutamate,Entity
all,O
along,O
the,O
treatment,O
period,O
",",O
at,O
a,O
daily,O
dose,O
of,O
three,O
times,O
500,O
mg,O
(,O
group,O
G,O
),O
",",O
and,O
20,O
had,O
received,O
a,O
placebo,O
(,O
group,O
P,O
),O
.,O
It,O
was,O
hypothesized,O
that,O
progestins,Entity
could,O
equilibrate,O
the,O
effects,O
of,O
the,O
estrogenic,O
stimulation,O
on,O
the,O
mammary,O
and,O
endometrial,O
target,O
tissues,O
of,O
women,O
on,O
hormonal,O
replacement,O
therapy,O
.,O
Experimental,O
design,O
consisted,O
of,O
four,O
groups,O
:,O
control,O
(,O
vehicle,O
alone,O
),O
",",O
GSPE,Entity
alone,O
",",O
drug,O
alone,O
and,O
GSPE+drug,Entity
.,O
Protective,O
effect,O
of,O
Terminalia,Entity
chebula,Entity
against,O
experimental,O
myocardial,Entity
injury,Entity
induced,O
by,O
isoproterenol,Entity
.,O
The,O
enhancement,O
of,O
aminonucleoside,Entity
nephrosis,Entity
by,O
the,O
co,O
-,O
administration,O
of,O
protamine,O
.,O
Azotemia,Entity
was,O
the,O
major,O
side,O
effect,O
recognized,O
",",O
and,O
it,O
occurred,O
in,O
11%,O
of,O
episodes,O
.,O
Studies,O
on,O
the,O
bradycardia,Entity
induced,O
by,O
bepridil,Entity
.,O
It,O
appears,O
from,O
these,O
data,O
that,O
hematologic,O
work,O
-,O
ups,O
may,O
be,O
useful,O
in,O
women,O
who,O
are,O
about,O
to,O
start,O
long,O
-,O
term,O
oral,Entity
contraceptive,Entity
therapy,O
.,O
The,O
present,O
study,O
was,O
designed,O
to,O
investigate,O
whether,O
nociceptin,Entity
/,O
orphanin,Entity
FQ,Entity
and,O
nocistatin,Entity
could,O
modulate,O
impairment,Entity
of,Entity
learning,Entity
and,Entity
memory,Entity
induced,O
by,O
scopolamine,Entity
",",O
a,O
muscarinic,O
cholinergic,O
receptor,O
antagonist,O
",",O
using,O
spontaneous,O
alternation,O
of,O
Y,O
-,O
maze,O
and,O
step,O
-,O
down,O
type,O
passive,O
avoidance,O
tasks,O
in,O
mice,O
.,O
There,O
was,O
a,O
significant,O
difference,O
among,O
groups,O
in,O
glucose,Entity
effectiveness,O
(,O
F(30,O
),O
=,O
4.18,O
;,O
Our,O
findings,O
do,O
suggest,O
that,O
CS,Entity
-,O
mediated,O
protection,O
is,O
dependent,O
on,O
the,O
action,O
of,O
the,O
intact,O
anionic,O
CS,Entity
molecule,O
(,O
non,O
-,O
hydrolyzable,O
CSE,Entity
was,O
as,O
protective,O
as,O
CS,Entity
),O
",",O
whose,O
mechanism,O
has,O
yet,O
to,O
be,O
defined,O
.,O
We,O
observed,O
elevated,O
lung,Entity
cancer,Entity
risks,O
(,O
N=283,O
),O
among,O
applicators,O
with,O
the,O
greatest,O
number,O
of,O
LT,O
(,O
RR=1.60,O
;,O
95%,O
CI,O
1.11,O
to,O
2.31,O
;,O
Ptrend=0.02,O
),O
and,O
IW,O
days,O
of,O
diazinon,Entity
use,O
(,O
RR=1.41,O
;,O
95%,O
CI,O
0.98,O
to,O
2.04,O
;,O
Ptrend=0.08,O
),O
.,O
However,O
",",O
caution,O
is,O
required,O
when,O
cyclophosphamide,Entity
or,O
anthracyclines,Entity
such,O
as,O
mitoxantrone,Entity
are,O
used,O
in,O
patients,O
with,O
a,O
possible,O
underlying,O
heart,Entity
damage,Entity
",",O
for,O
example,O
",",O
systemic,Entity
sclerosis,Entity
patients,O
.,O
A,O
phase,O
II,O
study,O
of,O
thalidomide,Entity
in,O
advanced,O
metastatic,O
renal,Entity
cell,Entity
carcinoma,Entity
.,O
This,O
case,O
contributes,O
to,O
the,O
previous,O
observations,O
that,O
non,O
-,O
metastasizing,O
hepatic,Entity
neoplasms,Entity
and,O
peliosis,Entity
can,O
develop,O
in,O
patients,O
with,O
androgen-,Entity
and,O
corticosteroid,Entity
-,O
treated,O
Fanconi,Entity
's,Entity
anemia,Entity
.,O
In,O
addition,O
to,O
this,O
",",O
when,O
high,O
concentrations,O
of,O
Mesna,Entity
were,O
administered,O
alone,O
significant,O
reductions,O
of,O
the,O
PRI,O
were,O
noted,O
",",O
than,O
with,O
IFO,Entity
acting,O
at,O
the,O
same,O
concentration,O
on,O
the,O
lymphocytes,O
.,O
Four,O
out,O
of,O
23,O
consecutive,O
patients,O
treated,O
with,O
high,O
-,O
dose,O
Ara,Entity
-,Entity
C,Entity
for,O
lymphomas,Entity
in,O
our,O
institution,O
developed,O
a,O
strikingly,O
similar,O
syndrome,O
during,O
the,O
perfusion,O
.,O
We,O
",",O
therefore,O
",",O
investigated,O
the,O
effects,O
of,O
the,O
histamine,Entity
1(H1,O
),O
receptor,O
antagonist,O
",",O
diphenhydramine,Entity
",",O
on,O
the,O
haemodynamic,O
changes,O
observed,O
after,O
cimetidine,Entity
in,O
ICU,O
patients,O
.,O
This,O
study,O
is,O
the,O
first,O
to,O
demonstrate,O
that,O
impairment,O
of,O
hepatocyte,O
TJs,O
occurs,O
heterogenously,O
in,O
the,O
liver,O
lobule,O
after,O
BDL,O
and,O
suggests,O
that,O
BDL,O
and,O
EE,Entity
treatments,O
produce,O
different,O
lobular,O
distributions,O
of,O
increased,O
paracellular,O
permeability,O
.,O
A,O
total,O
of,O
261,O
adverse,O
ocular,O
reactions,O
occurred,O
in,O
237,O
patients,O
who,O
received,O
isotretinoin,Entity
",",O
a,O
commonly,O
used,O
drug,O
in,O
the,O
treatment,O
of,O
severe,O
cystic,O
acne,Entity
.,O
As,O
described,O
earlier,O
",",O
administration,O
of,O
ibuprofen,Entity
was,O
followed,O
by,O
a,O
decrease,O
in,O
tonic,O
pain,Entity
but,O
-,O
relative,O
to,O
placebo,O
-,O
an,O
increase,O
in,O
correlates,O
of,O
phasic,O
pain,Entity
",",O
indicating,O
a,O
specific,O
effect,O
of,O
ibuprofen,Entity
on,O
the,O
interaction,O
between,O
the,O
pain,Entity
stimuli,O
under,O
these,O
special,O
experimental,O
conditions,O
.,O
A,O
total,O
of,O
205,O
patients,O
with,O
idiopathic,Entity
Parkinson,Entity
's,Entity
disease,Entity
were,O
investigated,O
.,O
Neuropeptide,O
-,O
Y,O
(,O
NPY,O
),O
is,O
expressed,O
by,O
granule,O
cells,O
and,O
mossy,O
fibres,O
of,O
the,O
hippocampal,O
dentate,O
gyrus,O
during,O
experimental,O
temporal,Entity
lobe,Entity
epilepsy,Entity
(,O
TLE,Entity
),O
.,O
Median,O
maximum,O
serum,O
levetiracetam,Entity
concentration,O
was,O
25.5,O
microg,O
/,O
mL,O
",",O
median,O
minimum,O
serum,O
levetiracetam,Entity
concentration,O
was,O
8.3,O
microg,O
/,O
mL,O
",",O
and,O
median,O
elimination,O
half,O
-,O
life,O
was,O
2.9,O
hours,O
.,O
Ketoprofen,Entity
but,O
not,O
acetaminophen,Entity
impaired,O
platelet,O
function,O
in,O
patients,O
with,O
SAH,Entity
.,O
ZnSO(4,Entity
),Entity
pretreatment,O
counteracted,O
BCNU,Entity
-,O
induced,O
inhibition,O
of,O
GR,O
and,O
depletion,O
of,O
GSH,Entity
and,O
resulted,O
in,O
significant,O
reduction,O
in,O
the,O
levels,O
of,O
MDA,Entity
and,O
TNFalpha,O
as,O
well,O
as,O
the,O
activity,O
of,O
caspase-3,O
.,O
The,O
negative,O
effects,O
of,O
Bisphenol,Entity
A,Entity
(,O
BPA,Entity
),O
on,O
neurodevelopment,O
and,O
behaviors,O
have,O
been,O
well,O
established,O
.,O
Isoniazid,Entity
was,O
discontinued,O
later,O
",",O
followed,O
by,O
a,O
dramatic,O
improvement,O
in,O
the,O
visual,O
acuity,O
.,O
Thrombotic,Entity
microangiopathy,Entity
is,O
a,O
well,O
-,O
known,O
problem,O
in,O
patients,O
following,O
renal,O
transplantation,O
.,O
Depending,O
on,O
the,O
dose,O
",",O
from,O
82%,O
to,O
95%,O
of,O
lovastatin,Entity
-,O
treated,O
women,O
achieved,O
the,O
National,O
Cholesterol,Entity
Education,O
Program,O
goal,O
of,O
LDL,O
cholesterol,Entity
levels,O
less,O
than,O
4.14,O
mmol,O
/,O
L,O
(,O
160,O
mg,O
/,O
dL,O
),O
",",O
and,O
40%,O
to,O
87%,O
achieved,O
the,O
goal,O
of,O
3.36,O
mmol,O
/,O
L,O
(,O
130,O
mg,O
/,O
dL,O
),O
.,O
The,O
case,O
of,O
a,O
40-year,O
-,O
old,O
patient,O
who,O
underwent,O
an,O
unsuccessful,O
cadaver,O
kidney,O
transplantation,O
and,O
was,O
treated,O
with,O
ethambutol,Entity
and,O
isoniazid,Entity
is,O
reported,O
.,O
Caffeine,Entity
did,O
not,O
alter,O
plasma,O
MHPG,Entity
levels,O
in,O
either,O
the,O
healthy,O
subjects,O
or,O
patients,O
.,O
11.8,O
ms,O
in,O
week,O
10,O
(,O
7,O
weekly,O
doses,O
of,O
4,O
mg,O
/,O
kg,O
doxorubicin,Entity
given,O
i.v,O
.,O
PURPOSE,O
:,O
Treatment,O
of,O
neuroblastoma,Entity
cell,O
lines,O
with,O
13-cis,Entity
-,Entity
retinoic,Entity
acid,Entity
(,O
cis,Entity
-,Entity
RA,Entity
),O
can,O
cause,O
sustained,O
inhibition,O
of,O
proliferation,O
.,O
Therefore,O
",",O
when,O
the,O
arrhythmia,Entity
is,O
present,O
in,O
this,O
population,O
",",O
reversible,O
causes,O
must,O
be,O
identified,O
and,O
resolved,O
.,O
Patients,O
receiving,O
concomitant,O
AmB,Entity
and,O
spironolactone,Entity
had,O
significantly,O
higher,O
plasma,O
potassium,Entity
levels,O
than,O
those,O
receiving,O
AmB,Entity
alone,O
(,O
P,O
=,O
0.0027,O
),O
.,O
A,O
new,O
infarct,Entity
-,O
avid,O
radiopharmaceutical,O
based,O
on,O
glucaric,Entity
acid,Entity
was,O
prepared,O
in,O
the,O
hospital,O
radiopharmacy,O
of,O
the,O
INCMNSZ,O
.,O
After,O
recovery,O
from,O
hypertension,Entity
",",O
the,O
activity,O
of,O
(,O
Na,Entity
",",O
K)-ATPase,Entity
increased,O
",",O
due,O
to,O
higher,O
affinity,O
of,O
the,O
ATP,Entity
-,O
binding,O
site,O
",",O
as,O
revealed,O
from,O
the,O
lowered,O
Km,O
value,O
for,O
ATP,Entity
.,O
The,O
results,O
indicate,O
that,O
rat,O
atrial,O
spontaneous,O
beating,O
is,O
more,O
dependent,O
on,O
[,O
Na]o,Entity
than,O
on,O
[,O
Ca]o,Entity
in,O
a,O
range,O
of,O
+,O
/-,O
We,O
speculate,O
on,O
the,O
possible,O
relation,O
of,O
the,O
current,O
findings,O
on,O
treating,O
different,O
epilepsy,Entity
-,O
associated,O
conditions,O
.,O
We,O
report,O
a,O
case,O
of,O
Wilson,Entity
's,Entity
disease,Entity
with,O
chronic,Entity
liver,Entity
disease,Entity
;,O
moreover,O
",",O
in,O
our,O
patient,O
",",O
presenting,O
also,O
with,O
high,O
levels,O
of,O
state,O
anxiety,Entity
without,O
depression,Entity
",",O
99mTc,O
-,O
ECD,O
-,O
SPECT,O
showed,O
cortical,O
hypoperfusion,O
in,O
frontal,O
lobes,O
",",O
more,O
marked,O
on,O
the,O
left,O
frontal,O
lobe,O
.,O
ACC-9653,Entity
and,O
phenytoin,Entity
sodium,Entity
Despite,O
precautions,O
this,O
adverse,O
reaction,O
recurred,O
on,O
re,O
-,O
exposure,O
to,O
intravenous,O
fluorescein,Entity
.,O
Pneumonia,Entity
was,O
the,O
most,O
common,O
infection,Entity
and,O
61%,O
of,O
59,O
episodes,O
were,O
cured,O
.,O
Transient,O
hemiparesis,Entity
:,O
a,O
rare,O
manifestation,O
of,O
diphenylhydantoin,Entity
toxicity,Entity
.,O
Of,O
158,O
asthmatic,Entity
patients,O
who,O
were,O
placed,O
on,O
inhaled,O
beclomethasone,Entity
",",O
15,O
(,O
9.5%,O
),O
developed,O
either,O
hoarseness,Entity
(,O
8),O
",",O
oral,O
thrush,Entity
(,O
6,O
),O
",",O
or,O
both,O
(,O
1,O
),O
.,O
No,O
more,O
tic,Entity
-,Entity
like,Entity
symptoms,Entity
or,O
other,O
side,O
effects,O
have,O
been,O
reported,O
.,O
The,O
number,O
of,O
nocturia,Entity
episodes,O
decreased,O
from,O
5.4,O
+,O
/-,O
In,O
bipolar,Entity
mania,Entity
",",O
the,O
incidence,O
of,O
EPS,Entity
",",O
including,O
akathisia,Entity
",",O
with,O
quetiapine,Entity
therapy,O
is,O
similar,O
to,O
that,O
with,O
placebo,O
.,O
OBJECTIVE,O
:,O
There,O
are,O
several,O
complications,O
associated,O
with,O
heroin,Entity
abuse,Entity
",",O
some,O
of,O
which,O
are,O
life,O
-,O
threatening,O
.,O
Patients,O
with,O
tamoxifen,Entity
-,O
induced,O
liver,Entity
dysfunction,Entity
may,O
be,O
at,O
increased,O
risk,O
for,O
granulosa,Entity
cell,Entity
tumors,Entity
because,O
of,O
alterations,O
in,O
tamoxifen,Entity
metabolism,O
.,O
CONCLUSION,O
:,O
Dexmedetomidine,Entity
in,O
high,O
doses,O
provides,O
adequate,O
sedation,O
for,O
pediatric,O
MRI,O
studies,O
.,O
In,O
patients,O
with,O
cardiomegaly,Entity
",",O
the,O
increase,O
in,O
heart,O
size,O
was,O
similar,O
in,O
both,O
groups,O
.,O
Drug,O
-,O
induced,O
arterial,O
spasm,Entity
relieved,O
by,O
lidocaine,Entity
.,O
These,O
data,O
suggest,O
distinct,O
differences,O
in,O
the,O
propensity,O
to,O
develop,O
LIDs,Entity
in,O
monkeys,O
with,O
different,O
rates,O
of,O
symptom,O
progression,O
or,O
symptom,O
durations,O
prior,O
to,O
levodopa,Entity
and,O
demonstrate,O
the,O
value,O
of,O
these,O
models,O
for,O
further,O
studying,O
the,O
pathophysiology,O
of,O
LIDs,Entity
.,O
These,O
data,O
might,O
indicate,O
that,O
the,O
generation,O
of,O
reactive,O
oxygen,Entity
species,O
and,O
activation,O
of,O
NF,O
-,O
kappaB,O
plays,O
a,O
more,O
central,O
role,O
in,O
seizure,Entity
-,O
associated,O
neuronal,Entity
damage,Entity
in,O
the,O
temporal,O
cortex,O
as,O
compared,O
to,O
the,O
hippocampal,O
hilus,O
.,O
This,O
open,O
-,O
labeled,O
",",O
multicenter,O
study,O
evaluated,O
the,O
safety,O
of,O
bedtime,O
niacin,Entity
extended,Entity
-,Entity
release,Entity
/,Entity
lovastatin,Entity
when,O
dosed,O
as,O
initial,O
therapy,O
and,O
patient,O
compliance,O
to,O
treatment,O
in,O
various,O
clinical,O
practice,O
settings,O
.,O
Five,O
patients,O
with,O
carcinoma,Entity
developed,O
thrombotic,Entity
microangiopathy,Entity
(,O
characterized,O
by,O
renal,Entity
insufficiency,Entity
",",O
microangiopathic,Entity
hemolytic,Entity
anemia,Entity
",",O
and,O
usually,O
thrombocytopenia,Entity
),O
after,O
treatment,O
with,O
cisplatin,Entity
",",O
bleomycin,Entity
",",O
and,O
a,O
vinca,Entity
alkaloid,Entity
.,O
Susceptibility,O
to,O
seizures,Entity
produced,O
by,O
pilocarpine,Entity
in,O
rats,O
after,O
microinjection,O
of,O
isoniazid,Entity
or,O
gamma,Entity
-,Entity
vinyl,Entity
-,Entity
GABA,Entity
into,O
the,O
substantia,O
nigra,O
.,O
There,O
were,O
no,O
instances,O
of,O
macroscopic,O
hematuria,Entity
.,O
She,O
received,O
a,O
second,O
cycle,O
of,O
nelarabine,Entity
without,O
additional,O
IT,O
prophylaxis,O
one,O
month,O
later,O
.,O
CONCLUSION,O
:,O
Toxic,Entity
hepatitis,Entity
is,O
a,O
potential,O
adverse,O
effect,O
of,O
antithyroid,O
drugs,O
which,O
warrants,O
",",O
as,O
for,O
haematological,O
disturbances,O
",",O
a,O
pre,O
-,O
therapeutic,O
determination,O
and,O
a,O
careful,O
follow,O
-,O
up,O
of,O
relevant,O
biological,O
markers,O
.,O
This,O
paper,O
presents,O
the,O
clinical,O
and,O
metabolic,O
findings,O
in,O
two,O
young,O
boys,O
with,O
long,O
-,O
standing,O
Kearns,Entity
-,Entity
Sayre,Entity
syndrome,Entity
.,O
She,O
was,O
re,O
-,O
induced,O
with,O
nelarabine,Entity
1500,O
mg,O
/,O
m(2,O
),O
on,O
days,O
1,O
",",O
3,O
",",O
and,O
5,O
with,O
1,O
dose,O
of,O
IT,O
cytarabine,Entity
100,O
mg,O
on,O
day,O
2,O
as,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
prophylaxis,O
.,O
The,O
average,O
levodopa,Entity
dose,O
decreased,O
from,O
813,O
mg,O
to,O
359,O
mg,O
.,O
GLEPP1,O
receptor,O
tyrosine,Entity
phosphatase,O
(,O
Ptpro,O
),O
in,O
rat,O
PAN,Entity
nephrosis,Entity
.,O
The,O
',O
long,O
-,O
term,O
',O
group,O
had,O
significant,O
glomerular,Entity
and,Entity
tubular,Entity
lesions,Entity
",",O
depressed,O
activities,O
of,O
mtDNA,O
-,O
encoded,O
NADH,O
dehydrogenase,O
and,O
cytochrome,O
-,O
c,O
oxidase,O
(,O
COX,O
),O
and,O
increased,O
citrate,Entity
synthase,O
activity,O
.,O
For,O
the,O
first,O
time,O
",",O
an,O
analytical,O
method,O
for,O
the,O
determination,O
of,O
carbachol,Entity
in,O
plasma,O
and,O
urine,O
has,O
been,O
developed,O
.,O
We,O
report,O
a,O
case,O
of,O
severe,O
citrate,Entity
toxicity,Entity
during,O
volunteer,O
donor,O
apheresis,O
platelet,O
collection,O
.,O
A,O
63,O
year,O
-,O
old,O
Caucasian,O
man,O
on,O
metoprolol,Entity
200,O
mg,O
/,O
day,O
for,O
stable,O
coronary,Entity
artery,Entity
disease,Entity
was,O
prescribed,O
a,O
90-day,O
course,O
of,O
oral,O
terbinafine,Entity
250,O
mg,O
/,O
day,O
for,O
onychomycosis,Entity
.,O
The,O
three,O
significant,O
predictors,O
of,O
dyskinesia,Entity
were,O
duration,O
of,O
levodopa,Entity
therapy,O
",",O
onset,O
age,O
",",O
and,O
total,O
daily,O
levodopa,Entity
dose,O
.,O
The,O
frequency,O
and,O
predictability,O
of,O
hematuria,Entity
are,O
not,O
precise,O
",",O
and,O
at,O
least,O
daily,O
monitoring,O
by,O
urine,O
Ophthalmologic,O
examinations,O
showed,O
ptosis,Entity
on,Entity
the,Entity
right,Entity
upper,Entity
lid,Entity
and,O
restricted,Entity
right,Entity
eye,Entity
movement,Entity
without,O
any,O
other,O
neurological,O
signs,O
.,O
Twenty,O
-,O
four,O
hours,O
after,O
hemorrhage,Entity
induction,O
",",O
hemorrhagic,O
blood,O
volume,O
was,O
quantified,O
using,O
a,O
photometric,O
hemoglobin,O
assay,O
.,O
Consequently,O
",",O
lithium,Entity
pretreatment,O
caused,O
a,O
fall,O
in,O
filtration,O
fraction,O
and,O
an,O
increase,O
in,O
fractional,O
Li,Entity
excretion,O
.,O
:,O
We,O
sent,O
a,O
questionnaire,O
concerning,O
complications,O
of,O
indocyanine,Entity
green,Entity
to,O
32,O
institutions,O
in,O
Japan,O
",",O
which,O
were,O
selected,O
on,O
the,O
basis,O
of,O
the,O
client,O
list,O
from,O
the,O
Topcon,O
Company,O
",",O
which,O
manufactures,O
the,O
indocyanine,Entity
green,Entity
fundus,O
camera,O
.,O
Hemodynamic,O
measurements,O
in,O
1,O
of,O
the,O
patients,O
demonstrated,O
an,O
increase,O
in,O
total,O
peripheral,O
resistance,O
and,O
essentially,O
no,O
change,O
in,O
cardiac,O
output,O
following,O
propranolol,Entity
therapy,O
.,O
However,O
",",O
one,O
month,O
after,O
switching,O
over,O
nifekalant,Entity
to,O
sotalol,Entity
",",O
a,O
short,O
duration,O
of,O
ST,O
elevation,O
was,O
documented,O
in,O
ECG,O
monitoring,O
at,O
almost,O
the,O
same,O
time,O
for,O
three,O
consecutive,O
days,O
.,O
Everolimus,Entity
",",O
a,O
derivative,O
of,O
sirolimus,Entity
",",O
seems,O
to,O
mediate,O
antileukemia,O
effects,O
.,O
Furthermore,O
",",O
it,O
appears,O
that,O
striatal,O
-,O
resident,O
microglia,O
respond,O
to,O
METH,Entity
with,O
an,O
activation,O
cascade,O
and,O
then,O
return,O
to,O
a,O
surveying,O
state,O
without,O
undergoing,O
apoptosis,O
or,O
migration,O
.,O
Calcitonin,O
injection,O
resulted,O
in,O
a,O
potentiation,O
of,O
haloperidol,Entity
-,O
induced,O
catalepsy,Entity
and,O
a,O
partial,O
prevention,O
of,O
apomorphine,Entity
-,O
induced,O
hyperactivity,Entity
.,O
After,O
adjustment,O
for,O
age,O
",",O
the,O
rate,O
ratio,O
of,O
VTE,Entity
in,O
users,O
of,O
third,O
-,O
generation,O
relative,O
to,O
second,O
-,O
generation,O
OCs,Entity
was,O
1.68,O
(,O
95%,O
CI,O
1.04,O
-,O
2.75,O
),O
.,O
Can,O
lidocaine,Entity
reduce,O
succinylcholine,Entity
induced,O
postoperative,Entity
myalgia,Entity
?,O
It,O
was,O
also,O
evident,O
that,O
",",O
by,O
titrating,O
the,O
dose,O
to,O
achieve,O
a,O
maximum,O
tolerated,O
dose,O
",",O
malformations,Entity
that,O
normally,O
occur,O
at,O
low,O
incidence,O
",",O
as,O
reported,O
from,O
previous,O
single,O
dose,O
studies,O
",",O
could,O
also,O
be,O
induced,O
with,O
ASA,Entity
given,O
at,O
multiple,O
doses,O
.,O
Clinical,O
assessment,O
as,O
well,O
as,O
blinded,O
ratings,O
of,O
Unified,O
Parkinson,Entity
's,Entity
Disease,Entity
Rating,O
Scale,O
(,O
UPDRS,O
),O
A,O
rechallenge,O
with,O
androgen,Entity
produced,O
symptoms,O
of,O
obstructive,Entity
sleep,Entity
apnea,Entity
that,O
abated,O
upon,O
withdrawal,O
of,O
the,O
hormone,O
.,O
Efficacy,O
and,O
safety,O
of,O
granisetron,Entity
",",O
a,O
selective,O
5-hydroxytryptamine-3,Entity
receptor,O
antagonist,O
",",O
in,O
the,O
prevention,O
of,O
nausea,Entity
and,O
vomiting,Entity
induced,O
by,O
high,O
-,O
dose,O
cisplatin,Entity
.,O
Eight,O
cancer,Entity
patients,O
in,O
the,O
terminal,O
stages,O
of,O
the,O
disease,O
treated,O
with,O
high,O
doses,O
of,O
intravenous,O
morphine,Entity
developed,O
hyperalgesia,Entity
.,O
A,O
rare,O
cause,O
",",O
drug,O
-,O
induced,O
vasculitis,Entity
",",O
may,O
result,O
from,O
the,O
production,O
of,O
antineutrophil,O
cytoplasmic,O
antibodies,O
(,O
ANCAs,O
),O
in,O
response,O
to,O
a,O
medication,O
.,O
For,O
each,O
of,O
the,O
three,O
tested,O
calcium,Entity
channel,O
blockers,O
(,O
diltiazem,Entity
",",O
verapamil,Entity
and,O
bepridil,Entity
),O
6,O
groups,O
of,O
mice,O
were,O
treated,O
by,O
two,O
different,O
doses,O
",",O
i.e.,O
2,O
and,O
10,O
mg,O
/,O
kg,O
/,O
i.p,O
.,O
",",O
or,O
an,O
equal,O
volume,O
of,O
saline,O
for,O
the,O
control,O
group,O
(,O
n,O
=,O
20,O
),O
;,O
15,O
minutes,O
later,O
",",O
all,O
the,O
animals,O
were,O
injected,O
with,O
a,O
single,O
50,O
mg,O
/,O
kg,O
/,O
i.p,O
.,O
OBJECTIVE,O
:,O
To,O
report,O
a,O
case,O
of,O
multiple,O
episodes,O
of,O
seizure,Entity
activity,O
in,O
an,O
AIDS,Entity
patent,O
following,O
amphotericin,Entity
B,Entity
infusion,O
.,O
The,O
catalepsy,Entity
induced,O
by,O
dopamine,Entity
antagonists,O
has,O
been,O
tested,O
and,O
the,O
possible,O
dopamine,Entity
subtypes,O
involved,O
in,O
catalepsy,Entity
was,O
determined,O
.,O
In,O
comparison,O
to,O
control,O
",",O
E,Entity
and,O
ED1-ED4,O
showed,O
highly,O
significant,O
analgesic,O
and,O
antiinflammatory,O
activities,O
(,O
p,O
<,O
0.001,O
),O
.,O
It,O
was,O
suggested,O
that,O
this,O
brain,O
stem,O
activation,O
is,O
inherent,O
to,O
the,O
migraine,Entity
attack,O
itself,O
and,O
represents,O
the,O
so,O
called,O
',O
migraine,Entity
generator,O
',O
.,O
caffeine-,Entity
but,O
not,O
pentylenetetrazole,Entity
-,O
induced,O
anxiogenic,O
effect,O
in,O
mice,O
.,O
Epidural,O
blood,O
flow,O
during,O
prostaglandin,Entity
E1,Entity
or,O
trimethaphan,Entity
induced,O
hypotension,Entity
.,O
SKF,Entity
38393,Entity
or,O
D-2,O
agonist,O
quinpirole,Entity
decreased,O
the,O
catalepsy,Entity
induced,O
by,O
fluphenazine,Entity
",",O
SCH,Entity
23390,Entity
or,O
sulpiride,Entity
.,O
Those,O
using,O
methadone,Entity
and,O
heroin,Entity
simultaneously,O
may,O
increase,O
risk,O
of,O
rhabdomyolysis,Entity
and,O
ischemic,Entity
stroke,Entity
.,O
The,O
muscle,Entity
spasms,Entity
disappeared,O
spontaneously,O
and,O
the,O
surgery,O
proceeded,O
without,O
further,O
problems,O
.,O
17beta,Entity
-,Entity
Estradiol,Entity
did,O
not,O
alter,O
the,O
onset,O
of,O
first,O
clonus,O
in,O
ovariectomized,O
rats,O
but,O
accelerated,O
it,O
in,O
males,O
.,O
This,O
was,O
a,O
prospective,O
",",O
single,O
-,O
intervention,O
study,O
of,O
consenting,O
adult,O
patients,O
undergoing,O
procedural,O
sedation,O
with,O
propofol,Entity
between,O
December,O
28,O
",",O
2002,O
",",O
and,O
October,O
31,O
",",O
2003,O
.,O
Since,O
plasma,O
pharmacokinetic,O
studies,O
showed,O
a,O
faster,O
busulfan,Entity
clearance,O
in,O
children,O
than,O
in,O
adults,O
",",O
this,O
new,O
dose,O
may,O
approximate,O
more,O
closely,O
the,O
adult,O
systemic,O
exposure,O
obtained,O
after,O
the,O
usual,O
16-mg,O
/,O
kg,O
total,O
dose,O
",",O
with,O
potential,O
inferences,O
in,O
terms,O
of,O
anticancer,O
or,O
myeloablative,O
effects,O
.,O
The,O
authors,O
describe,O
the,O
case,O
of,O
a,O
56-year,O
-,O
old,O
woman,O
with,O
chronic,O
",",O
severe,O
heart,Entity
failure,Entity
secondary,O
to,O
dilated,Entity
cardiomyopathy,Entity
and,O
absence,O
of,O
significant,O
ventricular,Entity
arrhythmias,Entity
who,O
developed,O
QT,Entity
prolongation,Entity
and,O
torsade,Entity
de,Entity
pointes,Entity
ventricular,Entity
tachycardia,Entity
during,O
one,O
cycle,O
of,O
intermittent,O
low,O
dose,O
(,O
2.5,O
mcg,O
/,O
kg,O
per,O
min,O
),O
In,O
rats,O
given,O
1%,O
BHA,Entity
",",O
RA,Entity
co,O
-,O
administered,O
at,O
a,O
dose,O
of,O
0.05,O
",",O
0.1,O
",",O
0.2,O
or,O
0.25%,O
showed,O
a,O
dose,O
-,O
dependent,O
enhancing,O
effect,O
on,O
the,O
development,O
of,O
the,O
BHA,Entity
-,O
induced,O
epithelial,Entity
hyperplasia,Entity
.,O
NIMO,Entity
attenuated,O
the,O
disruption,O
in,O
consolidation,O
of,O
long,O
-,O
term,O
memory,O
caused,O
by,O
NTG,Entity
but,O
did,O
not,O
improve,O
latency,O
in,O
the,O
absence,O
of,O
hypotension,Entity
.,O
The,O
20,O
deaths,O
",",O
52,O
hemorrhagic,Entity
and,Entity
thromboembolic,Entity
complications,Entity
",",O
and,O
21,O
surgical,O
procedures,O
to,O
manage,O
the,O
complications,O
confirm,O
the,O
seriousness,O
of,O
the,O
disorder,O
.,O
The,O
cardiac,O
depressant,O
actions,O
of,O
phenytoin,Entity
and,O
hypothermia,Entity
can,O
be,O
additive,O
.,O
However,O
",",O
yohimbine,Entity
and,O
meperidine,Entity
reduced,O
predominantly,O
the,O
dyskinetic,Entity
movements,O
.,O
Histopathological,O
examination,O
was,O
carried,O
out,O
to,O
confirm,O
the,O
myocardial,O
necrosis,Entity
.,O
In,O
the,O
ICU,O
",",O
we,O
found,O
rhabdomyolysis,Entity
",",O
acute,Entity
renal,Entity
failure,Entity
and,O
acute,O
respiratory,Entity
failure,Entity
.,O
In,O
the,O
last,O
few,O
years,O
delayed,O
reactions,O
several,O
hours,O
after,O
the,O
injection,O
of,O
radiographic,O
and,O
contrast,Entity
materials,Entity
(,O
PRC,Entity
),O
have,O
been,O
described,O
with,O
increasing,O
frequency,O
.,O
We,O
evaluated,O
the,O
tolerability,O
of,O
CE,Entity
in,O
a,O
group,O
of,O
patients,O
with,O
documented,O
history,O
of,O
adverse,O
cutaneous,Entity
reactions,Entity
to,O
P,Entity
and,O
N,Entity
associated,O
or,O
not,O
to,O
classic,O
NSAIDs,O
.,O
A,O
method,O
for,O
the,O
measurement,O
of,O
tremor,Entity
",",O
and,O
a,O
comparison,O
of,O
the,O
effects,O
of,O
tocolytic,O
beta,O
-,O
mimetics,O
.,O
Azathioprine,Entity
treatment,O
benefited,O
19,O
(,O
66%,O
),O
out,O
of,O
29,O
patients,O
suffering,O
from,O
severe,O
psoriasis,Entity
.,O
Triazolam,Entity
-,O
induced,O
brief,O
episodes,O
of,O
secondary,O
mania,Entity
in,O
a,O
depressed,Entity
patient,O
.,O
The,O
patient,O
has,O
been,O
followed,O
for,O
six,O
years,O
and,O
has,O
required,O
pharmacologic,O
doses,O
of,O
pyridoxine,Entity
to,O
control,O
her,O
behavior,O
.,O
l(-1,O
),O
),O
during,O
1.6%,O
sevoflurane,Entity
was,O
not,O
significant,O
from,O
that,O
during,O
0.8%,O
sevoflurane,Entity
",",O
indicating,O
a,O
celling,O
effect,O
.,O
While,O
use,O
of,O
high,O
dose,O
dexmedetomidine,Entity
is,O
associated,O
with,O
decreases,O
in,O
heart,O
rate,O
and,O
blood,O
pressure,O
outside,O
the,O
established,O
',O
awake,O
',O
norms,O
",",O
this,O
deviation,O
is,O
generally,O
within,O
20%,O
of,O
norms,O
",",O
and,O
is,O
not,O
associated,O
with,O
adverse,O
sequelae,O
.,O
Remission,O
induction,O
of,O
meningeal,Entity
leukemia,Entity
with,O
high,O
-,O
dose,O
intravenous,O
methotrexate,Entity
.,O
In,O
relatively,O
healthy,O
women,O
",",O
combined,O
continuous,O
HT,O
significantly,O
increased,O
the,O
risk,O
of,O
venous,Entity
thromboembolism,Entity
or,O
coronary,O
event,O
(,O
after,O
one,O
year,O
's,O
use,O
),O
",",O
stroke,Entity
(,O
after,O
3,O
years,O
),O
",",O
breast,Entity
cancer,Entity
(,O
after,O
5,O
years,O
),O
and,O
gallbladder,Entity
disease,Entity
.,O
We,O
report,O
a,O
57-year,O
-,O
old,O
woman,O
with,O
end,Entity
-,Entity
stage,Entity
renal,Entity
disease,Entity
receiving,O
continuous,O
ambulatory,O
peritoneal,O
dialysis,O
(,O
CAPD,O
),O
",",O
who,O
developed,O
slurred,O
speech,O
",",O
tremor,Entity
",",O
bizarre,O
behavior,O
",",O
progressive,O
mental,O
confusion,Entity
",",O
and,O
2,O
episodes,O
of,O
generalized,O
tonic,Entity
-,Entity
clonic,Entity
seizure,Entity
(,O
GTCS,Entity
),O
after,O
5,O
doses,O
of,O
piperacillin,Entity
/,Entity
tazobactam,Entity
(,O
2,O
g/250,O
mg,O
),O
were,O
given,O
for,O
bronchiectasis,Entity
with,O
secondary,Entity
infection,Entity
.,O
Increased,O
sulfation,O
and,O
decreased,O
7alpha,O
-,O
hydroxylation,O
of,O
deoxycholic,Entity
acid,Entity
in,O
ethinyl,Entity
estradiol,Entity
-,O
induced,O
cholestasis,Entity
in,O
rats,O
.,O
BACKGROUND,O
:,O
Our,O
aim,O
was,O
to,O
investigate,O
postoperative,O
complications,O
and,O
mortality,O
after,O
administration,O
of,O
aprotinin,O
compared,O
to,O
tranexamic,Entity
acid,Entity
in,O
an,O
unselected,O
",",O
consecutive,O
cohort,O
.,O
CONCLUSIONS,O
:,O
Sub,O
-,O
chronic,O
low,O
dose,O
GVG,Entity
potentiates,O
and,O
extends,O
the,O
inhibition,O
of,O
cocaine,Entity
-,O
induced,O
increases,O
in,O
dopamine,Entity
",",O
effectively,O
reducing,O
cumulative,O
exposures,O
and,O
the,O
risk,O
for,O
VFDS,O
.,O
KF17837,Entity
:,O
a,O
novel,O
selective,O
adenosine,Entity
A2A,O
receptor,O
antagonist,O
with,O
anticataleptic,O
activity,O
.,O
The,O
most,O
common,O
symptomatic,O
adverse,O
reactions,O
were,O
tremor,Entity
or,O
ataxia,Entity
(,O
35%,O
),O
",",O
nausea,Entity
and,O
anorexia,Entity
(,O
8%,O
),O
",",O
visual,Entity
halos,Entity
or,Entity
blurring,Entity
(,O
6%,O
),O
",",O
thyroid,Entity
function,Entity
abnormalities,Entity
(,O
6%,O
),O
and,O
pulmonary,Entity
interstitial,Entity
infiltrates,Entity
(,O
5%,O
),O
.,O
Administration,O
of,O
graded,O
doses,O
of,O
U,Entity
-,Entity
II,Entity
(,O
1,O
-,O
"10,000",O
ng,O
/,O
mouse,O
),O
provoked,O
:,O
(,O
1,O
),O
a,O
dose,O
-,O
dependent,O
reduction,O
in,O
the,O
number,O
of,O
head,O
dips,O
in,O
the,O
hole,O
-,O
board,O
test,O
;,O
(,O
2,O
),O
a,O
dose,O
-,O
dependent,O
reduction,O
in,O
the,O
number,O
of,O
entries,O
in,O
the,O
white,O
chamber,O
in,O
the,O
black,O
-,O
and,O
-,O
white,O
compartment,O
test,O
",",O
and,O
in,O
the,O
number,O
of,O
entries,O
in,O
the,O
central,O
platform,O
and,O
open,O
arms,O
in,O
the,O
plus,O
-,O
maze,O
test,O
;,O
and,O
(,O
3,O
),O
a,O
dose,O
-,O
dependent,O
increase,O
in,O
the,O
duration,O
of,O
immobility,O
in,O
the,O
forced,O
-,O
swimming,O
test,O
and,O
tail,O
suspension,O
test,O
.,O
However,O
",",O
temperature,O
effects,O
of,O
drugs,O
that,O
have,O
been,O
used,O
to,O
manipulate,O
brain,O
DA,Entity
neurotransmission,O
confound,O
interpretation,O
of,O
the,O
data,O
.,O
After,O
5,O
weeks,O
of,O
bupropion,Entity
use,O
",",O
the,O
subject,O
experienced,O
a,O
generalized,O
tonic,O
clonic,O
seizure,Entity
after,O
staying,O
up,O
nearly,O
all,O
night,O
packing,O
and,O
moving,O
to,O
a,O
new,O
residence,O
.,O
In,O
a,O
more,O
complex,O
task,O
commonly,O
used,O
to,O
evaluate,O
major,O
akinetic,Entity
symptoms,O
of,O
PD,Entity
patients,O
",",O
5,O
mg,O
/,O
kg,O
AMN082,Entity
reverses,O
the,O
increased,O
reaction,O
time,O
to,O
respond,O
to,O
a,O
cue,O
of,O
bilateral,O
6-OHDA,Entity
-,O
lesioned,O
rats,O
.,O
Lovastatin,Entity
and,O
simvastatin,Entity
are,O
both,O
effective,O
and,O
well,O
-,O
tolerated,O
agents,O
for,O
lowering,O
elevated,O
levels,O
of,O
serum,O
cholesterol,Entity
.,O
Role,O
of,O
activation,O
of,O
bradykinin,Entity
B2,O
receptors,O
in,O
disruption,O
of,O
the,O
blood,O
-,O
brain,O
barrier,O
during,O
acute,O
hypertension,Entity
.,O
The,O
paralysis,Entity
is,O
temporary,O
",",O
and,O
watchful,O
waiting,O
with,O
restriction,O
of,O
activity,O
is,O
the,O
recommended,O
management,O
.,O
This,O
uncoupling,O
effect,O
on,O
oxidative,O
phosphorylation,O
was,O
not,O
detectable,O
after,O
short,O
-,O
term,O
exposure,O
to,O
cocaine,Entity
",",O
suggesting,O
that,O
these,O
mitochondrial,Entity
abnormalities,Entity
were,O
a,O
late,O
rather,O
than,O
a,O
primary,O
event,O
in,O
the,O
pathological,O
response,O
to,O
cocaine,Entity
.,O
Nicotine,Entity
does,O
not,O
appear,O
to,O
enhance,O
thrombosis,Entity
among,O
humans,O
.,O
STZ,Entity
induced,O
glial,O
activation,O
",",O
apoptotic,O
cell,O
death,O
and,O
post,O
synaptic,O
neurotoxicity,Entity
in,O
rat,O
brain,O
.,O
Comparing,O
the,O
relative,O
sensitivity,O
to,O
central,O
depression,Entity
and,O
excitation,O
revealed,O
that,O
rats,O
were,O
least,O
likely,O
to,O
have,O
convulsions,Entity
at,O
doses,O
that,O
did,O
not,O
first,O
cause,O
loss,Entity
of,Entity
consciousness,Entity
",",O
while,O
cats,O
most,O
clearly,O
showed,O
marked,O
central,O
excitatory,O
actions,O
.,O
Haloperidol,Entity
induced,O
a,O
significantly,O
higher,O
incidence,O
(,O
p,O
On,O
the,O
13th,O
day,O
",",O
antinociceptive,O
effects,O
were,O
assessed,O
using,O
a,O
model,O
of,O
inflammatory,O
nociception,O
",",O
pain,Entity
-,O
induced,O
functional,O
impairment,O
model,O
",",O
and,O
the,O
charcoal,Entity
meal,O
test,O
was,O
used,O
to,O
evaluate,O
the,O
intestinal,O
transit,O
.,O
These,O
results,O
may,O
be,O
relevant,O
to,O
the,O
use,O
of,O
FZP,Entity
in,O
clinical,O
situations,O
in,O
which,O
there,O
is,O
increased,O
neural,O
excitability,O
",",O
such,O
as,O
epilepsy,Entity
or,O
sedative,O
-,O
hypnotic,O
drug,O
withdrawal,O
.,O
The,O
aim,O
of,O
the,O
present,O
study,O
was,O
to,O
review,O
the,O
data,O
accumulated,O
so,O
far,O
on,O
the,O
use,O
of,O
LMWH,Entity
in,O
this,O
patient,O
population,O
and,O
to,O
discuss,O
its,O
applicability,O
in,O
common,O
practice,O
.,O
Eight,O
deaths,O
and,O
liver,O
rupture,Entity
in,O
18,O
patients,O
attest,O
to,O
the,O
seriousness,O
of,O
this,O
new,O
potentially,O
lethal,O
adverse,O
phenomenon,O
.,O
Given,O
its,O
excellent,O
tolerance,O
profile,O
and,O
low,O
toxicity,Entity
",",O
further,O
evaluation,O
of,O
VNB,Entity
in,O
combination,O
therapy,O
is,O
warranted,O
.,O
Clinicians,O
are,O
exhorted,O
to,O
pay,O
close,O
attention,O
when,O
initiating,O
levofloxacin,Entity
therapy,O
in,O
patients,O
taking,O
medications,O
with,O
epileptogenic,O
properties,O
that,O
are,O
CYP1A2,O
substrates,O
.,O
Highly,O
active,O
antiretroviral,O
therapy,O
(,O
HAART,O
),O
has,O
significantly,O
reduced,O
morbidity,O
and,O
mortality,O
of,O
acquired,Entity
immunodeficiency,Entity
syndrome,Entity
(,O
AIDS,Entity
),O
",",O
but,O
has,O
resulted,O
in,O
an,O
increase,O
in,O
cardiac,Entity
and,Entity
skeletal,Entity
myopathies,Entity
.,O
Dothiepin,Entity
also,O
produced,O
fewer,O
CNS,O
and,O
cardiovascular,O
effects,O
.,O
DATA,O
SYNTHESIS,O
:,O
New,O
evidence,O
from,O
1,O
good,O
-,O
quality,O
RCT,O
",",O
1,O
good,O
-,O
quality,O
meta,O
-,O
analysis,O
",",O
and,O
2,O
fair,O
-,O
quality,O
subanalyses,O
of,O
RCTs,O
demonstrates,O
that,O
aspirin,Entity
use,O
reduces,O
the,O
number,O
of,O
CVD,Entity
events,O
in,O
patients,O
without,O
known,O
CVD,Entity
.,O
Thyroid,O
function,O
and,O
urine,O
-,O
concentrating,O
ability,O
during,O
lithium,Entity
treatment,O
.,O
Serum,O
C3,O
complement,O
levels,O
were,O
significantly,O
reduced,O
in,O
ALF,Entity
patients,O
compared,O
with,O
control,O
subjects,O
(,O
P,O
<,O
0.0005,O
),O
.,O
These,O
results,O
provide,O
empirical,O
support,O
for,O
conducting,O
a,O
further,O
study,O
of,O
bupropion,Entity
.,O
The,O
intensity,O
of,O
headache,Entity
and,O
nausea,Entity
was,O
measured,O
with,O
a,O
100-mm,O
visual,O
analog,O
scale,O
.,O
In,O
patients,O
with,O
impaired,Entity
renal,Entity
and,Entity
liver,Entity
function,Entity
",",O
and,O
those,O
who,O
need,O
long,O
-,O
term,O
pain,Entity
control,O
",",O
pethidine,Entity
may,O
cause,O
excitatory,O
central,O
nervous,O
system,O
(,O
CNS,O
),O
effects,O
through,O
its,O
neurotoxic,Entity
metabolite,O
",",O
norpethidine,Entity
",",O
resulting,O
in,O
irritability,Entity
and,O
seizure,Entity
attack,O
.,O
Increase,O
of,O
Parkinson,Entity
disability,Entity
after,O
fluoxetine,Entity
medication,O
.,O
A,O
positive,O
lymphocyte,O
transformation,O
test,O
with,O
indomethacin,Entity
in,O
vitro,O
further,O
substantiates,O
the,O
potential,O
role,O
of,O
this,O
drug,O
in,O
causing,O
aplastic,Entity
anemia,Entity
in,O
a,O
susceptible,O
patient,O
.,O
Cholinergic,O
convulsant,O
sensitivity,O
was,O
examined,O
in,O
alcohol,Entity
-,O
na,O
ve,O
The,O
mechanism,O
of,O
water,Entity
intoxication,Entity
is,O
discussed,O
in,O
regard,O
to,O
these,O
cases,O
.,O
injection,O
of,O
methyl,Entity
beta,Entity
-,Entity
carboline-3-carboxylate,Entity
(,O
beta,Entity
-,Entity
CCM,Entity
),O
",",O
an,O
inverse,O
agonist,O
of,O
the,O
GABA(A,Entity
),O
receptor,O
benzodiazepine,Entity
site,O
.,O
These,O
results,O
suggest,O
that,O
activation,O
tasks,O
such,O
as,O
"""""""""",O
speaking,O
aloud,O
"""""""""",O
could,O
be,O
used,O
for,O
objective,O
assessment,O
of,O
dyskinesia,Entity
severity,O
.,O
These,O
results,O
suggest,O
that,O
hypertension,Entity
after,O
chronic,O
intrarenal,O
noradrenaline,Entity
infusion,O
is,O
produced,O
by,O
relatively,O
higher,O
levels,O
of,O
circulating,O
noradrenaline,Entity
and,O
by,O
triggering,O
of,O
an,O
additional,O
intrarenal,O
pressor,O
mechanism,O
.,O
The,O
serum,O
level,O
of,O
potassium,Entity
was,O
observed,O
to,O
be,O
8.4,O
mequiv,O
Ketamine,Entity
reduced,O
both,O
the,O
area,O
of,O
brush,O
-,O
evoked,O
and,O
punctate,O
-,O
evoked,O
Myxedema,Entity
coma,Entity
is,O
a,O
life,O
threatening,O
condition,O
that,O
carries,O
a,O
mortality,O
reaching,O
as,O
high,O
as,O
20%,O
with,O
treatment,O
.,O
Similarly,O
",",O
ganglionic,O
blockade,O
with,O
hexamethonium,Entity
caused,O
a,O
significantly,O
greater,O
fall,O
in,O
LNNA,Entity
hypertensive,Entity
rats,O
(,O
76,O
+,O
/-,O
To,O
further,O
validate,O
the,O
hypothesis,O
that,O
the,O
anti,O
-,O
cocaine,Entity
effects,O
of,O
the,O
novel,O
ligands,O
involved,O
antagonism,O
of,O
sigma,O
receptors,O
",",O
an,O
antisense,O
oligodeoxynucleotide,Entity
against,O
sigma1,O
receptors,O
was,O
also,O
shown,O
to,O
significantly,O
attenuate,O
the,O
convulsive,Entity
and,O
locomotor,O
stimulatory,O
effects,O
of,O
cocaine,Entity
.,O
Reversible,O
cholestasis,Entity
with,O
bile,Entity
duct,Entity
injury,Entity
following,O
azathioprine,Entity
therapy,O
.,O
METHODS,O
:,O
Subjects,O
(,O
n,O
=,O
114,O
),O
undergoing,O
extraction,O
of,O
impacted,O
third,O
molars,O
received,O
either,O
2%,O
lidocaine,Entity
or,O
0.5%,O
bupivacaine,Entity
before,O
surgery,O
and,O
either,O
rofecoxib,Entity
50,O
mg,O
or,O
placebo,O
orally,O
90,O
min,O
before,O
surgery,O
and,O
for,O
the,O
following,O
48,O
h.,O
Oral,O
mucosal,O
biopsies,O
were,O
taken,O
before,O
surgery,O
and,O
48,O
h,O
after,O
surgery,O
.,O
In,O
contrast,O
with,O
the,O
literature,O
",",O
serum,O
levels,O
of,O
angiogenesis,O
factors,O
did,O
not,O
change,O
significantly,O
by,O
pegylated,Entity
interferon,Entity
and,O
ribavirin,Entity
therapy,O
.,O
Amiloride,Entity
reduced,O
the,O
drinking,O
and,O
urine,O
volume,O
of,O
rats,O
in,O
an,O
acute,O
(,O
6,O
or,O
12,O
h,O
),O
and,O
a,O
subacute,O
(,O
3,O
days,O
),O
experiment,O
.,O
The,O
underlying,O
mechanism,O
of,O
withdrawal,Entity
-,Entity
emergent,Entity
RS,Entity
in,O
the,O
present,O
case,O
may,O
have,O
been,O
related,O
to,O
the,O
pharmacological,O
profile,O
of,O
risperidone,Entity
",",O
a,O
serotonin,Entity
-,O
dopamine,Entity
antagonist,O
",",O
suggesting,O
the,O
pathophysiologic,O
influence,O
of,O
the,O
serotonin,Entity
system,O
in,O
the,O
development,O
of,O
RS,Entity
.,O
In,O
male,O
animals,O
",",O
repeated,O
apomorphine,Entity
treatment,O
induced,O
a,O
gradual,O
development,O
of,O
aggressive,Entity
behavior,Entity
as,O
evidenced,O
by,O
the,O
increased,O
intensity,O
of,O
aggressiveness,Entity
and,O
shortened,O
latency,O
before,O
the,O
first,O
attack,O
toward,O
the,O
opponent,O
.,O
The,O
possible,O
role,O
of,O
low,O
pH,O
as,O
well,O
as,O
total,O
volume,O
as,O
potential,O
factors,O
in,O
causing,O
neurotoxicity,Entity
was,O
evaluated,O
.,O
potentiated,O
the,O
anticataleptic,O
effects,O
of,O
a,O
subthreshold,O
dose,O
of,O
"L-3,4-dihydroxyphenylalanine",Entity
(,O
L,Entity
-,Entity
DOPA,Entity
;,O
25,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
T.,Entity
chebula,Entity
extract,Entity
pretreatment,O
was,O
found,O
to,O
ameliorate,O
the,O
effect,O
of,O
isoproterenol,Entity
on,O
lipid,O
peroxide,Entity
formation,O
and,O
retained,O
the,O
activities,O
of,O
the,O
diagnostic,O
marker,O
enzymes,O
.,O
anti,O
-,O
inflammatory,O
drugs,O
",",O
sodium,Entity
salicylate,Entity
",",O
phenylbutazone,Entity
",",O
indomethacin,Entity
",",O
ibuprofen,Entity
and,O
mefenamic,Entity
acid,Entity
",",O
on,O
seizures,Entity
produced,O
by,O
pilocarpine,Entity
.,O
Acute,O
confusion,Entity
induced,O
by,O
a,O
high,O
-,O
dose,O
infusion,O
of,O
5-fluorouracil,Entity
and,O
folinic,Entity
acid,Entity
.,O
Postoperatively,O
",",O
a,O
significantly,O
higher,O
incidence,O
of,O
seizures,Entity
was,O
found,O
in,O
Group,O
T,O
(,O
4.6%,O
vs,O
1.2%,O
",",O
P,O
The,O
moderate,O
-,O
dose,O
group,O
received,O
5,O
mg,O
/,O
kg,O
/,O
day,O
PDN,Entity
released,O
from,O
a,O
subcutaneous,O
implant,O
.,O
Treatment,O
with,O
a,O
PJ34,Entity
significantly,O
improved,O
cardiac,Entity
dysfunction,Entity
and,O
increased,O
the,O
survival,O
of,O
the,O
animals,O
.,O
85,O
percent,O
of,O
patients,O
with,O
dyskinesias,Entity
were,O
relieved,O
of,O
symptoms,O
",",O
regardless,O
of,O
whether,O
the,O
pallidotomies,O
were,O
performed,O
with,O
the,O
Gamma,O
Knife,O
or,O
radiofrequency,O
methods,O
.,O
One,O
patient,O
group,O
developed,O
sinus,Entity
tachycardias,Entity
in,O
the,O
setting,O
of,O
a,O
massive,O
carbamazepine,Entity
overdose,Entity
.,O
This,O
new,O
case,O
of,O
RPGN,Entity
in,O
the,O
course,O
of,O
D,Entity
-,Entity
penicillamine,Entity
treatment,O
emphasizes,O
the,O
need,O
for,O
frequent,O
monitoring,O
of,O
renal,O
function,O
and,O
evaluation,O
of,O
urinary,O
sediment,O
and,O
proteinuria,Entity
in,O
these,O
patients,O
.,O
Sex,O
",",O
age,O
",",O
diagnosis,O
(,O
bipolar,Entity
I,Entity
vs.,O
bipolar,Entity
II,Entity
),O
",",O
and,O
additional,O
treatment,O
did,O
not,O
affect,O
the,O
risk,O
of,O
switching,O
.,O
Conversely,O
",",O
brain,O
normetanephrine,Entity
concentration,O
was,O
increased,O
from,O
saline,O
control,O
by,O
amantadine,Entity
in,O
the,O
BALB,O
/,O
C,O
mice,O
.,O
Treatment,O
of,O
ovarian,Entity
cancer,Entity
with,O
a,O
combination,O
of,O
cis,Entity
-,Entity
platinum,Entity
",",O
adriamycin,Entity
",",O
cyclophosphamide,Entity
and,O
hexamethylmelamine,Entity
.,O
Mature,O
male,O
and,O
female,O
mice,O
from,O
six,O
inbred,O
stains,O
were,O
tested,O
for,O
susceptibility,O
to,O
behavioral,O
seizures,Entity
induced,O
by,O
a,O
single,O
injection,O
of,O
cocaine,Entity
.,O
Other,O
ECG,O
parameters,O
before,O
the,O
application,O
of,O
d,Entity
",",Entity
l,Entity
-,Entity
sotalol,Entity
did,O
not,O
identify,O
patients,O
at,O
increased,O
risk,O
for,O
torsades,Entity
de,Entity
pointes,Entity
.,O
Curcumin,Entity
co,O
-,O
administration,O
did,O
not,O
cause,O
any,O
significant,O
alteration,O
in,O
the,O
serum,O
concentrations,O
of,O
both,O
phenobarbitone,Entity
as,O
well,O
as,O
carbamazepine,Entity
.,O
In,O
recent,O
studies,O
increased,O
amounts,O
of,O
nitric,Entity
oxide,Entity
(,O
NO,Entity
),O
and,O
apoptosis,O
have,O
been,O
implicated,O
in,O
various,O
pathological,O
conditions,O
in,O
the,O
kidney,O
.,O
Due,O
to,O
the,O
risk,O
of,O
this,O
tachycardia,Entity
inducing,O
myocardial,Entity
ischemia,Entity
",",O
we,O
would,O
not,O
recommend,O
the,O
use,O
in,O
elderly,O
patients,O
of,O
any,O
of,O
the,O
ephedrine,Entity
/,O
propofol,Entity
/,O
mixtures,O
studied,O
.,O
In,O
addition,O
",",O
PILO,Entity
injected,O
animals,O
exhibited,O
a,O
reduction,O
in,O
the,O
number,O
of,O
NPY,O
-,O
immunoreactive,O
interneurons,O
compared,O
with,O
controls,O
.,O
We,O
studied,O
20,O
patients,O
receiving,O
long,O
-,O
term,O
carbonic,O
anhydrase,O
inhibitor,O
treatment,O
for,O
periodic,O
paralysis,Entity
and,O
myotonia,Entity
.,O
Furthermore,O
",",O
reduction,O
of,O
ER,O
stress,O
in,O
the,O
TM,O
with,O
sodium,Entity
4-phenylbutyrate,Entity
prevented,O
dexamethasone,Entity
-,O
induced,O
ocular,Entity
hypertension,Entity
in,O
WT,O
mice,O
.,O
The,O
current,O
study,O
investigated,O
the,O
visual,O
fields,O
and,O
visual,O
electrophysiology,O
of,O
eight,O
patients,O
with,O
known,O
vigabatrin,Entity
-,O
attributed,O
visual,Entity
field,Entity
loss,Entity
",",O
three,O
of,O
whom,O
were,O
reported,O
previously,O
.,O
A,O
mean,O
overall,O
dose,O
of,O
etomidate,Entity
17.4,O
microgram,O
/,O
kg,O
/,O
min,O
.,O
The,O
effects,O
of,O
continuous,O
positive,O
airway,O
pressure,O
(,O
CPAP,O
),O
on,O
cardiovascular,O
dynamics,O
and,O
pulmonary,O
shunt,O
(,O
QS,O
/,O
QT,O
),O
were,O
investigated,O
in,O
12,O
dogs,O
before,O
and,O
during,O
sodium,Entity
nitroprusside,Entity
infusion,O
that,O
decreased,O
mean,O
arterial,O
blood,O
pressure,O
40,O
-,O
50,O
per,O
cent,O
.,O
Systemic,O
vascular,O
resistance,O
was,O
increased,O
by,O
PPA,Entity
28%,O
(,O
from,O
1710,O
+,O
/-,O
This,O
rat,O
study,O
demonstrated,O
a,O
synergistic,O
nephrotoxic,Entity
effect,O
of,O
CsA,Entity
plus,O
SRL,Entity
",",O
whereas,O
FK506,Entity
plus,O
SRL,Entity
was,O
better,O
tolerated,O
.,O
Induction,O
by,O
paracetamol,Entity
of,O
bladder,Entity
and,Entity
liver,Entity
tumours,Entity
in,O
the,O
rat,O
.,O
Myoclonic,Entity
",",Entity
atonic,Entity
",",Entity
and,Entity
absence,Entity
seizures,Entity
following,O
institution,O
of,O
carbamazepine,Entity
therapy,O
in,O
children,O
.,O
In,O
London,O
and,O
Toronto,O
154,O
patients,O
who,O
met,O
DSM,O
-,O
III,O
criteria,O
for,O
panic,Entity
disorder,Entity
with,O
agoraphobia,Entity
were,O
randomised,O
to,O
alprazolam,Entity
or,O
placebo,O
.,O
The,O
therapeutic,O
use,O
of,O
selective,O
DA,Entity
D1,O
receptor,O
agonists,O
such,O
as,O
SKF-82958,Entity
(,O
"6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze",Entity
pine,Entity
hydrobromide,Entity
),O
and,O
A-77636,Entity
(,O
[,Entity
1R,Entity
",",Entity
3S,Entity
],Entity
"3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo",Entity
pyran,Entity
hydrochloride,Entity
),O
seems,O
limited,O
because,O
of,O
their,O
duration,O
of,O
action,O
",",O
which,O
is,O
too,O
short,O
for,O
SKF-82958,Entity
(,O
<,O
1,O
hr,O
),O
and,O
too,O
long,O
for,O
A-77636,Entity
(,O
>,O
20,O
The,O
seizures,Entity
were,O
successfully,O
treated,O
with,O
sodium,Entity
thiopental,Entity
in,O
addition,O
to,O
succinylcholine,Entity
in,O
1,O
patient,O
.,O
FS,O
containing,O
aprotinin,O
or,O
different,O
concentrations,O
of,O
tAMCA,Entity
(,O
0.5,O
-,O
47.5,O
mg,O
/,O
ml,O
),O
were,O
applied,O
to,O
the,O
pial,O
surface,O
of,O
the,O
cortex,O
of,O
anaesthetized,O
rats,O
.,O
In,O
addition,O
",",O
subcutaneous,O
delivery,O
of,O
the,O
neutralizing,O
agent,O
will,O
not,O
be,O
associated,O
with,O
the,O
risk,O
of,O
inadequate,O
urinary,O
mesna,Entity
concentrations,O
",",O
such,O
as,O
in,O
a,O
patient,O
taking,O
oral,O
mesna,Entity
who,O
experiences,O
severe,O
ifosfamide,Entity
-,O
induced,O
emesis,Entity
and,O
is,O
unable,O
to,O
absorb,O
the,O
drug,O
.,O
This,O
study,O
measured,O
the,O
objective,O
and,O
subjective,O
neurocognitive,O
effects,O
of,O
a,O
single,O
10-mg,O
dose,O
of,O
immediate,O
-,O
release,O
oxycodone,Entity
in,O
healthy,O
",",O
older,O
(,O
>,O
65,O
years,O
),O
",",O
and,O
middle,O
-,O
aged,O
(,O
35,O
to,O
55,O
years,O
),O
adults,O
who,O
were,O
not,O
suffering,O
from,O
chronic,O
or,O
significant,O
daily,O
pain,Entity
.,O
The,O
initiated,O
hepatocytes,O
in,O
the,O
liver,O
were,O
assayed,O
as,O
the,O
gamma,O
-,O
glutamyltransferase,O
(,O
gamma,O
-,O
GT,O
),O
positive,O
foci,O
formed,O
following,O
a,O
2-week,O
selection,O
regimen,O
consisting,O
of,O
dietary,O
0.02%,O
2-acetylaminofluorene,Entity
coupled,O
with,O
a,O
necrogenic,O
dose,O
of,O
CCl4,Entity
.,O
A,O
repeat,O
work,O
-,O
up,O
revealed,O
further,O
elevations,O
in,O
aminotransferase,O
levels,O
",",O
and,O
liver,O
biopsy,O
revealed,O
evidence,O
of,O
moderate,O
-,O
to,O
-,O
severe,O
drug,Entity
toxicity,Entity
.,O
Warfarin,Entity
-,O
induced,O
cerebral,Entity
haemorrhages,Entity
are,O
a,O
major,O
clinical,O
problem,O
with,O
a,O
high,O
fatality,O
rate,O
.,O
Italian,O
Tamoxifen,Entity
Prevention,O
Study,O
.,O
Delirium,Entity
during,O
clozapine,Entity
treatment,O
:,O
incidence,O
and,O
associated,O
risk,O
factors,O
.,O
While,O
she,O
was,O
weak,O
",",O
2-Hz,O
repetitive,O
stimulation,O
revealed,O
a,O
decrement,O
without,O
significant,O
facilitation,O
at,O
rapid,O
rates,O
or,O
after,O
exercise,O
",",O
suggesting,O
postsynaptic,Entity
neuromuscular,Entity
blockade,Entity
.,O
Tolerance,O
and,O
antiviral,O
effect,O
of,O
ribavirin,Entity
was,O
studied,O
in,O
6,O
patients,O
with,O
Argentine,Entity
hemorrhagic,Entity
fever,Entity
(,O
AHF,Entity
),O
of,O
more,O
than,O
8,O
days,O
of,O
evolution,O
.,O
TAC,Entity
has,O
been,O
shown,O
to,O
be,O
a,O
potent,O
immunosuppressive,O
agent,O
for,O
solid,O
organ,O
transplantation,O
in,O
pediatrics,O
.,O
Immunosuppressive,O
drugs,O
have,O
been,O
used,O
during,O
the,O
last,O
30,O
years,O
in,O
treatment,O
of,O
patients,O
with,O
severe,O
rheumatoid,Entity
arthritis,Entity
.,O
CONCLUSION,O
:,O
Our,O
results,O
did,O
not,O
lend,O
strong,O
support,O
to,O
the,O
view,O
that,O
the,O
genetic,O
variation,O
of,O
the,O
DRD2,O
gene,O
plays,O
a,O
major,O
role,O
in,O
the,O
individually,O
variable,O
adverse,O
effect,O
induced,O
by,O
chlorpromazine,Entity
",",O
at,O
least,O
in,O
Chinese,O
patients,O
with,O
schizophrenia,Entity
.,O
Direct,O
comparison,O
between,O
sham,O
and,O
real,O
rTMS,O
effects,O
showed,O
no,O
significant,O
difference,O
in,O
clinician,O
-,O
assessed,O
dyskinesia,Entity
severity,O
.,O
The,O
pharmacokinetics,O
of,O
famotidine,Entity
are,O
reviewed,O
",",O
with,O
no,O
change,O
in,O
its,O
metabolism,O
in,O
the,O
elderly,O
population,O
seen,O
.,O
Doxorubicin,Entity
induces,O
a,O
self,O
-,O
perpetuating,O
nephropathy,Entity
characterized,O
by,O
early,O
glomerular,Entity
and,Entity
late,Entity
-,Entity
onset,Entity
tubular,Entity
lesions,Entity
in,O
rats,O
.,O
A,O
morphometric,O
study,O
of,O
isoproterenol,Entity
induced,O
myocardial,O
fibrosis,Entity
.,O
When,O
tacrolimus,Entity
side,O
effects,O
persist,O
despite,O
dose,O
reduction,O
",",O
conversion,O
to,O
cyclosporine,Entity
-,O
based,O
immunosuppression,O
(,O
CyA,O
),O
is,O
necessary,O
.,O
The,O
development,O
of,O
tolerance,O
to,O
the,O
muscular,Entity
rigidity,Entity
produced,O
by,O
morphine,Entity
was,O
studied,O
in,O
rats,O
.,O
Allergic,Entity
reaction,Entity
to,O
5-fluorouracil,Entity
infusion,O
.,O
The,O
80,O
patients,O
in,O
the,O
study,O
consecutively,O
received,O
either,O
iopromide,Entity
(,O
group,O
A,O
",",O
n,O
=,O
40,O
),O
or,O
iohexol,Entity
In,O
the,O
initial,O
6,O
months,O
since,O
it,O
's,O
introduction,O
",",O
12,O
overdose,Entity
cases,O
have,O
been,O
reported,O
to,O
The,O
National,O
Poisons,O
Information,O
Centre,O
.,O
Total,O
blindness,Entity
with,O
a,O
transient,O
tonic,Entity
pupillary,Entity
response,O
",",O
denervation,O
supersensitivity,O
",",O
and,O
abnormal,O
visual,O
-,O
evoked,O
potentials,O
developed,O
in,O
a,O
54-year,O
-,O
old,O
man,O
after,O
the,O
use,O
of,O
quinine,Entity
sulfate,Entity
for,O
leg,Entity
cramps,Entity
.,O
Reversible,O
valproic,Entity
acid,Entity
-,O
induced,O
dementia,Entity
:,O
a,O
case,O
report,O
.,O
Rabbit,Entity
syndrome,Entity
(,O
RS,Entity
),O
is,O
a,O
rare,O
extrapyramidal,O
side,O
effect,O
caused,O
by,O
prolonged,O
neuroleptic,O
medication,O
.,O
The,O
reaction,O
may,O
be,O
mediated,O
by,O
the,O
presence,O
of,O
antibodies,O
reactive,O
against,O
platelets,O
in,O
the,O
presence,O
of,O
quinine,Entity
.,O
administration,O
of,O
IFS,Entity
.,O
We,O
compared,O
these,O
results,O
with,O
those,O
previously,O
obtained,O
with,O
kainic,Entity
acid,Entity
(,O
KA,Entity
),O
",",O
a,O
potent,O
glutamate,Entity
agonist,O
.,O
Studies,O
with,O
long,O
-,O
term,O
lamivudine,Entity
administration,O
should,O
be,O
performed,O
to,O
determine,O
if,O
prolonged,O
suppression,O
of,O
HBV,O
DNA,O
can,O
be,O
achieved,O
.,O
Heart,O
and,O
liver,O
patients,O
had,O
more,O
infections,Entity
than,O
cyclosporine,Entity
renal,O
patients,O
but,O
fewer,O
infections,Entity
than,O
the,O
Aza,Entity
renal,O
patients,O
.,O
These,O
episodes,O
reversed,O
after,O
the,O
administration,O
of,O
diazepam,Entity
1,O
mg,O
intravenously,O
.,O
Both,O
drugs,O
impaired,Entity
immediate,Entity
free,Entity
recall,Entity
but,O
the,O
decrease,O
was,O
greater,O
for,O
diazepam,Entity
than,O
propranolol,Entity
.,O
Drug,O
studies,O
using,O
the,O
indirect,O
antiglobulin,O
test,O
were,O
strongly,O
positive,O
with,O
trimethoprim,Entity
and,O
trimethoprim,Entity
-,Entity
sulfamethoxazole,Entity
but,O
negative,O
with,O
sulfamethoxazole,Entity
.,O
In,O
the,O
8-wk,O
group,O
",",O
MIBG,Entity
accumulation,O
in,O
the,O
right,O
and,O
left,O
ventricular,O
wall,O
was,O
18%,O
and,O
14%,O
of,O
that,O
in,O
controls,O
",",O
respectively,O
(,O
p,O
less,O
than,O
0.001,O
),O
.,O
These,O
observations,O
",",O
in,O
conjunction,O
with,O
clinical,O
and,O
laboratory,O
evidence,O
of,O
extravascular,O
hemolysis,Entity
",",O
are,O
consistent,O
with,O
drug,O
-,O
induced,O
hemolytic,Entity
anemia,Entity
",",O
possibly,O
involving,O
both,O
drug,O
-,O
adsorption,O
and,O
autoantibody,O
formation,O
mechanisms,O
.,O
in,O
users,O
of,O
low,O
-,O
dose,O
(,O
<,O
or,O
=,O
325,O
mg,O
daily,O
),O
aspirin,Entity
(,O
n,O
=,O
1051,O
),O
and,O
nonusers,O
of,O
aspirin,Entity
(,O
n,O
=,O
6883,O
),O
.,O
",",O
Ato,Entity
could,O
prevent,O
endothelial,O
We,O
report,O
a,O
woman,O
with,O
coronary,Entity
artery,Entity
disease,Entity
who,O
developed,O
a,O
markedly,O
prolonged,Entity
QT,Entity
interval,Entity
and,O
torsades,Entity
de,Entity
pointes,Entity
(,O
TdP,Entity
),O
after,O
taking,O
ketoconazole,Entity
for,O
treatment,O
of,O
fungal,Entity
infection,Entity
.,O
These,O
data,O
demonstrate,O
that,O
administration,O
of,O
MP,Entity
before,O
and,O
after,O
TDI,O
reduces,O
the,O
frequency,O
and,O
severity,O
of,O
the,O
arthralgia,Entity
-,O
myalgia,Entity
syndrome,O
.,O
Flestolol,Entity
:,O
CONCLUSIONS,O
:,O
Familial,O
thyroid,Entity
illness,Entity
is,O
a,O
risk,O
factor,O
for,O
hypothyroidism,Entity
and,O
hypercalcemia,Entity
during,O
lithium,Entity
therapy,O
.,O
In,O
this,O
article,O
",",O
we,O
report,O
an,O
interesting,O
case,O
of,O
a,O
young,O
woman,O
who,O
presented,O
with,O
this,O
rare,O
type,O
of,O
reverse,O
apical,Entity
ballooning,Entity
syndrome,Entity
occurring,O
after,O
amphetamine,Entity
use,O
.,O
However,O
",",O
in,O
many,O
cases,O
",",O
the,O
exencephalic,Entity
brain,O
tissue,O
was,O
preserved,O
with,O
more,O
or,O
less,O
reduction,O
during,O
this,O
period,O
.,O
These,O
data,O
suggest,O
a,O
similarity,O
between,O
postalcoholic,O
Wernicke,Entity
-,Entity
Korsakoff,Entity
syndrome,Entity
and,O
the,O
patient,O
with,O
tolazamide,Entity
-,O
induced,O
Nicotine,Entity
(,O
0.25,O
mg,O
/,O
kg,O
),O
pretreatment,O
blocked,O
the,O
caffeine-,Entity
but,O
not,O
pentylenetetrazole,Entity
-,O
induced,O
anxiety,Entity
.,O
The,O
OCT,O
results,O
in,O
these,O
patients,O
with,O
EMB,Entity
-,O
induced,O
optic,Entity
neuropathy,Entity
show,O
considerable,O
loss,O
especially,O
of,O
the,O
temporal,O
fibers,O
.,O
OBJECTIVE,O
:,O
Quetiapine,Entity
is,O
a,O
dibenzothiazepine,O
derivative,O
",",O
similar,O
to,O
clozapine,Entity
",",O
which,O
has,O
the,O
highest,O
risk,O
of,O
causing,O
blood,Entity
dyscrasias,Entity
",",O
especially,O
neutropenia,Entity
.,O
OBJECTIVE,O
:,O
To,O
compare,O
the,O
antihypertensive,O
efficacy,O
of,O
a,O
new,O
angiotensin,Entity
II,Entity
antagonist,O
",",O
valsartan,Entity
",",O
with,O
a,O
reference,O
therapy,O
",",O
amlodipine,Entity
.,O
Orthostatic,Entity
hypotension,Entity
occurs,O
following,O
alpha,O
2-adrenoceptor,O
blockade,O
in,O
chronic,O
prazosin,Entity
-,O
pretreated,O
conscious,O
spontaneously,O
hypertensive,Entity
rats,O
.,O
1,O
.,O
Decision,O
-,O
analytic,O
techniques,O
were,O
used,O
to,O
estimate,O
the,O
cost,O
of,O
treating,O
RIHA,Entity
.,O
We,O
therefore,O
investigated,O
the,O
long,O
-,O
term,O
safety,O
of,O
danazol,Entity
by,O
performing,O
a,O
retrospective,O
chart,O
review,O
of,O
60,O
female,O
patients,O
with,O
hereditary,Entity
angioedema,Entity
treated,O
with,O
danazol,Entity
for,O
a,O
continuous,O
period,O
of,O
6,O
months,O
or,O
longer,O
.,O
Two,O
separate,O
equimolar,O
doses,O
(,O
0.2,O
and,O
0.4,O
mumol,O
),O
of,O
either,O
cocaine,Entity
or,O
BE,Entity
were,O
injected,O
ventricularly,O
in,O
unanesthetized,O
juvenile,O
rats,O
.,O
Thalidomide,Entity
and,O
sensory,Entity
neurotoxicity,Entity
:,O
a,O
neurophysiological,O
study,O
.,O
CCNU,Entity
was,O
used,O
most,O
commonly,O
in,O
the,O
treatment,O
of,O
lymphoma,Entity
",",O
mast,Entity
cell,Entity
tumour,Entity
",",O
brain,Entity
tumour,Entity
",",O
histiocytic,Entity
tumours,Entity
and,O
epitheliotropic,Entity
lymphoma,Entity
.,O
All,O
the,O
lesions,O
in,O
dentate,O
",",O
inferior,O
colliculus,O
",",O
pons,O
",",O
and,O
medullas,O
had,O
been,O
resolved,O
completely,O
on,O
follow,O
-,O
up,O
MRIs,O
in,O
5,O
patients,O
",",O
but,O
in,O
1,O
patient,O
of,O
them,O
",",O
corpus,O
callosal,Entity
lesion,Entity
persisted,O
.,O
terbutaline,Entity
5,O
mg,O
t.i.d,O
.,O
15,O
cases,O
of,O
cimetidine,Entity
-,O
associated,O
mental,O
confusion,Entity
have,O
been,O
reported,O
.,O
Pharmacology,O
of,O
gamma,Entity
-,Entity
aminobutyric,Entity
acidA,Entity
receptor,O
complex,O
after,O
the,O
in,O
vivo,O
administration,O
of,O
the,O
anxioselective,O
and,O
anticonvulsant,O
beta,Entity
-,Entity
carboline,Entity
derivative,O
abecarnil,Entity
.,O
RESULTS,O
:,O
Cyclophosphamide,Entity
treatment,O
increased,O
the,O
spontaneous,O
pain,Entity
behaviors,O
scores,O
.,O
33.7,O
(,O
risperidone,Entity
),O
.,O
Injections,O
of,O
ketamine,Entity
in,O
doses,O
from,O
100,O
microgram,O
to,O
3,O
mg,O
into,O
the,O
artery,O
produced,O
a,O
depression,Entity
of,O
the,O
SA,O
nodal,O
activity,O
by,O
a,O
direct,O
action,O
.,O
All,O
had,O
myofibre,O
necrosis,Entity
but,O
only,O
3,O
had,O
an,O
inflammatory,O
infiltrate,O
.,O
No,O
correlation,O
could,O
be,O
demonstrated,O
between,O
cumulative,O
dose,O
of,O
doxorubicin,Entity
and,O
cardiac,O
status,O
",",O
except,O
for,O
heart,O
rate,O
variability,O
.,O
The,O
effect,O
of,O
high,O
dose,O
D,Entity
-,Entity
penicillamine,Entity
treatment,O
on,O
aortic,O
permeability,O
to,O
albumin,O
and,O
on,O
the,O
ultrastructure,O
of,O
the,O
vessel,O
.,O
This,O
complication,O
appears,O
to,O
represent,O
a,O
significant,O
new,O
toxicity,Entity
of,O
high,O
-,O
dose,O
etoposide,Entity
therapy,O
for,O
malignant,Entity
glioma,Entity
.,O
A,O
selective,O
dopamine,Entity
D4,O
receptor,O
antagonist,O
",",O
NRA0160,Entity
:,O
a,O
preclinical,O
neuropharmacological,O
profile,O
.,O
As,O
a,O
consequence,O
of,O
blocking,O
I(f,O
),O
",",O
clonidine,Entity
reduced,O
the,O
slope,O
of,O
the,O
diastolic,O
depolarization,O
and,O
the,O
frequency,O
of,O
pacemaker,O
potentials,O
in,O
sinoatrial,O
node,O
cells,O
from,O
wild,O
-,O
type,O
and,O
alpha2ABC,O
-,O
knockout,O
mice,O
.,O
At,O
48,O
h,O
after,O
surgery,O
",",O
12,O
patients,O
in,O
both,O
groups,O
still,O
suffered,O
from,O
myalgia,Entity
(,O
not,O
significant,O
),O
.,O
Prolonged,O
left,Entity
ventricular,Entity
dysfunction,Entity
occurs,O
in,O
patients,O
with,O
coronary,Entity
artery,Entity
disease,Entity
after,O
both,O
dobutamine,Entity
and,O
exercise,O
induced,O
myocardial,Entity
ischaemia,Entity
.,O
Abdominal,O
ultrasound,O
showed,O
an,O
adrenal,O
mass,O
",",O
and,O
postoperative,O
histologic,O
examination,O
confirmed,O
the,O
diagnosis,O
of,O
pheochromocytoma,Entity
.,O
CONCLUSIONS,O
:,O
We,O
conclude,O
that,O
in,O
transplants,O
",",O
there,O
is,O
a,O
strong,O
association,O
between,O
well,O
-,O
developed,O
PTCR,O
and,O
TG,Entity
",",O
while,O
the,O
significance,O
of,O
mild,O
PTCR,O
and,O
its,O
predictive,O
value,O
in,O
the,O
absence,O
of,O
TG,Entity
is,O
unclear,O
.,O
Effects,O
of,O
cromakalim,Entity
and,O
pinacidil,Entity
on,O
large,O
epicardial,O
and,O
small,O
coronary,O
arteries,O
in,O
conscious,O
dogs,O
.,O
These,O
cells,O
proliferated,O
further,O
",",O
replacing,O
the,O
most,O
part,O
of,O
the,O
nodules,O
",",O
and,O
with,O
this,O
process,O
hepatomas,Entity
appeared,O
to,O
have,O
been,O
formed,O
.,O
poly,Entity
-,Entity
L,Entity
-,Entity
lactid,Entity
acid,Entity
nanoparticles,O
was,O
used,O
as,O
a,O
model,O
of,O
colloidal,O
drug,O
delivery,O
system,O
",",O
able,O
to,O
trespass,O
the,O
BBB,O
.,O
Moreover,O
",",O
L,O
-,O
NOArg,O
and,O
7-NI,O
but,O
not,O
L,O
-,O
NIL,O
intensify,O
antihyperalgesic,O
activity,O
of,O
HOE,Entity
140,Entity
or,O
des,Entity
-,Entity
Arg10HOE,Entity
140,Entity
in,O
toxic,Entity
neuropathy,Entity
.,O
6beta,O
-,O
hydroxylase,O
were,O
increased,O
by,O
bile,O
diversion,O
and,O
suppressed,O
by,O
EE,Entity
.,O
8.3,O
micrograms,O
after,O
propranolol,Entity
and,O
8.3,O
+,O
/-,O
Laboratory,O
testing,O
has,O
revealed,O
a,Entity
falling,Entity
platelet,Entity
count,Entity
",",O
increased,O
resistance,O
to,O
heparin,Entity
",",O
and,O
aggregation,O
of,O
platelets,O
by,O
the,O
patient,O
's,O
plasma,O
when,O
heparin,Entity
is,O
added,O
.,O
Conversion,O
to,O
SRL,Entity
prevented,O
CsA,Entity
-,O
induced,O
renal,Entity
damage,Entity
evolution,O
(,O
absent,O
/,O
mild,O
grade,O
lesions,O
),O
",",O
while,O
NGAL,O
(,O
serum,O
versus,O
urine,O
),O
seems,O
to,O
be,O
a,O
feasible,O
biomarker,O
of,O
CsA,Entity
replacement,O
to,O
SRL,Entity
.,O
Seizure,Entity
frequencies,O
before,O
and,O
after,O
initiation,O
of,O
levetiracetam,Entity
treatment,O
were,O
compared,O
",",O
and,O
adverse,O
effects,O
were,O
recorded,O
.,O
The,O
pharmacodynamic,O
parameters,O
assessed,O
included,O
induction,O
and,O
emergence,O
times,O
",",O
respiratory,O
and,O
cardiovascular,O
effects,O
",",O
and,O
pain,Entity
on,O
injection,O
.,O
NMS,Entity
due,O
to,O
ziprasidone,Entity
reported,O
in,O
the,O
literature,O
.,O
This,O
was,O
a,O
multicenter,O
",",O
randomized,O
",",O
open,O
-,O
label,O
study,O
in,O
adult,O
smokers,O
with,O
heart,Entity
disease,Entity
",",O
hypertension,Entity
not,O
controlled,O
by,O
medication,O
",",O
and/or,O
diabetes,Entity
mellitus,Entity
.,O
Male,O
Sprague,O
-,O
Dawley,O
rats,O
were,O
injected,O
with,O
saline,O
on,O
postnatal,O
day,O
(,O
P,O
),O
20,O
",",O
or,O
a,O
convulsant,O
dose,O
of,O
pilocarpine,Entity
on,O
P20,O
or,O
P45,O
.,O
Toxicities,Entity
included,O
hepatotoxicity,Entity
",",O
malaise,Entity
",",O
and,O
dose,O
-,O
limiting,O
nephrotoxicity,Entity
.,O
A,O
61-year,O
-,O
old,O
man,O
was,O
treated,O
with,O
combination,O
chemotherapy,O
incorporating,O
cisplatinum,Entity
",",O
etoposide,Entity
",",O
high,O
-,O
dose,O
5-fluorouracil,Entity
(,O
"2,250",O
mg,O
/,O
m2/24,O
hours,O
),O
and,O
folinic,Entity
acid,Entity
for,O
an,O
inoperable,O
gastric,Entity
adenocarcinoma,Entity
.,O
Direct,Entity
thrombin,Entity
inhibitors,Entity
are,O
appropriate,O
",",O
evidence,O
-,O
based,O
alternatives,O
to,O
heparin,Entity
in,O
patients,O
with,O
a,O
history,O
of,O
HIT,Entity
",",O
who,O
need,O
to,O
undergo,O
percutaneous,O
coronary,O
intervention,O
.,O
Seven,O
of,O
the,O
13,O
patients,O
had,O
exhibited,O
a,O
subclinical,O
hypertensive,Entity
state,O
before,O
cyclosporin,Entity
A,Entity
therapy,O
.,O
BACKGROUND,O
:,O
The,O
use,O
of,O
appetite,O
suppressants,O
in,O
Europe,O
has,O
been,O
associated,O
with,O
the,O
development,O
of,O
primary,Entity
pulmonary,Entity
hypertension,Entity
(,O
PPH,Entity
),O
.,O
wt,O
),O
and,O
intravenous,O
PS,Entity
(,O
2,O
separated,O
doses,O
of,O
2.5,O
mg/100,O
g,O
body,O
wt,O
),O
for,O
four,O
days,O
.,O
Bradycardia,Entity
induced,O
by,O
biperiden,Entity
is,O
attributed,O
to,O
the,O
speed,O
of,O
injection,O
and,O
to,O
a,O
dose,O
-,O
related,O
dual,O
effect,O
of,O
atropine,Entity
-,O
like,O
drugs,O
on,O
muscarine,Entity
receptors,O
.,O
In,O
addition,O
",",O
a,O
statistically,O
significant,O
reduction,O
was,O
also,O
observed,O
on,O
the,O
level,O
of,O
GABA,Entity
and,O
glycine,Entity
but,O
less,O
than,O
a,O
drastic,O
reduction,O
of,O
glutamate,Entity
and,O
aspartate,Entity
level,O
.,O
1.5%,O
),O
",",O
whereas,O
the,O
effect,O
of,O
parasympathetic,O
blockade,O
by,O
atropine,Entity
on,O
HR,O
was,O
similar,O
in,O
both,O
strains,O
.,O
Risk,O
factors,O
of,O
sensorineural,Entity
hearing,Entity
loss,Entity
in,O
preterm,O
infants,O
.,O
A,O
calcineurin,O
inhibitor,O
combined,O
with,O
methotrexate,Entity
is,O
the,O
standard,O
prophylaxis,O
for,O
graft,Entity
-,Entity
versus,Entity
-,Entity
host,Entity
disease,Entity
(,O
GVHD,Entity
),O
after,O
allogeneic,O
hematopoietic,O
stem,O
cell,O
transplantation,O
(,O
HSCT,O
),O
.,O
Epsilon,Entity
aminocaproic,Entity
acid,Entity
(,O
EACA,Entity
),O
has,O
been,O
used,O
to,O
prevent,O
rebleeding,O
in,O
patients,O
with,O
subarachnoid,Entity
hemorrhage,Entity
(,O
SAH,Entity
),O
.,O
High,O
frequency,O
stimulation,O
of,O
the,O
subthalamic,O
nucleus,O
(,O
STN,O
),O
is,O
known,O
to,O
ameliorate,O
the,O
signs,O
and,O
symptoms,O
of,O
advanced,O
Parkinson,Entity
's,Entity
disease,Entity
.,O
Although,O
an,O
indicator,O
of,O
renal,Entity
tubular,Entity
dysfunction,Entity
",",O
an,O
increased,O
urinary,O
N,O
-,O
acetyl,O
-,O
beta,O
METH,Entity
depleted,O
DA,Entity
",",O
caused,O
microglial,O
activation,O
",",O
and,O
increased,O
body,O
temperature,O
in,O
CX3CR1,O
knockout,O
mice,O
to,O
the,O
same,O
extent,O
and,O
over,O
the,O
same,O
time,O
course,O
seen,O
in,O
wild,O
-,O
type,O
controls,O
.,O
Biochemical,O
effects,O
of,O
Solidago,O
virgaurea,O
extract,O
on,O
experimental,O
cardiotoxicity,Entity
.,O
Nephrotoxicity,Entity
was,O
assessed,O
by,O
measuring,O
the,O
concentrations,O
of,O
creatinine,Entity
and,O
urea,Entity
in,O
the,O
plasma,O
and,O
reduced,O
glutathione,Entity
(,O
GSH,Entity
),O
in,O
the,O
kidney,O
cortex,O
",",O
and,O
by,O
light,O
microscopic,O
examination,O
of,O
kidney,O
sections,O
.,O
Moreover,O
calcitonin,O
induced,O
a,O
significant,O
decrease,O
in,O
nigral,O
GAD,O
activity,O
but,O
no,O
change,O
in,O
striatal,O
DA,Entity
and,O
DOPAC,Entity
concentration,O
or,O
GAD,O
activity,O
.,O
Simultaneous,O
impairment,O
of,O
other,O
enzymes,O
in,O
the,O
BS,Entity
biosynthetic,O
pathways,O
may,O
contribute,O
to,O
overall,O
effects,O
of,O
EE,Entity
on,O
BS,Entity
synthesis,O
.,O
The,O
association,O
between,O
opioid,O
dose,O
and,O
QT,O
",",O
and,O
methadone,Entity
dose,O
and,O
reporting,O
of,O
syncope,Entity
was,O
assessed,O
using,O
multivariate,O
linear,O
regression,O
and,O
logistic,O
regression,O
",",O
respectively,O
.,O
Digitalis,Entity
arrhythmia,Entity
",",O
which,O
is,O
suppressed,O
by,O
Na,Entity
channel,O
blockers,O
",",O
was,O
induced,O
by,O
intermittent,O
intravenous,O
(,O
i.v,O
.,O
),O
Necrotising,Entity
fasciitis,Entity
after,O
bortezomib,Entity
and,O
dexamethasone,Entity
-,O
containing,O
regimen,O
in,O
an,O
elderly,O
patient,O
of,O
Waldenstrom,Entity
macroglobulinaemia,Entity
.,O
Both,O
drugs,O
were,O
immediately,O
discontinued,O
",",O
and,O
the,O
patient,O
recovered,O
after,O
subsequent,O
nicardipine,Entity
and,O
verapamil,Entity
treatment,O
.,O
Unfractionated,Entity
heparin,Entity
(,O
UH,Entity
),O
is,O
currently,O
the,O
substitute,O
for,O
selected,O
patients,O
.,O
A,O
case,O
of,O
thoracic,Entity
hematomyelia,Entity
secondary,O
to,O
anticoagulant,O
therapy,O
is,O
presented,O
.,O
One,O
of,O
the,O
latter,O
two,O
patients,O
further,O
experienced,O
a,O
cytolytic,O
hepatitis,Entity
which,O
appeared,O
after,O
Benzylthiouracil,Entity
(,O
Basd,Entity
ne,Entity
),O
had,O
replaced,O
carbimazole,Entity
.,O
Lifetime,O
treatment,O
of,O
mice,O
with,O
azidothymidine,Entity
(,O
AZT,Entity
),O
produces,O
myelodysplasia,Entity
.,O
Electrocardiographic,O
changes,O
and,O
cardiac,Entity
arrhythmias,Entity
in,O
patients,O
receiving,O
psychotropic,O
drugs,O
.,O
Genetic,O
separation,O
of,O
tumor,Entity
growth,O
and,O
hemorrhagic,Entity
phenotypes,O
in,O
an,O
estrogen,Entity
-,O
induced,O
tumor,Entity
.,O
AIDA,Entity
in,O
doses,O
of,O
7.5,O
-,O
15,O
microg/0.5,O
microl,O
diminished,O
the,O
haloperidol,Entity
-,O
induced,O
muscle,Entity
rigidity,Entity
.,O
Sulpiride,Entity
did,O
not,O
affect,O
the,O
magnitude,O
of,O
a,O
steroid,Entity
-,O
induced,O
LH,O
surge,O
or,O
the,O
percentage,O
of,O
GnRH,O
neurons,O
activated,O
during,O
the,O
surge,O
.,O
/,O
min,O
of,O
ketamine,Entity
proved,O
safe,O
and,O
effective,O
.,O
We,O
hypothesized,O
that,O
increased,O
venous,O
smooth,O
muscle,O
(,O
venomotor,O
),O
tone,O
plays,O
a,O
role,O
in,O
Nomega,Entity
-,Entity
nitro,Entity
-,Entity
L,Entity
-,Entity
arginine,Entity
(,O
LNNA,Entity
),O
hypertension,Entity
through,O
these,O
mechanisms,O
.,O
When,O
tumors,Entity
were,O
treated,O
with,O
a,O
single,O
dose,O
of,O
cyclophosphamide,Entity
(,O
60,O
mg,O
/,O
kg,O
i.p,O
.,O
),O
5,O
days,O
after,O
implantation,O
",",O
a,O
growth,O
delay,O
with,O
a,O
subsequent,O
regrowth,O
of,O
the,O
tumors,Entity
was,O
observed,O
.,O
These,O
results,O
suggest,O
that,O
1,O
),O
both,O
SOD,O
and,O
DMTU,Entity
have,O
protective,O
effects,O
on,O
GM,Entity
-,O
mediated,O
nephropathy,Entity
",",O
2,O
),O
the,O
mechanisms,O
for,O
the,O
protective,O
effects,O
differ,O
for,O
SOD,O
and,O
DMTU,Entity
",",O
and,O
3,O
),O
superoxide,Entity
anions,O
play,O
a,O
critical,O
role,O
in,O
GM,Entity
-,O
induced,O
renal,O
vasoconstriction,O
.,O
Pretreatment,O
with,O
naloxazone,Entity
significantly,O
blocked,O
morphine,Entity
analgesia,Entity
",",O
catalepsy,Entity
and,O
hypothermia,Entity
at,O
a,O
dose,O
which,O
completely,O
eliminated,O
high,O
-,O
affinity,O
binding,O
in,O
brain,O
membranes,O
.,O
Based,O
on,O
a,O
score,O
of,O
8,O
on,O
the,O
Naranjo,O
adverse,Entity
drug,Entity
reaction,Entity
probability,O
scale,O
",",O
telithromycin,Entity
was,O
the,O
probable,O
cause,O
of,O
acute,O
hepatitis,Entity
in,O
this,O
patient,O
",",O
and,O
pathological,O
findings,O
suggested,O
drug,O
-,O
induced,O
toxic,Entity
hepatitis,Entity
.,O
Pooled,O
analysis,O
of,O
the,O
effects,O
of,O
other,O
inotropic,O
drugs,O
shows,O
an,O
excess,O
mortality,O
and,O
there,O
is,O
a,O
possibility,O
that,O
digoxin,Entity
may,O
increase,O
mortality,O
after,O
myocardial,Entity
infarction,Entity
(,O
MI,Entity
),O
.,O
